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ABSTRACT 
Protein aggregations of β-Amyloid (Aβ) and Tau are alone not sufficient to account 
for all the symptoms and progression of Alzheimer’s Disease (AD), as such there is 
much emphasis upon the immune component of the disease. The cells of the brain 
that are capable of initiating an immune response are microglia; these are 
derivatives of hematopoietic cells and they have the capacity to phagocytose and 
clear Aβ aggregates or release cytokines such as TNF-, in a neurotoxic role, 
promoting apoptosis of the surrounding neurons and hence aiding disease 
progression. 
To uncover the precise role of microglia in terms of AD we propose a protocol to 
enable differentiation of microglia from human embryonic stem cells (hESCs). The 
protocol we propose is a two-step differentiation procedure i) hESCs to monocytes 
followed by ii) ES-derived monocytes to microglia.  
Chapter 3: Exogenous over-expression of PU.1, a transcription factor vital in both 
the onset of haematopoiesis and the terminal differentiation of monocytes and 
microglia, was revealed to enable differentiation to a hematopoietic fate. 
Chapter 4: hESCS were differentiated to monocyte-like cells (CD45+/CD11b+) 
through culture in the presence of the hematopoietic growth factors; M-CSF and IL-3.  
Chapter 5: focuses on the differentiation of ES-derived monocytes to microglia. It 
shows that monocytes cultured in astrocyte conditioned medium give rise to cells 
that are IBA-1+/Glut5+/CD45low/NG2low/CD80+/CD11c+ and have a ramified 
   
 
 
microglial phenotype, which upon stimulation with Aβ(1-42) can become activated to 
the amoeboid phenotype. 
The development of the protocol for the generation of microglia holds great 
importance in terms of creating in vitro models for AD research as a whole and can 
be extended to the differentiation of patient IPSCs that contain mutations in genes 
associated with innate immunity or SNPs associated with AD risk, disease onset and 
progression. 
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1.  INTRODUCTION 
1.1 MICROGLIA 
1.1.1 GLIAL CELLS 
The brain tissue is composed of two groups of cells, neurons and glia, the former are 
cells capable of initiating action potentials, synthesizing neurotransmitters and using 
the synthesized neurotransmitters to transmit signals across synapses. The latter are 
a group of cells that, unlike neurons, are unable to transduce action potentials but 
are vital for the correct functioning of neurons and in the maintenance of brain 
homeostasis. Glia encompass both macroglia and microglia, two functionally and 
developmentally distinct groups of cells. 
Although diverse in their function, neurons and macroglia are intricately linked 
through cell lineage and their differentiation during the development of the embryonic 
central nervous system (CNS) and in adult neurogenesis. During development of the 
brain, a portion of the embryonic ectoderm becomes specialized forming the 
neuroectoderm. These signals include noggin and chordin, which function through 
the inhibition of BMP4, a TGFβ family protein that represses a neural fate (Sporle & 
Schughart, 1997, Bronner-Fraser & Fraser, 1997). 
The neuroepithelial cells of the neuroectoderm differentiate into radial glial cells 
(RGCs) and acquire features common to astrocytes, including; the presence of 
glycogen granules and glial fibrillary acidic protein (GFAP), and act as progenitors for 
both neurons and glia during development (Costa et al. 2010; Doestsh 2003). RGCs 
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are elongated between the ventricular and pial surfaces, these cells then undergo 
expansion through symmetrical division to increase the stem cell pool, but at the 
onset of neurogenesis they divide asymmetrically generating a stem cell that 
remains in the ventricular zone and a neuron, which migrates radially, utilising the 
radial glia as a scaffold, thickening the structure of the brain (Merkle and Alvarez-
Buylla 2006). Due to the increased complexity of the human cerebral cortex there is 
a second set of progenitors within the outer subventricaular zone, which enables 
neurogenesis to occur at both the ventricular zone and the outer subventricular zone, 
during mid gestation (Hansen et al. 2010). When neurogenesis is near completion 
the RGCs revert to symmetrical divisions resulting in the formation of glial cells (Sun 
et al. 2003). At birth, in mammals, the RGCs differentiate into astrocyte-like cells and 
oligodendrocytes, in the ventral regions. The astrocytes, in particular, are thought to 
provide the stem cell niche for adult neurogenesis in the olfactory blub and 
hippocampus through asymmetric divisions (Doestsh 2003).  
Macroglial cells were first described by Virchow, in the middle of the 19th century, as 
neuroectoderm-derived non-neuronal cells (Virchow 1846). They are numerous, 
diverse cells and although intricately linked to neurons their functions are far from 
analogous. Later in the 19th century it was deduced that macroglia comprise both the 
oligodendrocytes and astrocytes along with ependymal cells that line the brain 
ventricles (Merrill 1987).  
Oligodendrocytes are the central nervous system equivalent of the peripheral 
Schwann cells, their profuse processes wrap around the closely associated neurons 
forming the insulating myelin sheath surrounding axons and increasing the 
transduction velocity of action potentials (Heneka et al. 2010). The importance of the 
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oligodendrocyte myelin sheath is evident in diseases where the myelination of axons 
is disrupted. Multiple sclerosis (MS) for instance is an autoimmune disease, but 
during the initial progressive stage loss of myelination in MS lesions is due to 
oligodendrocyte cell death, rather than inflammation (De Keyser et al. 2008). 
Astrocytes are the most abundant cells of the human brain, they are 
characteristically star shaped cells that are organised into vast networks, which not 
only maintain the Blood Brain Barrier (BBB) and provide structural and metabolic 
support to neurons, but actively influence neurotransmission through calcium 
dependent glutamate release (Bushong et al. 2004; Parpura et al. 1994). Astrocytes 
are so fundamental in the maintenance of brain homeostasis that they are implicated 
in many pathologies, from migraines to epilepsy, where Ca2+ levels in astrocytes are 
key in causing excessive depolarization of surrounding neurons, and astrocytes are 
also fundamental in the progression of many neurodegenerative diseases (De 
Keyser et al. 2008). 
Whereas astrocytes and oligodendrocytes derive from neuroepithelium, microglia are 
now thought to have a mesodermal origin, invading the developing brain from 
embryonic blood islands and bone marrow in the adult. Microglia are thought of as 
brain macrophages and their physiological function extends beyond immunity to 
glutamate-dependent release of neurotrophic factors; BDNF and NGF and 
monitoring the function of neurons as well as removal of cellular debris and 
pathogens, much like tissue macrophages (Liang et al. 2010). Microglia are also 
implicated in pathologies including HIV associated neurocognitive disorder (HAND) 
and multiple sclerosis, as well as Parkinson’s and Alzheimer’s disease. 
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1.1.2 MICROGLIAL ORIGIN 
Microglia were first described within the third element, neither neuron nor astrocyte, 
by Cajal (1913) before his student del Rio-Hortega (1919) unearthed microglia from 
the oligodendrocyte – microglial composite of the third element in the early twentieth 
century where their origin has been debated ever since. There are many hypotheses 
regarding microglial derivation in early development; (1) a neuroectodermal origin 
from glioblasts in the same manner as astrocytes and oligodendrocytes, (2) yolk sac 
derived mesenchymal tissue associated with neuroepithelium or (3) invasion of blood 
monocytes (Chan, Kohsaka, & Rezaie, 2007).  
Although a haematopoietic nature of microglia is generally now accepted, several 
studies have shown evidence that at least some of the microglial population could be 
of neuroectodermal origin. Autoradiographic studies by Kitamura et al. (1984) 
showed that there is continuous differentiation of microglia from the glioblasts in the 
grey matter, which are also the source of astrocytes and oligodendrocytes. Labeling 
of neuroepithelial and microglial fractions taken from the developing rat brain showed 
cells positive for lipocortin-I, a protein responsible for mediating anti-inflammatory 
responses induced by glucocorticoids, within both fractions indicating a potential 
neuroepithelial origin (Fredoroff 1995; Flower and Rothwell 1994). Further evidence 
for their neuroectodermal origin came from culturing mouse neuroepithelial cells, free 
of Mac-I+ microglial precursors, which lead to the production of microglia and 
macrophage-like cells (Hao et al. 1991).  
The neuroectodermal theory of microglial origin has been contested by the more 
likely haematopoietic route. Much evidence is in support of the latter hypothesis as it 
was determined that microglia share not only function but also marker and enzyme 
expression with tissue macrophages (Ling et al. 1982; Boya et al. 1979; Cuadros 
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and Navascués 1998). This overwhelming similarity to macrophages leads to the 
conclusion that microglia are indeed members of the mononuclear phagocyte family 
and moreover, closely related to monocytes and macrophages (Cuadros and 
Navascués 1998). This is by no means a modern idea, it was suggested by del Rio-
Hortega, soon after their discovery, that microglia were of mesodermal rather than 
neuroectodermal origin (del Rio-Hortega 1932).  
A close link has been made between the yolk sac and microglial precursors. Alliot et 
al. (1999) showed that the number and appearance of microglial precursors in the 
neural folds is preceded by their appearance in the yolk sac where their numbers 
continue to outnumber those in the brain (Figure 1.1). Work by Ginhoux et al. 
(Ginhoux et al. 2010), suggests that microglial cells are visible in the neuroepithelium 
in mice from day E10.5, Theiler stage 16, equivalent to Carnegie stage 13 or day 28 
in human embryogenesis, whilst others suggest that human microglia are present 
from the second trimester. From birth and throughout adult life renewal of microglial 
cells can occur via invasion of circulating blood monocytes across a permeable BBB 
or through microglial self-renewal (Davoust et al. 2008). 
Upon accepting that microglial cells could originate from outside of the nervous 
system, the question became how and when do haematopoietic cells enter nervous 
tissue? There are three possible routes of mesodermal cell entry to the brain; 1) from 
the meninges through the pial surface, 2) from the ventricles through the ventricular 
layer and 3) from the blood stream through the BBB. The meninges, the membrane 
surrounding the CNS, were the first proposed route of entry by del-Rio-Hortega who 
described the pial margins as a sizeable source of microglia (del Rio-Hortega 1932). 
The ventricles also pose as entry sites of microglia into the brain, macrophage cells 
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have been found within the ventricle along with evidence to show microglial cells in 
the process of crossing the ventricular layer (Jordan & Thomas 1988; Navascués et 
al. 1996). Finally the blood stream, which although more problematic in the mature 
brain, due to the BBB, it is a route that provides entry to large numbers of microglial 
precursors during development prior to the formation of the BBB proper and could be 
the route of entry during pathologies and in old age where the BBB becomes 
permeable. Here the invading microglial precursors attach to vessel walls through 
the ICAM-I homing and adhesion system, which as has been implicated in monocyte 
invasion into other tissues, again compounding the close relationship between 
macrophages and microglia (Cuadros and Navascués 1998).  
 
Figure 1.1. Origin of Microglia 
At Carnegie stage 11 the Aorta-Gonad-Mesonephors (AGM) develops and is the site of primitive 
haematopoeisis until the liver adopts the role at stage 13 in development. It is at this stage that a 
large number of CD34+ haematopoietic stem cells (HSCs) are observed. These HSCs further 
differentiate into Granulocyte Macrophage precursors (GMPs) which allow for the formation of many 
cells of the haematopoietic system, including monocytes and microglia which enter the developing 
brain prior to the formation of the BBB proper and proliferate in situ until birth. Monocytes have the 
capacity to form macrophages and dendritic cells and also microglia, by the invasion of circulating 
monocytes into the adult brain especially under pathological conditions where the BBB is not fully 
intact. 
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1.1.3 MICROGLIA AND THEIR HEMATOPOIETIC PRECURSORS 
Embryonic haematopoiesis provides the necessary precursors for microglia. The 
process begins in the yolk sac where hematopoietic precursors migrate into the 
mesenchyme and are subsequently surrounded by epithelial cells, which aggregate 
and form the blood islands of early embryonic haematopoiesis enabling survival of 
the fetus until haematopoiesis at the AGM is initiated (McGrath and Palis 2005; Palis 
and Yoder 2001). The blood islands are thought to contain the haemangioblast, a 
cell type with the capability to differentiate into blood or endothelial cells in the 
absence or presence of the VEGF receptor,FLK1, respectively. It has been shown 
that FLK1 deficient mice are unable to form primitive embryonic blood cells (Palis 
and Yoder 2001). FLK1 is not required for their definitive differentiation, which is 
instead dependent on RUNX1, a transcription factor that is up regulated at the 
haemangioblast stage, which has the ability to bind to the downstream regulatory 
elements of CD34, thus promoting the formation of the Haematopoietic Stem Cell, 
HSC (Lacaud et al. 2002; Yokomizo et al. 2008; Levantini et al. 2011).  
The yolk sac is primarily utilized in erythrocyte production to oxygenate the 
developing fetus prior to hematopoiesis in the AGM, liver and ultimately bone 
marrow; but there are also limited numbers of macrophages produced (Sasaki & 
Matsamura 1986). These fetal macrophages differ from their adult counterparts, as 
they do not derive from monocytes but instead, derive from their own macrophage 
precursor (Moore and Metcalf 1970). It has also been seen in mice that yolk sac 
derived cells, whether distinct from the macrophage precursor is unknown, migrate 
to the CNS and form microglia (Palis et al. 1999). This is known as the first wave of 
microglial engraftment during the non-vascular period, forming embryonic microglia.  
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The resultant HSC colonizes the liver and spleen, followed by the bone marrow 
where normal hematopoiesis ensues and the focus becomes granulopoiesis rather 
than eyrthropoiesis, with the formation of neutrophils, eosinophils and basophils 
along with monocytes and lymphocytes (Figure 1.2). These monocytes are then able 
to traverse the developing BBB where they differentiate into bone-marrow derived 
microglia, forming the adult microglial population. There is a lack of distinction from 
the literature as to whether fetal haematopoiesis and the formation of this HSC is 
primitive or definitive in nature, but this could be the reason that there seem to be 
two distinct popultaions of microglia, which could be divided based on their 
expression of HOXB8. Chen et al. (2010) showed that only the bone marrow derived 
microglia were HOXB8+, which represented only 40% of the total microglial pool, 
whilst the remaining 60% of microglia were HOXB8- and thus have an origin outside 
of the bone marrow, potentially the yolk sac.  
Microglial maintenance in adult life is quite different to that of the colonization of 
microglial of the CNS in the foetus. Microglia, unlike their tissue macrophage 
counterparts, have the ability to self-renew enabling the microglial pool to be 
replenished even though the blood brain barrier is intact.  Microglial engraftment 
from bone marrow derived cells has long been a source for study by many groups. 
Ablation of native immune cells followed by the transplantation of GFP marked donor 
cells leads to invasion of the choroid plexus, leptomeniges and perivascular regions 
by donor cells (Tanaka et al. 2003).  But few donor cells have been seen infiltrating 
the brain parenchyma proper (Kennedy 1997). A study by Priller et al. (2001) 
showed that 4 months post-transplantation 25% of the microglial pool was donor 
derived. Kinetic studies of microglia recruitment have shown that although derived 
from bone marrow cells, microglia are engrafted much more slowly than other 
  1.Introduction 
9 
 
macrophages where 89% of splenic macrophages were found to be of donor origin 
after just 4 weeks and nearly two thirds of alveolar macrophages were donor derived 
by 12 months post-transplantation (Kennedy and Abzowitz 1997). 
Invasion of donor cells to the inner regions of the brain can be enhanced by brain 
injury, where these cells become indistinguishable from endogenous microglia and 
develop into a major mechanism of the disease pathology. Under certain conditions, 
in models of bacterial meningitis for example, bone marrow derived microglia 
recruitment can occur after the onset of disease, where their function is largely 
skewed toward tissue repair rather than the inflammation associated with disease 
pathology (Djukic et al. 2006). Conversely Ajami et al. (2011) suggested that 
although microglia can be derived from the bone marrow in their model of EAE due 
to the normal mechanism for their exclusion failing, these cells do not remain in the 
endogenous microglial pool subsequent to the pathology instead they suggest that 
microglia are maintained in situ through a process of self-renewal via a small number 
of precursor cells. But engraftment of donor cells to the brain during injury has posed 
as an attractive route for the delivery of genetically modified cells to the CNS to 
prevent further damage caused by the pathology and to aid recovery. 
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Figure 1.2. Adult Hematopoeisis  
Haematopoietic stem cells (HSCs) are capable of self renewal, in order to keep a pool of pluripotent 
cells, and this occurs under the influence of IL-1, IL-3, IL-6, IL-11, SCF and LIF. The transcription 
factor GATA-1 induces lineage commitment to a Megakaryocyte-Erythrocyte Progenitor (MEP). The 
cytokines IL-3, IL-6, IL-11, GM-CSF and TPO induce meagakaryocyte differentiation whereas IL-3, 
IL-9 and EPO result in the formation of erythrocytes. PU.1, on the other hand, induces the 
differentiation of a lymphoid myeloid precursor (LMP) from the HSC. PU.1 and GATA-1 antagonise 
each other which keep the HSC differentiation fates unbiased.  Expression of the transcription factors 
Pax5 and Notch result in the formation of a Common Lymphoid Precursor (CLP). B-cells are formed 
under the influence of IL-1, IL-4, IL-6 and IL-7 or IL-2, IL-3 and IL-4 result in the formation of T-cells. 
Pax5 and Notch are inhibitors of C/EBPα, the transcription factor required for the development of the 
Granulocyte Monocyte Progenitor (GMP). The GMP can differentiate into either granulocytic or 
monocytic precursors, which depends on the level of PU.1 expression. Low levels of PU.1 and 
C/EBPα commit the GMPs to granulocytic precursors (CFU-G) whereas high levels of PU.1, induced 
by C/EBPα, along with IL-3, G-CSF and GM-CSF result in monocytic precursors (CFU-M). CFU-G 
are able to, under the influence of Gfi-1, differentiate into neutrophils, eosinophils or basophils. Egr-
1,2 expression and secretion of IL-3, M-CSF and GM-CSF results in CFU-M differentiation to 
monocytes, which ultimately mature into macrophages or microglia (Modified from Friedman 2006 
and Dale 2008).  
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As suggested microglia can be derived from monocytes, both during development 
and throughout adult life, monocytes are also the precursors to macrophages and as 
such both macrophages and microglia behave similarly, with a capacity to 
phagocytose and present antigens to T-cells. They also express many of the same 
surface markers, making it extremely difficult to distinguish between the two 
populations of cells. A list of markers (Table 1.1) that showed differential expression 
between macrophages and microglia was compiled by Guilleman and Brew (2004) 
but they concluded that only under Electron Microscopy (EM) could the cells be truly 
distinguished. Scanning EM showed that microglia were identifiable by a surface 
covered in spines compared to the smooth exterior of the macrophage, but a 
consensus profile of marker expression was also determined for the identification of 
microglia; CD68+, CD45low, CD11chigh, MHC-II+, CD14+, IBA-1+ (Guillemin and Brew 
2004).  
The most universally utilised stain for microglial identification is IBA-1, a protein that 
has a role within the histocompatibility complex and in calcium binding. IBA-1 is 
expressed exclusively by microglia in brain slices, but when removed from the remit 
of the brain, expression is found in monocytic lineage cells in other organs (Ito et al. 
1998; Imai et al. 1996). The search for a specific marker for the characterization of 
microglia found that antibodies against the human glucose transporter, GLUT5, 
could be used in the place of IBA-1 for identifying microglia (Sasaki et al. 2003). 
GLUT5, in human tissue, is advantageous over IBA-1 as it is able to stain microglia 
specifically, even over the other closely related cells such as the perivascular 
macrophage ( Kettenmann et al. 2011). 
  1.Introduction 
12 
 
Kettenmann et al. (1993) also describe another means of macrophage and microglia 
distinction; electrophysiology. They found that microglia only express inwardly 
rectifying potassium channels making them highly susceptible to depolarization 
events whereas macrophages are less prone to depolarization as they possess 
outwardly rectifying potassium channels. 
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Marker Early Haematopoietic Precursor Macrophage Microglia 
FLK1 ++ +* +* 
RUNX1 ++ - +* 
CD34 ++ - +* 
PU.1 +++ ++ ++ 
Ki-67 + - + 
CD11c  - + +++ 
CD11b - ++ ++ 
CD14 - + - 
CD45 + +++ + 
CD80 - - + 
NG2 - ++ - 
IBA-1 - +* ++ 
GLUT5 - +* ++ 
Kir2.1 - + ++ 
NaV1.5 - + + 
NaV1.6 - + ++ 
RFD7 - +++ - 
Substance P - + +++ 
α1-chymotrypsin - ++ - 
Table 1.1. Comparison of Marker Expression in Early Haematopoietic Cells, 
Macrophages and Microglia 
The expected expression profile for each stage of differentiation can be used to identify the 
generated cell type. Although a specific marker for the identification of microglia is difficult to find, 
the difference in the presence of numerous markers compared to macrophages can lead to a 
positive identification of microglia. Of note are the differences in proliferation (Ki-67), CD11c and 
CD45. Asterisks denote expression only when the cell is activated. 
(Modified from Guillemin and Brew 2004) 
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1.1.4 ION CHANNELS IN MICROGLIA 
Microglia express numerous ion channels from Cl- to H+ as well as K+ and Na+ 
channels that are fundamental in their correct functioning. The most controversial of 
which are the voltage-gated Na+ channels. Such channels open only in response to 
a current, where the activation gate in the -subunit can open to allow Na+ ions to 
flow into the cell causing depolarization. At the peak of depolarization the pore is 
plugged by the inactivation gate to prevent reactivation. The channel has a built in 
filter to only allow passage of Na+ ions, in the form of the negatively charged amino 
acid lining of the pore and the pore size; large enough to enable a single Na+ ion and 
an associated water molecule. This family of channels has numerous isoforms with 
the majority being expressed in the nervous system during development. Microglia 
on the other hand only express three of the ten isoforms, NaV1.1, 1.5 and 1.6, with 
NaV1.6 being the most prominent in cultured rodent microglia (Black and Waxman, 
2009). Controversy lays with the tetrodotoxin (TTX) insensitive NaV1.5 channels, 
which seem to be the focus of human microglial studies, but neglected in rodent 
experiments (Nicholson 2009). These channels have been found to be linked to the 
activation state of the cells, those challenged with Lipopolysaccharide (LPS) or CNS 
damage show an increase in expression of those channels. Blocking the channels 
with TTX or phenytoin leads to a reduction in microglial activation. 
Rodent microglia also have a distinctive pattern of K+ channel expression, which 
enables ramified microglia to be distinguished from macrophage. When inactive and 
immature, microglia show activity of only inwardly rectifying K+ channels, with very 
little activity of the outward or voltage gated channels (Kettenman et al. 1993). 
Inwardly rectifying channels are able to pass positively charged ions, current, into the 
cell much more easily than out. This enables the cell to maintain a negative resting 
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membrane potential. In microglia the inwardly rectifying K+ channels resemble those 
of the Kir2.1 channels and enable the maintenance of a negative membrane 
potential, which facilitates the influx of Ca2+ ions that are required for proliferation. 
When activated by either hypoxia, CNS damage or immune onslaught, the cells 
transform from the quiescent ramified cell to the ameboid form, a state very similar if 
not indistinguishable from a macrophage, there is then activity from the voltage 
gated K+ channels. In rodents there has been a proposed link between KV1.3 and the 
production of the pro-inflammatory cytokines IL-1β and TNFα. In the case of IL-1β a 
decrease in the concentration of intracellular potassium, through efflux via KV 
channels, is required to facilitate the functioning of ICE/Caspase 1, the enzyme 
required to cleave pro-IL-1β to the active cytokine. KV channels are also present in 
microglia subsequent to attachment to a substratum due to changes in the structure 
of the membrane (McLarnon et al. 1997). Although a valuable marker for rodent 
microglia the presence of Kir channel activity and the absence of activity from KV 
channels is less pronounced in human microglia where the majority of cells possess 
activity from both channels (McLarnon et al. 1997). 
Another proposed important K+ channel in microglia is the small conductance 
Ca2+/calmodulin activated K+ channel (KCNN4/KCa3.1/SK4/IK1). Cell 
hyperpolarisation leads to an influx of Ca2+ through voltage-gated Ca2+ channels, 
which binds to the calmodulin (CaM). CaM binds to its binding domain within the 
intracellular portion of the KCa3.1 channel, which causes a conformational change 
and the subsequent mechanical opening of the pore to allow K+ ions to move out of 
the cell. Treating microglial with TRAM-34, a KCa3.1 inhibitor, was shown to 
decrease microglial activation and the resultant neuronal death (Reushal at al 2007). 
It is hypothesized that the KCa3.1 microglial activation is mediated by the p38 MAPK 
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pathway, which could be initiated through the osmotic shock of K+ efflux or due to the 
increased production of IL-1β, since ICE functions when the concentration of 
intracellular potassium decreases.  
Work specific to AD showed that the P2X7 ATP gated cation channel is up regulated 
around the sites of amyloid plaques in murine models of the disease. There are 
several P2X receptors expressed in microglia; P2X1 and P2X4 are seen in 
embryonic immature microglia, their expression then decreases with maturity 
coinciding with the up-regulation of P2X7. Much work with P2X7 receptors has 
shown that they increase the release of pro-inflammatory cytokines and are involved 
in neuropathic pain, another area of interest in microglia research. Along with the 
P2X receptors are the P2Y family, these are metabotropic G-protein coupled 
receptors and of particular interest to microglia is the P2Y12 receptor. ATP addition 
causes a multitude of responses based upon its concentration. A low concentration 
of ATP would initiate chemotaxis to the site of injury, where the concentration of ATP 
increases causing phagocytosis and cytokine secretion. These responses are 
mediated through influx of cations through P2X7, causing migration and a later efflux 
of K+ ions through P2Y12 responsible for the secretion of cytokines. P2X7 has also 
been shown to be up regulated in activated microglia after injury and during MS and 
ALS. It has been proposed to be vital in the mediation of microglial lead neuronal 
injury (Skaper 2011). 
CLIC1 a chloride channel is also seen to translocate from its intracellular cytosolic 
location to the plasma membrane upon exposure to Aβ. The physiological function of 
CLIC1 in microglia is grounded within proliferation, which is dependent upon chloride 
conductance. But in rodent models a challenge by Aβ leads to an increase in both 
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protein level and functionality of CLIC1, which simultaneously leads to the production 
of reactive oxygen species and TNFα. Blocking of these channels by a specific 
inhibitor leads to the prevention of TNFα release and thus neuronal apoptosis 
(Novarivo et al. 2004).  
Certain microglial functions are dependent on the co-operation of multiple channels 
(Figure 1.3). Proliferation is a process that is dependent on Ca2+, as such inwardly 
rectifying K+ channels maintain the negative membrane potential to increase the 
driving force of Ca2+ across the membrane through Ca2+ release – activated Ca2+ 
channels (CRACs). Migration is also controlled through two different ion channels; 
voltage independent Cl- channels and Ca2+ -dependent K+ channels, the efflux of KCl 
leads to water efflux through osmosis and the retraction of the rear end of the cell. 
Activation to the ameboid phenotype is also dependent on multiple channels. Cation 
channels in the cell body and K+/Cl- co-transporters in the processes result in an 
increase in osmolarity in the cell body due to cation influx causing water to enter the 
cell and the cell body to swell. KCl efflux from the processes, decreases osmolarity 
and water leaves, causing shrinkage and retraction of the processes.  
As such ion channels can be used as a tool to monitor the activation state of 
microglial cells and whilst less valuable for human microglia macrophage distinction 
they do pose the potential to be therapeutic targets for neurodegenerative diseases 
and other cognitive or CNS impairments that are linked to microglia.  
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Figure 1.3. Function of Ion Channels in Microglia 
(A) Proliferation requires Ca2+, to increase the flow of Ca2+ CRAC channels a negative membrane 
potential is required and is created by the inward flow of K+ through channels such as Kir2.1.  
(B) Migration is a process of retraction and swelling regulated by voltage independent Cl- channels and 
Ca2+ -dependent K+ channels. The loss of KCl leads to the loss of water through osmosis and the 
retraction of the rear end of the cell. The swelling of the leading edge of the cell is controlled by voltage 
gated sodium channels, flow of Na+ into the cell causes the uptake of water through osmosis and the 
swelling of the cell. Similary to retraction (C) ramification is the result of shrinkage caused by the efflux of 
Cl- through CLIC1 channels and the loss of water, forming the characteristic processes of the ramified 
cell.  
(D) Activation from ramified to ameboid, due to cation channels in the cell body and that result in influx of 
cations so water enter the cell leading to the cell body swelling. K+/Cl- co-transporters in the processes 
lead to KCl efflux, decreasing the osmolarity so water leaves, and the processes retract.  
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1.1.5 PHENOTYPES OF MICROGLIA 
Microglia can further be subdivided based on their phenotype, generally either 
ramified or ameboid (Figure 1.4). Ameboid cells are the first phenotype to colonise 
the developing brain from their monocyte precursors, where they proliferate in situ 
throughout gestation and development before differentiating into the mature ramified 
cells during the postnatal period (Perry et al. 1985). The ameboid cells are rounded 
with extremely short processes, highly motile and capable of phagocytosis, 
functioning as fully activated tissue macrophages (Rezaie & Male 2002). It is thought 
that these ameboid cells shape the evolving brain by phagocytosing the excess 
neurons produced during development (Killackey 1984). 
 
 
 
 
 
 
 
 
  ACTIVATION 
  MATURATION 
Figure 1.4. Microglial phenotypes 
Microglia can be seen in various phenotypic forms, from the activated rounded ameboid cell to the 
resting or surveying process laden ramified cell. Ameboid cells are able to mature into those of a 
ramified nature and ramified cells are able to undergo activation to an ameboid cell. 
Adapted from Kim & de Vellis (2005) 
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In the developed brain the ameboid cells give rise to an immune dampened version 
of microglia; the ramified microglial cells. The cell body becomes smaller and the 
processes increase in length and complexity (Davis et al. 1994). Since their 
proliferative capacity has ceased and motility decreased they survey the brain 
parenchyma through building, withdrawing and re-building their processes into new, 
unchecked areas. This enables the large microglial network to survey the entire 
milieu within only a few hours (Hanisch and Kettenmann 2007). 
The functionality of both phenotypes of microglia was confirmed through genome 
wide transcriptome analysis by Parakalan et al. (2012). They were able to conclude 
that ameboid microglia expressed genes required for the development of the 
nervous and immune system, as well as genes for cell migration; suggesting that 
they are the first to arrive during development and are also motile. Ameboid cells 
also have an active cell cycle with the expression of myc genes and cyclinA2, B2 
and D1, so are proliferative but are also able to undergo apoptosis with high 
expression of caspase genes; casp2 and casp3. Conversely the immune dampened 
ramified cells show high levels of expression of genes involved in myelination, 
antigen presentation and were also shown to express CamK2, Grin2c and S100b all 
of which are involved in the modulation of synaptic transmission (Parakalan et al. 
2012). 
The processes of monocyte maturation through the transient ameboid state to the 
down regulated brain macrophage, the ramified cell and their re-activation to an 
immune competent cell is still not fully understood. It has been suggested that the 
transition is aided by differential septin expression, where ameboid cells express 
Sept7 compared to the expression of Sept4 in ramified cells. The ramification of 
  1.Introduction 
21 
 
microglia could also be caused by the expression of Lsp1 found in ramified cells but 
absent in the ameboid state. Over-expression of Lsp1 in highly motile melanoma cell 
lines was shown to dramatically decrease motility and lead to the formation of hair 
like projections as seen in the transition from motile rounded ameboid cells to 
dormant spiky ramified cells. 
 It is known however, that microglia are maintained in a quiescent, ramified state 
through the ‘calming’ influence of receptor ligand pairs situated on the membranes of 
neurons and microglia. Interactions between these pairs; neuronal CD200 and 
microglial CD200-R and neuronal CX3CR1 and microglial CX3CR1-R, dampen 
microglial activation (Vilhardt 2005). Disruptions between these signals, due to 
neuronal damage, cause activation of ramified cells to an activated, ameboid 
phenotype. Other activating factors have been discovered, such as IFN-γ, LPS and 
tPA, although the mechanism behind their function has yet to be found (Suzumura et 
al. 1991). The same study by Suzumura et al. (1991) showed that rod shaped 
microglial cells found around lesioned areas, with a presumptively active role, did not 
produce superoxide anions but did incorporate BrdU to a greater extent than the 
other phenotypes, suggesting that the rod shaped cells are the proliferative 
intermediate phenotype of microglia and this phenotype could be induced through 
the addition of GM-CSF. 
Another phenotype of microglia has also been suggested, although not found in the 
normal healthy brain. These are the giant multinucleated cells found during viral 
infections in particular HIV-1 and is considered a hallmark of the immunodeficiency 
virus. Their function is even less well understood than the ramified and ameboid 
phenotypes, with suggestions ranging from conglomeration of several activated cells, 
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collection of exhausted cells with no beneficial or detrimental function to an abnormal 
cell produced as a by-product of the disease state (Davis et al. 1994). 
1.1.6 MICROGLIAL FUNCTION IN HEALTH AND DISEASE 
Although microglia are the resident immune cells of the brain, they have a vast range 
of functions beyond those of pathogen removal. They are able to secrete cytokines 
IGF-1, NGF and BDNF, in a glutamate dependent manner, promoting 
oligodendrocyte functioning and neurogenesis (Liang et al. 2010). In an anti-
inflammatory role they can secrete IL-10 and TGFβ which induce a neuroprotective 
effect on neurons, as shown in traumatic injury and stroke models (Neumann et al. 
2006). Conversely they can also secrete pro-inflammatory cytokines; IL-1β and 
TNFα, which are thought to be neurotoxic.  
Phagocytosis by microglia is essential for the maintenance of brain homeostasis, by 
removing cellular debris as well as pathogens. Phagocytosis occurs subsequent to 
chemotaxis to the site of concern due to the presence of two receptor types; Toll-like 
receptors (TLRs) and phosphatidylserine (PS) recognising receptors (Schiegelmich 
et al. 2011). TLRs recognise microbial patterning and lead to phagocytosis of 
pathogens along with the secretion of pro-inflammatory cytokines (Lehnardt 2010). 
PS recognising receptors such as TREM2, recognise PS ‘eat-me’ signals on 
apoptotic cells resulting in anti-inflammatory phagocytosis with the release of IL-10 
and TGFβ (Neher et al. 2011; Schiegelmich et al. 2011). The phagocytic function of 
microglia is also important in structuring synapses. The complement component C3 
is expressed on all synapses and microglia enabled with the C3 receptor target 
certain synapses for removal in order to organise neuronal connections (Martin et al. 
2007). 
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Besides their physiological functions microglia have been implicated in pathological 
states including many neurodegenerative diseases, from those specifically with 
immunological links such as HIV associated neurocognitive disorder (HAND) and 
multiple sclerosis to those without; Parkinson’s and Alzheimer’s disease. 
The HIV virus targets mononuclear cells, such as monocytes and macrophages 
along with CD4+ T cells (Deeks 2011). Since microglia are derivatives of primitive 
monocytes they are also a target of HIV once it crosses the BBB (Strazza et al. 
2011). The result of microglia infection is an innate immune response and the 
production of neurotoxic factors that lead to both the dementia symptoms and 
neuropsychiatric disorders found in HAND (Deeks 2011).  
Multiple sclerosis is an autoimmune disease that leads to attack on the myelin 
sheaths of neurons in the CNS. It has been known for many years that TH17, TH1 
and B cells have major pathological roles in the progression of the disease, but more 
recently a microglial role emerged in the EAE mouse model of the disease (Priller et 
al. 2001). Here it was found that microglia played two important roles in the disease; 
antigen presentation to T-cells and secretion of IL-6, IL-23, IL-1β and TGFβ aiding 
the differentiation and activation of TH17 cells (Saijo and Glass 2011). 
In Parkinson’s disease there is a characteristic loss of dopaminergic neurons from 
the substantia nigra and accumulations of α-synuclein which leads to both 
astrogliosis and microglial activation (Mattson 2000). The activation of microglia 
occurs through the Pattern Recognition Receptors (PRRs) and purinergic receptors 
leading to the secretion of toxic cytokines leading to neuronal loss.  
Similarly, Alzheimer’s disease results in the loss of neurons in the frontal cortex and 
limbic system as a result of protein aggregations; extracellular aggregations of 
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Amyloid β (Aβ) and intracellular tau tangles created from hyperphosphorylated tau. 
Microglial activation results through TLRs, NLRP3 and RAGE in response to the 
aggregations, leading to secretion of cytotoxic cytokines and neuronal death but 
microglia can also phagocytose aggregated Aβ in a neuroprotective role (Heneka et 
al. 2010). 
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1.2 ALZHEIMER’S DISEASE 
1.2.1 ALZHEIMER’S DISEASE 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that was first 
noted by German neurologist Alois Alzheimer, after whom the disease is named. AD 
leads to neuronal atrophy in the frontal cortex and many areas of the limbic system 
including the hippocampus and amygadala (Findeis 2007; Heneka 2006). These 
areas are most associated with memory, learning and emotions, the abilities most 
affected in sufferers of the disease. Along with the characteristic symptoms involving 
memory defects, many sufferers also experience problems with speech, obsessive 
behavior is established, along with incontinence and disturbed sleep. These 
symptoms develop in advanced stages of the disease into dysphagia accompanied 
by loss of appetite and consequent weight loss. This can coincide with hallucinations 
and an increase in violent behavior that is worsened at night. Severe AD patients are 
also more prone to infection due and as such death is often attributed to factors 
other than AD. Medications currently prescribed in the UK focus on delaying the 
development of AD to minimize the severity of symptoms for as long as possible, 
most commonly acetylcholine esterase inhibitors; donepezil, galantamine and 
rivastigmine, are prescribed in the early stages of the disease and NMDA-type 
glutamate receptor inhibitor memantine is given during the latter stages, but there is 
no current cure.  
AD is considered by many a disease of old age, but sufferers can be divided into two 
groups depending on age at onset. Early onset or familial AD affects an individual 
prior to old age, and is associated with genetic mutations situated within genes 
coding for elements of the Amyloid Precursor Protein (APP) processing pathway 
(Tanzi and Bertram 2001). More common are afflictions later in life, subsequent the 
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seventh decade of life, and are classed as late or sporadic onset AD (Simard et al. 
2006). In these cases an accumulation of risk factor gene variants, environmental 
influences and age play the biggest roles. 
1.2.2 MECHANISMS OF ALZHEIMER’S DISEASE 
The mechanisms that underpin onset and progression of Alzheimer’s disease are not 
fully understood in the sporadic onset cases, what is known is that there are two 
hallmarks of the disease; Amyloid plaques and Neurofibrillary tangles, whose 
relationship with each other and with AD are not, as of yet, clear.  
Much insight into the amyloid hypothesis has come from studies involving early 
onset sufferers, where genetics play the most fundamental role. From these studies 
it was found that many of the genetic mutations revolved around the production of 
Amyloid Precursor Protein (APP) and it’s processing via the Presenillin (PSEN) 1 
and 2 γ-secretase components (Tanzi and Bertram 2001). The physiological function 
of APP is thought to be in the formation of synapses, around which the protein is 
localized (Priller et al. 2006). In the healthy brain APP is digested by α-secretase, a 
non-amyloidogenic route, which results in soluble APP (sAPP) production. 
Alternatively β-secretase and subsequent γ-secretase digestion results in the release 
of Aβ, the amyloidogenic path (Figure 1.5) (LaFerla et al. 2006). The formation of AB 
is not, on its own, pathological. It is released constantly in non-AD individuals but the 
difference lays in the rate of clearance, which physiologically equals the rate of 
production. It is only when the balance is tipped that Aβ will aggregate. A slowing in 
Aβ clearance is seen with age; hence the age relation to AD, but the production of 
Aβ can also increase through mutation so that there are greater amounts of Aβ 
present than can be cleared. These aggregations form senile or amyloid plaques that 
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are composed of, in the main, two forms of Aβ, Aβ40 and Aβ42. The difference 
between each fragment lies in the number of amino acid residues, with the latter 
being more hydrophobic and most inclined to aggregate.  
The alternative hypothesis is that of neurofibrillary or tau tangles (NFTs). Tau is an 
intracellular protein associated with the microtubules and functions in their 
stabilization (Cleveland et al. 1977). In Alzheimer’s disease there is hyper-
phosphorylation of Tau leading to the formation of paired helical filaments (PHL) 
which result in NFTs. The underlying cause of the phosphorylation can be explained 
by either an imbalance in the protein kinases and phosphatases in the cell or by a 
mutation in the MAPT gene that encodes the tau protein (Pittman et al. 2006). The 
aggregations accumulate, destabilizing the microtubules and disrupting neuronal 
axon transport, making the cell less functional until the neuron ultimately dies, aiding 
AD progression. 
The Amyloid Hypothesis has been disputed as the cause of AD and instead more 
emphasis has been placed on the NFTs as the underlying mechanism of disease. 
However, both aggregations occur during disease progression and which precedes 
the other is still unclear. It is also suggested that both amyloid plaques and NFTs are 
required for the onset of AD. But this said, amyloid plaques have been found in the 
postmortem brains of non-AD sufferers and NFTs alone are seen in familial pre-
senile dementia cases (Sumi et al. 1992).  
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Figure 1.5. APP Processing and Aggregation 
Amyloid Precursor Protein (APP) can be acted upon by either α – secretase or β – secretase in a non 
– amyloidogenic or amyloidogenic process. In the non – amyloidogenic process, APP is cleaved by α 
– secretase (1) to release sAPPα from the membrane (2). sAPPα contains the C-terminal region of 
the β-Amyloid protein meaning that subsequent cleavage will not result in a protein fragment capable 
of aggregation. During the amyloidogenic process though APP is cleaved by β – secretase (3) 
resulting in the release of the soluble sAPPβ fragment from the membrane. The protein remaining in 
the membrane is cut by γ – secretase (4) and β – Amyloid (Aβ) is released (6). Due to its small size 
and hydrophobic nature the only stable conformation available for the protein is for it to aggregate 
with other Aβ fragments forming dimers (7) then oligomers (8) and finally plaques (9), which are the 
characteristic feature of AD.  
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Thus the intimate link between aggregated Aβ and Tau can be explained through 
one of three theories. 1) Amyloid aggregation, due to a slowing of Aβ clearance with 
age, causes an imbalance between intracellular protein kinases and phosphatases 
that leads to tau hyper-phosphorylation and ultimately the formation of NFTs. 2) 
Mutations in the MAPT gene cause an increased likelihood of hyper-phosphorylation 
and tangle formation that disrupts the neuronal axon transport system, along which 
APP is transported to the synapses where it functions, so the cleavage products of 
the APP are now in close proximity increasing the chance of aggregation and plaque 
formation, as well as disturbing synapse function. 3) Both aggregations could occur 
independently but when amyloid plaques and NFTs are in the same susceptible 
region of the brain, the cortex or limbic system, their effects synergise leading to the 
symptoms associated with AD. This latter hypothesis gives the possibility that both 
aggregations are separate entities and also can be of distinct origin, whether genetic 
or environmental in nature, but are  able to propagate each other in the case of AD. 
1.2.3 MICROGLIAL ROLES IN ALZHEIMER’S DISEASE 
The role of the immune system in AD progression has been speculated upon for 
many years, as mentioned both Amyloid plaques and NFTs can be found in the 
brains of non-AD patients and many of the classical AD symptoms cannot be 
explained solely by aggregation. As well as this treatment of AD sufferers with Non-
Steroidal Anti-Inflammatory Drugs (NSAIDs) and the immunization of patients 
against Aβ had beneficial consequences on halting memory loss (Mcgeer et al. 
1996; Wisniewski and Konietzko 2008). The possible benefits of antibody therapy 
has also been speculated upon, there is much evidence that suggests the immune 
system plays a major role in this disease.  
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As mentioned, the immune cells of the brain are microglia and they, like 
macrophages, have many cell surface receptors for the detection and presentation of 
foreign proteins to T cells. Amongst these receptors is a receptor complex 
comprising of CD36, CD47 and β1-integrin for the recognition of fibrilar Aβ (fAβ) 
(Bamberger et al. 2003). This complex along with CD14 and Toll-Like Receptors 
(TLRs) 2 and 4 are responsible for the activation and motility of microglia, in their 
response to senile plaques (Reed-Geaghan et al. 2009). It was recently shown that 
TREM2, a mononuclear phagocyte surface receptor expressed by microglia and is 
involved in the phagocytosis of apoptotic cells and the inhibition of inflammatory 
responses, has six variants (Guerreiro et al. 2013). The presence of these variants 
drastically increase the risk of AD through impaired TREM2 function leading to a 
decrease in phagocytosis and an increase in inflammation, which not only adds 
evidence to the theory of inflammation in AD but also links microglial function in the 
disease onset and progression.  
Further GWAS studies highlighted HLA-DRB1, HLA-DRB5, ABCA7 and CD33 as 
comprising variants that increase the risk of AD (Lambert et al. 2013; Rosenthal and 
Kamboh 2014). All of these play a role in the immune system with the HLA genes 
encoding for the MHCII gene, vital for the presentation of antigens on lymphocytes 
and macrophages as well as microglia. Genetic variants of the HLA-DRB genes 
could lead to a down regulation of MHC-II leading to an increase in cytotoxicity and 
an increase in inflammation (Butovsky et al. 2005). ABCA7 is an ATP-binding 
cassette gene involved in lipid transport. It was noted that the expression of ABCA7 
was amongst the highest in the microglia within the hippocampus where it functions 
to aid the phagocytosis of Aβ (Kim et al. 2005). Variants of the gene, as seen in AD, 
would result in less Aβ clearance and increased plaque formation. CD33 encodes for 
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a sialic acid binding immunoglobulin-like lectin, which is able to initiate cell-cell 
interactions in immune cells. Studies have shown that there is an increase in the 
expression of CD33 on the microglia of AD brains, where it inhibits the uptake of 
Aβ(1-42) and thus plaque clearance (Griciuc et al. 2014). 
The GWAS studies and the resultant risk factor genes associated with microglia 
highlight their two major functions with regard to AD; inflammation and phagocytosis 
and it is here that their role in AD in disputed (Figure 1.6). They are able to 
phagocytose and clear Aβ in a neuroprotective role but conversely they are also 
capable of secreting cytokines, such as TNFα, IL-4 and IL-1β, of which some are 
neurotoxic, in response to the senile plaque (El Khoury and Luster 2008). These 
cytokines are not only toxic to neurons but they are also able to influence the 
phagocytic capacity and thus the neuroprotective effect of the microglia themselves. 
IL-4 rich environments promote both the phagocytic and neurogenesis capacity of 
microglia whereas the presence of IL-1β, during inflammation, inhibits phagocytosis. 
Therefore newly invading microglial cells, from the bone marrow, may have a greater 
neuroprotective role in AD as they have not been subjected to the inhibitory IL-1β 
environment (Koeingsknecht-Talboo and Landreth 2005; Simard et al. 2006). 
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Figure 1.6. Microglial Roles in Alzhiemer’s Disease 
Microglia are able to contact and communicate with neighbouring neurons though the CX3CR1/CX3CL1 
receptor ligand complex, enabling microglia to verify the status of the neuron in their physiological role 
and retaining the ramified state. Microglia also have a SRA, CD36, integrin α6/β1, CD47 complex, which 
along with CD14 and TLR2 and 4, recognize and bind Aβ. This activates a three parallel cascades 
beginning with Src activation followed by the activation of i) NFKB leading to the production of pro-
inflammatory cytokines IL-Iβ and TNFα, ii) p38 and the production of reactive oxygen species from 
NADPH Oxidase and iii) Vav, followed by Rac and the phagocytosis of Amyloid plaques. The former 
processes result in apoptosis of the surrounding neurons, aiding AD progression, whereas the latter 
results in the clearance of the aggregations and the decrease of amyloid load. 
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1.2.4 CURRENT MODELS OF ALZHEIMER’S DISEASE 
Although mouse models are by far the most common animal model of AD, other non-
mammalian models also exist such as; those of the fruit fly, Drosophila sp, and worm 
Caenorhabditis elegans (Chan & Bonini 2000; Link 2005). Mouse models of AD have 
been largely based on the genetic disturbances in early onset disease rather than 
the accumulation of risk factors that underpins the more common sporadic form. 
There are transgenic models (PDAPP, Tg2576, APP23, TgCRND8 and J20), 
expressing the mutant human forms of the APP processing gene, to knock-in and 
knock-out models whereby the APP processing enzyme γ-secretase activity and 
gene expression are affected respectively (Reviewed in (Mineur et al. 2005)) .  
Work on PDAPP mice and m266 antibody treatment to decrease amyloid burden 
and reverse memory deficits paved the way for the bapineuzumab antibody clinical 
trial some ten years later (Dodart et al. 2002). The Semagacestat γ-secretase 
inhibitor development and phase III clinical trials in 2010 were undoubtedly 
influenced by experiments carried out on mouse models such as those by Comery et 
al. (2005) where inhibition of γ-secretase by N-[N-(3,5-difluorophenacetyl)-L-alanyl]-
S-phenylglycine-t-butylester (DAPT) in Tg2576 mice showed improved fear 
conditioning and thus better hippocampal function. Although none of these clinical 
trials were successful as there was no significant difference between drug treated 
and placebo treated patients, models of AD are vital for the emergence of new 
therapeutic strategies. 
Animal models, even non-mammalian models, of the disease have proved valuable 
in the study of AD in earlier years and, mouse models in particular, will always have 
their place in whole animal drug testing but however close the mouse model comes 
to paralleling AD onset and progression such models will never serve as the best 
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model for a human disease. The alternative lies in modeling a human disease with 
human cells in vitro, with the advent of Induced pluripotent Stem cell (IPS) 
technology, fibroblasts from AD sufferers can be re-programmed to stem cell like 
cells and then re-differentiated into any cell type of the body, enabling Alzheimer’s 
specific and even patient specific culture models to be created. 
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1.3 STEM CELLS 
1.3.1 HUMAN EMBRYONIC STEM CELLS 
Stem cells can be classified as either adult stem cells or embryonic stem cells 
(hESCs). The former are generally multipotent, and can give rise to only a limited 
range of cell types i.e. hematopoietic stem cells that are committed to producing only 
blood cells. hESCs, on the other hand are pluripotent, that is, they are taken from the 
inner cell mass of a blastocyst and are capable of differentiating into any of the 
various cell types within the three germ layers; endoderm, mesoderm or ectoderm. 
Although their differentiation capacity is vast, pluripotent hESCs are unable to 
differentiate into extra-embryonic tissue, which is the role of the outer trophoblast 
(Figure 1.7).  
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Figure 1.7. Totipotency, Pluripotency, Multipotency and Unipotency in 
Embryogenesis 
The fertilized ovum or zygote is totipotent (able to form embryonic and extra-embryonic tissue). It 
undergoes multiple mitotic cleavages to result in the formation of a spherical mass of 16 cells, the 
morula. The final cleavage creates 128 cells that form the blastocyst. The blastocyst is composed 
of the outer trophoblast and the pluripotent inner cell mass. Before gastrulation the trophoblast 
differentiates into the outer syncytiotrophoblast and the inner cytotrophoblast, which is responsible 
for the formation of the placenta. Several inner mass cells quickly differentiate into endoderm cells 
that form the space for the yolk sac, which ultimately becomes the amniotic cavity. The floor of the 
cavity is formed composed of the embryonic disk. The morphology of the disk changes from oval 
to pear shaped and there is the formation of the primitive streak, formed by a thickening of the 
ectoderm. At the sides of the primitive streak the mesoderm cells differentiate. These three layers 
are the multipotent progenitors responsible for the formation of unipotent embryonic tissue. 
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During the 1980s it was shown by both Martin and Evans, independently, that the 
inner cell mass can be cultured in vitro. Many groups had previously struggled to 
achieve the same result due to the lack of inner cell mass cells within the blastocyst 
at the time of harvest. To counter this Evans et al. (1981) delayed the implantation of 
blastocysts for several days, allowing inner mass cells to accumulate, by increasing 
progesterone levels and removing the ovaries post-fertilisation. Martin (1981) used a 
carcinoma cell line to condition media and cultured inner cell mass cells from late 
blastocysts on feeder layers. Both methods resulted in the formation of colonies that 
were comparable to an embryonic carcinoma cell and were capable of forming 
teratomas containing all three germ layers, indicative of pluripotent cells. More than a 
decade later hESC lines were derived, using cleavage stage embryos that were 
created via in vitro fertilization. Methods similar to those carried out by Evans et al. 
(1981) were used to initially form five different cell lines; H1, 13, 14, 7 and 9. The 
latter two lines were of a normal XX karyotype, whereas the remainder were of a 
normal XY karyotype. All the lines were positive for the surface markers; SSEA3, 
SSEA4, TRA-1-60 and TRA-1-81, which are known to also characterize the ES cells 
from non-human primates (Thomson et al. 1998). 
Since their discovery the mechanisms behind the maintenance of pluripotency in 
ESCs has been a source of interest. It is now known that ESCs require a feeder 
layer of irradiated mouse embryonic fibroblasts (MEFi) in order to sustain 
pluripotency and in feeder-free conditions mESCs require the addition of LIF to 
maintain an undifferentiated state (Williams et al. 1988). LIF functions through a 
JAK/STAT pathway that utilizes the LIF-R and gp130 cell surface receptors. 
Activation of these receptors ultimately leads to the dimerisation of STATs, 
predominantly STAT3, and their translocation to the nucleus leading to gene 
  1.Introduction 
38 
 
transcription (Niwa et al. 1998). Interestingly one binding element of this STAT3 is 
within the Nanog promoter region leading to up regulation of this gene (Suzuki et al. 
2006). Although important in mESC maintenance the LIF/STAT3 pathway, 
fundamental for diapause in the mouse embryo, is not activated under the 
maintenance conditions for hESC pluripotency where bFGF and soluble factors from 
MEFs are required for the activation of TGFβ signaling through Smads (Dahéron et 
al. 2013).  
Nanog, along with Oct4 and Sox2 are indispensible in the regulation of the inner cell 
mass and are critical in early cell fate decisions, where the loss of Oct4 for example 
leads to the inner cell mass reverting to trophoblast and over-expression leading to 
the cells joining the extra embryonic endoderm lineage (Loh et al. 2006; Suzuki et al. 
2006). Nanog has also been shown to bind Smad1 and inhibit BMP induced 
differentiation, confirming the importance of the TGFβ signaling through Smad2/3 in 
the maintenance of pluripotency (Suzuki et al. 2006; James et al. 2005). 
These groundbreaking discoveries regarding ESCs and maintaining their pluripotent 
state and the understanding of signaling pathways that lead to their differentiation 
enabled the in vivo differentiation of cells to be mimicked in vitro. This allowed a cell 
type of interest to be created, through chemically defined media, environmental 
conditions and through exogenous over-expression of the required genes. This 
inherent plasticity in hESCs has proved most useful in modeling both tissues and 
diseases, but for the latter hESCs have their limitations, in that they do not contain 
the problematic features of the cells afflicted by the disease such as genetic 
mutations. 
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1.3.2 IN VITRO DIFFERENTIATION POTENTIAL OF ES CELLS 
An important marker of pluripotent embryonic stem cells is their ability to differentiate 
into any of the three germ layers. This capacity has been harnessed by many groups 
in order to create a supply of the cell type of interest. An example of ectodermal 
differentiation is the development of protocols for the production of neural lineage 
cells. The addition of retinoic acid, NGF and EGF to cultures or culturing in the 
presence of stromal cell lines or on matrigel all enhance the neural differentiation 
potential of ES cells and such techniques have yielded dopaminergic neurons to 
create a Parkinson’s disease model (Freed and Greene 2001). 
Groups have also succeeded in the formation of blood cells by culturing cystic 
embryoid bodies that form the blood islands from which blood cells emanate during 
development (Karlsson et al. 2008). Feeder layers have again been important in the 
mesoderm differentiation and OP9 cells are common place for the development of all 
types of haematopoietic cells (Lim et al. 2013). Finally endoderm differentiation of 
hESCs has been able to yield some insulin secreting cells with the characteristics of 
pancreatic docrine cells, which holds great hope for the treatment of diabetes (Kroon 
et al. 2008). 
1.3.3 INDUCED PLURIPOTENT STEM CELLS  
Once a somatic cell has reached terminal differentiation, they no longer have the 
capacity to differentiate and take on the role of the mature cell type. But several 
years ago Takahashi et al. (2007), produced the first human induced pluripotent 
stem cells (iPSCs), which enabled terminally differentiated somatic cells to be ‘re-
programmed’  to a stem cell like state. This was achieved by the transfection of 
pluripotency genes; Oct4, Sox2, c-Myc and Klf4, into human fibroblasts, which 
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reverted to stem cell morphology in less than four weeks (Takahashi et al. 2007). 
The cells could then be treated in the same way as a hESC allowing subsequent 
differentiation to any other cell type allowing the formation of disease specific models 
and with patient specific cells. 
1.3.4 EMBRYONIC AND INDUCED PLURIPOTENT STEM CELLS IN DISEASE 
With the advent of hESCs dawned a new wave of excitement due to the endless 
supply of cells of interest and the possibility of transplantation to cure the incurable? 
Pathological conditions such as myocardial infarction, vascular damage, neuro-repair 
and diabetes have been improved by introducing ES cells into mouse models of 
these diseases.  
There have been improvements in rat models of myocardial infarction on 
transplantation of beating ES-derived cells cardiomyocytes (Min et al. 2002). 
Vascular structures have been made by the isolation of PECAM-1+ cells from hES 
endothelium differentiation and seeding on scaffolds that are then grown 
subcutaneously in SCID mice (Levenberg et al. 2002; Putnam and Mooney 1996). 
Brustle et al. (1997 and 1999) made two discoveries upon differentiation of ES cells 
into neuronal cells and also glial precursors. The former cells were shown to be 
functional and differentiate into region specific cells when transplanted into the 
developing mouse brain, whilst the latter were able to reverse the pathological 
phenotype found in the demyelinating disease Pelizaeus-Merzbacher. Positive 
strides towards Parkinson’s treatment were made in rat models of the disease when 
partial recovery was witnessed upon transplantation of mES-derived dopaminergic 
neurons (Kim et al. 2002). Unfortunately this was not the outcome when neural cells 
from human fetal brain were introduced into Parkinson’s patients. There was no 
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significant improvement in disease and some two years later many developed 
dyskinesia (Freed et al. 2001). Although largely unsuccessful this study did prove 
that these embryonic neural progenitors could survive in a human host, which none 
the less shows that there is an impending for the future for ES transplantation. Taken 
together all these studies show that ES cells have a potential to successfully model 
human disease and ultimately aid recovery through drug development and 
transplantation genetically modified ES-derived cells. 
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1.4 AIMS 
A protocol for deriving microglia from human embryonic stem cells has, as of yet, not 
been published but methods for their derivation from mouse embryonic stem cells 
has been successful. Groups have utilised the five step method devised by Lee et al. 
(2000) for the differentiation of neural cells from ES cells. Tsuchiya et al (2005) 
produced a neuronal culture via this method and then by the addition of GM-CSF 
Mac1+ cells were formed and isolated for microglial culture. Napoli et al (2009) and 
Buetner et al (2010) both utilised the five step method to first create neuroectoderm 
and then a mixed brain culture from which Napoli et al isolated the IBA-1+ cells 
whereas Buetner et al isolated the myeloid precursors and cultured further to 
differentiate to microglia. All these methods are indeed very similar and require 
differentiation to a neuronal lineage prior to the formation of microglia and all use 
large number of growth factors and expensive medium to achieve their goal.  
Forsberg et al. (2008) and others including Sievers et al. (1994) produced microglia 
from monocytes. A logical step since microglia are most likely derivatives of 
monocytic cells. Forsberg et al. (2008) was able to reprogram murine adult neural 
stem cells to monocytes by the over-expression of the myeloid transcription factor, 
PU.1. These were then transplanted into mouse brain and further differentiated into 
microglia due to the influence of the surrounding cells. Along the lines of 
environmental influence Sievers et al. (1994) showed that it was possible to create 
microglial-like cells from blood monocytes and splenic macrophages by co-culturing 
them with astrocytes, they also found that direct contact with astrocytes was 
unnecessary and using medium conditioned by astrocytes functioned just as well 
indicating that factors secreted by astrocytes are key in the transition from monocyte 
to microglia.  
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As monocyte to microglia transition is relatively straightforward in the case of 
astrocyte conditioned medium then a method that includes hES to monocyte 
followed by microglia transition would seem useful. Many of the published methods 
for the production of haematopoietic cells are growth factor, and so cost, intensive. 
Evseenko et al. (2010) used a basal induction medium containing VEGF, bFGF, 
BMP4 and Activin A to induce mesoderm followed by their culture on OP9 feeder 
cells to result in the differentiation of mesoderm to haematopoietic cells. Chadwick et 
al. (2003) cultured EBs in a differentiation medium that contained six growth factors; 
SCF, Flt3-ligand, IL-3, IL-6, GM-CSF and BMP4 for haematopoietic commitment. 
One method that differed from the growth factor demanding protocols was that of 
Karlsson et al. (2008), where EBs are cultured in the presence of bFGF and plated 
down using medium containing only MCSF and IL3 to form ‘factory’ like structures 
that result in the formation on non-adherent monocytic cells.  
The definitive aim of the project is to devise a protocol for the differentiation of 
hESCs to microglial-like cells. Since we have established protocols for the 
differentiation of hESCs to neural precursors and the over-expression of PU.1 in the 
work by Forsberg et al. requires little growth factor intervention this also poses an 
attractive route to monocyte formation.  
A second strategy in the effort to differentaitate hESCs to monocytes is a method 
similar to that of Karlsson et al. (2008) and the more recent adaptation of that work 
by van Wilgenburg et al. (2013). These studies show that monocytes can be 
produced from hESCs and IPSCs with minimal growth factors. This said, the cell 
lines available for differentiation in this project differ from those used previously. 
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For the final differentiation step to microglial-like cells, the ES-derived monocytes will 
be cultured in astrocyte conditioned media (ACM) to mimic the environmental cues 
that bombard monocytes that cross the BBB in vivo, and has been described by 
Sievers et al. (1994). Once the protocol is established the functionality of the 
resulting microglial-like cells will be examined through phagocytosis, chemotaxis and 
cytokine secretion. 
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2.  MATERIALS AND MET HODS 
2.1 MATERIALS 
2.1.1 CELL CULTURE REAGENTS 
 Cell Lines 
Name Source 
H9 hESCs WiCell 
THP-1 Monocytes Dr. Dipak Ramji, Cardiff University 
 
 MEF Media 
Components Amount Company (Cat #) 
DMEM GlutaMAX 450ml  GIBCO (31965080) 
Fetal Bovine Serum 
Penicillin/Streptomycin 
(5000U/5000μg) 
10% (50ml) 
50U/50µg 
(5ml) 
 GIBCO (10439024) 
GIBCO (15070063) 
 
 H9 Media 
Components Amount Company (Cat #) 
Knockout DMEM 425ml  GIBCO (10829018) 
Knockout Serum Replacement 
Non-Essential Amino Acids 
L-Glutamine (200mM) 
Penicillin/Streptomycin 
(5000U/5000μg) 
Β-Mercaptoathanol 
FGF2 
15% (75ml) 
1% (5ml) 
2mM (5ml) 
50U/50µg 
(5ml) 
0.1mM (3.5μl) 
10ng/ml 
 GIBCO (10828028) 
GIBCO (11140035) 
GIBCO (25030024) 
GIBCO (15070063) 
 
Sigma (M3148) 
Peprotech (100-18B) 
 
 
 XVIVO Factory Media 
Components Amount Company (Cat #) 
XVIVO 15 media 500ml  Lonza (BE04-418) 
L-Glutamine (200mM) 
Penicillin/Streptomycin 
(5000U/5000µg) 
B-Mercaptoethanol 
2mM (5ml) 
50U/50µg 
(5ml) 
50μM (1.75μl) 
 GIBCO (25030024) 
GIBCO (15070063) 
 
Sigma (M3148) 
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 XVIVO Factory Complete Media 
Components Amount Company (Cat #) 
XVIVO Factory Media 50ml   
M-CSF 
IL-3 
100ng/ml 
50ng/ml 
 Miltenyi (130-096-491) 
Miltenyi (130-093-909) 
 
 Monocyte Maintenance Media 
Components Amount Company (Cat #) 
RPMI1640 ( No Glutamine) 450ml  GIBCO (31870025) 
Fetal Bovine Serum 
L-Glutamine (200mM) 
Penicillin/Streptomycin 
(5000U/5000µg) 
50ml 
2mM (5ml) 
50U/50µg 
(5ml) 
 GIBCO (10439024) 
GIBCO (25030024) 
GIBCO (15070063) 
 
 ADF Media 
Components Amount Company (Cat #)                                              
Advanced DMEM/F12 (1:1) 500ml  GIBCO (12634028) 
CD Lipid Concentrate 
L-Glutamine (200mM) 
Insulin 
Transferrin 
B-Mercaptoethanol 
Penicillin/Streptomycin 
(5000U/5000µg) 
5ml 
2mM (5ml) 
14μg/ml 
7.5μg/ml 
0.1mM (3.5μl) 
50U/50µg  
(5ml) 
 GIBCO (11905031) 
GIBCO (25030024) 
Sigma (I6634) 
Sigma (T8158) 
Sigma (M3148) 
GIBCO (15070063) 
  
 ADF/SB/LDN (EB Culture) 
Components Amount Company (Cat #)                                              
ADF media 50ml   
SB431542 
LDN 193189 
10µM 
0.5µM 
 AbCam (ab120163) 
Stemgent (04-0019) 
   
 
 ADF/FGF (Adherent Rosette Culture) 
Components Amount Company (Cat #)                                              
ADF media 50ml   
FGF2 5ng/ml  Peprotech (100-18B) 
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 Astrocyte Conditioned Media 
Components Amount Company (Cat #) 
DMEM/F12 (1:1) 500ml  GIBCO (11330057) 
NeuroBrew 21 
L-Glutamine 
Penicillin/Streptomycin 
(5000U/5000µg) 
10ml 
20mM (5ml) 
50U/50µg 
 Miltenyi (130093566) 
GIBCO (25030024) 
GIBCO (15070063) 
 
 Other Cell Culture Reagents 
0.05% Trypsin (GIBCO 25300054) 
1x PBS pH7.4 (GIBCO 10010015) 
Accutase (PAA Laboratories L11-007) 
Antibiotic-Antimycotic (GIBCO 15240062) 
BD Matrigel (BD Biosciences 354230) 
Bovine Serum Albumin (Sigma A9418) 
Collagenase type IV (GIBCO 17104019) 
dH2O (GIBCO 15230188) 
DMSO (Sigma D2650) 
EmbryoMax 0.1% Gelatin Solution (Millipore ES-006-B) 
FBS (GIBCO 26140079) 
Ficoll-Paque PLUS (Stem Cell Technologies 07957) 
G418 Geneticin (GIBCO 1011-027) 
Human Plasma Fibronectin (Millipore FC010-10MG) 
Methylcellulose Media with GFs Minus EPO (RnD Systems HSC004) 
Mouse Laminin (Stemgent 06-0002) 
Poly-L-Lysine  Hydrobromide   (Sigma P5899) 
Trypan blue (Sigma T8154) 
Y-27632 Rho Kinase Inhibitor (Abcam ab120129) 
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2.1.2 SOLUTIONS, BUFFERS AND ENZYMES 
 1X TAE buffer 
Components Amount Company (Cat #) 
50x TAE Buffer 20ml  MPBIO (11TAE50X01) 
dH2O Up to 1 L   
 
 1% Agarose gel 
Components Amount Company (Cat #) 
Agarose 
 
Safeview 
Guanosine 
1g 
 
250μl 
1mM 
 Melford Laboratories  
(MB1200) 
NBS Bio (NBS-SV1) 
Sigma (G6264) 
1xTAE Buffer 100ml   
 
 Orange G Loading buffer 
Components Amount Company (Cat #) 
Glycerol 
10X TAE 
Orange G 
25ml 
25ml 
0.175g 
 
 
Sigma (G9012) 
MPBIO (11TAE50X01) 
Sigma (O3756) 
 
 Platinum Taq PCR  
Components Amount Company (Cat #) 
cDNA from monocytes 
Primer Pair 
Platinum Taq Buffer (10x) 
MgSO4 (50mM) 
DMSO 
dNTPs (25mM) 
Platinum Taq - HF 
60ng 
0.5µl 
2.5µl 
1μl 
0.6μl 
1μl 
0.25μl 
  
MWG (See Below) 
Invitrogen (11304-011) 
Invitrogen (11304-011) 
Sigma (D9170)  
Promega (U1420) 
Invitrogen (11304-011) 
RNAse Free dH2O Up to 25µl  Ambion (AM9937) 
 
 Kanamycin LB Agar 
Components Amount Company (Cat #) 
LB 4g  Invitrogen (12780-052) 
Agar 
dH2O 
Kanamycin 
3g 
200ml 
50mg/ml 
 Invitrogen (22700-025) 
 
Sigma (K400) 
 
 Kanamycin LB Media 
Components Amount Company (Cat #) 
LB 
dH2O 
Kanamycin 
4g 
200ml 
50mg/ml 
 Invitrogen (12780-052) 
 
Sigma (K400) 
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 Restriction Digest Enzymes 
Enzyme     (Recognition Site (5’-
3’)) 
Company(Cat #) Supplied Buffer(s) 
BamHI – HF           (G^GATCC) NEB (R3136)  NEB 4 
EcoRI – HF            (G^AATTC) 
XhoI                       (C^TCGAG) 
AscI                       (GG^CGCGCC) 
SalI – HF               (G^TCGAC) 
AseI                       (AT^TAAT) 
BglII                       (A^GATCT) 
NEB (R3101) 
NEB (R0146) 
NEB (R0558) 
NEB (R3138) 
NEB (R0526) 
NEB (R0144) 
 NEB 4 
NEB 4 + BSA 
NEB 4 
NEB 4 
NEB 3 
NEB 3 
 
 Double Restriction Digest  
Components Amount Company (Cat #) 
DNA  5 -10μl   
5x Restriction Buffer (3/4) 
Restriction Enzyme (1) 
Restriction Enzyme (2) 
BSA 
dH2O 
5μl 
1μl 
1μ 
0.1μl 
Up to 25μl 
 NEB  (See Above) 
NEB  (See Above) 
NEB  (See Above) 
NEB  (See Above) 
GIBCO (15230-188) 
 
 T4 DNA Ligase Ligation 
Components Amount Company (Cat #) 
Vector: Insert 
T4 DNA Ligase Buffer (10x) 
T4 DNA Ligase 
dH2O 
1:3 
2µl 
1µl 
Up to 20µl 
  
NEB (M0202) 
NEB (M0202) 
GIBCO (15230-188) 
 
 
 4% Paraformaldhyde (PFA), pH 7-8 
Components Amount Company  (Cat #) 
Paraformaldehyde 5g  Sigma  (P5148) 
1x PBS (pH7.4) 
dH2O 
25ml 
50ml 
 GIBCO (10010-015) 
GIBCO (15230-188) 
 
 
 Immunocytochemistry Blocking Solution For External Markers 
Components Amount Company  (Cat #) 
Bovine Serum Albumin (BSA) 
Normal Serum (Goat/Rabbit) 
3% 
2% 
 Sigma  (A9418) 
Dako (X0907/X0902) 
1x PBS (pH7.4) Up to 50ml  GIBCO (10010-015) 
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 Immunocytochemistry Blocking Solution For Internal Markers 
Components Amount Company  (Cat #) 
Bovine Serum Albumin (BSA) 
Normal Serum (Goat/Rabbit) 
Triton X-100 
3% 
2% 
0.1% 
 Sigma  (A9418) 
Dako    (X0907/X0902) 
Sigma  (T8787) 
1x PBS (pH7.4) Up to 50ml  GIBCO (10010-015) 
 
 
 Histology - Sorenson’s Buffer, pH 6.8 
Components Amount Company (Cat #) 
KH2PO4 
Na2HPO4 
dH2O 
3.33g 
1.28g 
500ml 
 Sigma (P9791) 
Sigma (S3264) 
 
 
 Histology - 5% Giemsa  
Components Amount Company (Cat #) 
Giemsa Stain 2.5ml  BDH (35086) 
Sorenson’s Buffer Up to 50ml   
 
 Reverse Transcription (RT) Mix 
Components Amount Company (Cat #) 
RNA 1-10μl   
Random Primers (1/12 dilultion) 
dNTPS (10mM) 
First Strand Buffer (5x) 
DTT (10mM) 
RNAse Out 
RNAse-free dH2O 
SuperScript III 
1μl 
1μl 
4μl 
2μl 
1μl 
Up to 19ul 
1μl 
 Invitrogen (48190011) 
Invitrogen (18427013) 
Invitrogen (18080044) 
Invitrogen (18080044) 
Invitrogen (10777019) 
Ambion      (AM9937) 
Invitrogen (18080044) 
 
 
 QPCR Mix 
 
 
 
 
 
 
 
 
 
 
Components Amount Company (Cat #) 
cDNA 1μl   
Primer Mix (1/100 dilution) 
SYBR Green Master Mix (2x) 
RNAse-Free dH2O 
1μl 
10μl 
8μl 
 MWG (Section 2.1.3) 
Finnzymes (F-470L) 
Ambion (AM9937) 
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 Western Blot - 10% Acrylamide Gel (Resolving Gel)  
Components Amount Company (Cat #) 
30% Acrylamide/Bis (37.5:1) 3.3ml  BioRad (161-0158) 
1.5mM Tris pH8.8 
10% SDS 
10% APS 
TEMED 
ddH2O 
2.5ml 
100μl 
100μl 
20μl 
4ml 
  
 
Roche (10708976001) 
Sigma (L4390) 
Sigma (A3678) 
Sigma (T7024) 
 
 Western Blot  - Acrylamide Gel (Stacking Gel)  
Components Amount Company (Cat#) 
30% Acrylamide/Bis (37.5:1) 1.67ml  BioRad (161-0158) 
0.5mM Tris pH6.6 
10% SDS 
10% APS 
TEMED 
ddH2O 
2.5ml 
100μl 
100μl 
20μl 
5.83ml 
  
 
Roche (10708976001) 
Sigma (L4390) 
Sigma (A3678) 
Sigma (T7024) 
 
 Western Blot  - Running Buffer (10x) pH8.3  
Components Amount Company (Cat #) 
Tris Base 30.2g  Roche (10708976001) 
Glycine 
SDS 
ddH2O 
144g 
10g 
Up to 1L 
  
 
Sigma (G8898) 
Sigma (L4390) 
 
 
 Western Blot  - Transfer Buffer (1x)  
Components Amount Company (Cat #) 
Tris Base 3.03g  Roche (10708976001) 
Glycine 
Methanol 
 
ddH2O 
14.4g 
200ml 
 
Up to 1L 
  
 
Sigma (G8898) 
FisherScientific 
(M400017) 
 
 Western Blot Blocking Solution 
Components Amount Company (Cat #) 
Powdered Milk 5%  Marvel 
1x PBS (pH7.4) 
Tween 
50ml 
0.1% 
  
 
GIBCO (10010-015) 
Sigma (P9416) 
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2.1.3 PRIMERS 
PU.1 Amplification Primers (Purchased from MWG) 
Primer Forward Reverse 
PU.1 AACGGATCCATGTTACAGGCTGCAAAAT AACGGATCCTCAGTGGGGCGGGTGGCGC 
 
QPCR Primers (Purchased from MWG) 
Primer Forward Reverse 
Oct4 GCAGCTCGGAAGGCAGAT TGGATTTTAAAAGGCAGAGACTTG 
Nanog CAGCCCCGATTCTTCCACCAGTCCC CGGAAGATTCCCAGTCGGGTTCACC 
Flk1 GGCCCAATAATCAGAGTGGCA CCAGTGTCATTTCCGATCACTTT 
RUNX1 CTGCCCATCGCTTTCAAGGT GCCGAGTAGTTTTCATCATTGCC 
CD34 TGGACCGCGGCTTTGCT CCCTGGGTAGGTAACTCTGGG 
CD45 CATTTGGCTTTGCCTTTCTG TTCTCTTTCAAAGGTGCTTGC 
PU.1 CCAGCTCAGATGAGGAGGAG CAGGTCCAACAGGAACTGGT 
NG2 AGAAGCAAGTGCTCCTCTCG CCACTCAGCAGTCAGACCCT 
CD11c GGAAGACCCTTCTCCAAAGC CAGAGGAGCTGACAGCCTTC 
CD80 AGGGAACATCACCATCCAG CAAACTCGCATCTACTGGCA 
IBA-1 GCTGAGCTATGAGCCAAACC TCATCCAGCCTCTCTTCCTG 
IL-1B ACAGATGAAGTGCTCCTTCCA GTCGGAGATTCGTAGCTGGAT 
TNF-a CCCAGGGACCTCTCTCTAATC ATGGGCTACAGGCTTGTCACT 
Kir2.1 GGTTTGCTTTGGCTCAGTCG GAACATGTCCTGTTGCTGGC 
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NaV1.5 CATTTCAGGGCTGAAGACCA GGCAGAAGACTGTGAGGACC 
NaV1.6 GGCAATGTTTCAGCTCTACGC ATTGTCTTCAGGCCTGGGATT 
 
2.1.4 ANTIBODIES 
 Immunocytochemistry Antibodies 
1o Antibody (ICC)  Supplier (Cat #) Host Dilution 
Oct4  Santa Cruz (SC-5279) Mouse Mono (IgG2A) 1/100 
SOX2  Millipore (AB5603) Rabbit Poly (IgG) 1/200 
PU.1  Santa-Cruz (SC-352) Rabbit Poly (IgG) 1/50 
RUNX1  Abcam (ab61753) Rabbit Poly (IgG) 1/267 
FLK1  Abcam (ab2349) Rabbit Poly (IgG) 1/80 
CD34  Abcam (ab6330) Mouse Mono (IgG1) 1/100 
CD45  RnD (MAB1430) Mouse Mono (IgG1) 1/100 
CD11b  Abcam (ab8878) Rat Mono (IgG2b) 1/50 
IBA-1  Abcam (ab5076) Goat Poly (IgG) 1/100 
B-Tubulin III  Sigma (T8660) Mouse Mono (IgG2B) 1/400 
ZO-1  BD Bioscience (610966) Mouse Mono (IgG1) 1/500 
GLUT5  RnD (MAB1349) Mouse Mono (IgG2A) 1/100 
Aβ  Abcam(ab2539) Rabbit Poly (IgG) 1/100 
 
2o Antibody (ICC)  Supplier Dilution 
Alexa Fluor Goat Anti-Mouse IgG 488  Invitrogen (A11001) 1/400 
Alexa Fluor Goat Anti-Mouse IgG 594  Invitrogen (A11032) 1/400 
Alexa Fluor Goat Anti-Rabbit IgG 488  Invitrogen (A11034) 1/400 
Alexa Fluor Goat Anti – Rabbit IgG 594  Invitrogen (A11037) 1/400 
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 FACS Antibodies 
Conjugated Antibody   Company (Cat#) 
CD34 – PECy7   e-Bioscience (25-0349-42) 
CD45 – FITC  e-Bioscience (11-9459-42) 
CD11b - APC  e-Bioscience (17-0118-42) 
 
 Western Blot Antibodies 
 
 
 
 
 
 
 
 
 
 
 
 
Alexa Fluor Chicken Anti-Rat IgG 594  Invitrogen (A21471) 1/400 
Alexa Fluor Donkey Anti-Goat IgG 488  Invitrogen (A11055) 1/400 
1o Antibody (WB) Company (Cat#) Host Dilution 
Β-Actin Sigma (A2228) Mouse Mono (IgG2A) 1/10000 
PU.1 Santa-Cruz    (SC-352) Rabbit Poly (IgG) 1/200 
2o Antibody (WB) Company (Cat#) Host Dilution 
ECL α-Mouse  HRP GE Healthcare (NA931V) Mouse IgG 1/10000 
ECL α-Rabbit  HRP GE Healthcare (NIF824) Rabbit IgG 1/10000 
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2.1.5 CONSUMABLES 
 
 
 
 
 
0.2ml thin wall dome cap tube  (Alpha Labs LW2130AS) 
1.5ml plastic tube  (Alpha Labs LW2410) 
10 cm non-adherent culture plates  (Sterilin PDS-140-050F) 
10cm adherent culture plates (NUNC 150350) 
10μl, 20μl, 200μl, 1000μl pipette tips  (Fisher scientific FB781-00, 06,10,12) 
14 gauge needles  (Monoject 200011) 
15ml tubes  (Corning 430766) 
18mm (0.16mm Thickness) Glass Cover Slips (VWR 631-0153) 
20ml, 60ml eccentric tip syringes  (BD Bio 300613, 300866) 
24 well plates  (NUNC TKT-190-010Y) 
3.5cm culture plates  (NUNC IVF-150-255T) 
50ml tubes  (Corning 430897) 
5ml round bottom tubes  (BD Falcon 352058) 
5ml, 10ml, 25ml stripettes  (Corning CC109, CC114, CC116) 
6 well plates  (NUNC TKT-190-110E) 
6cm adherent culture plates  (NUNC TKT-110-0105) 
6cm non-adherent culture plates (Sterilin 101RT/IRR) 
Amersham Hybond – ECL  (GE Healthcare RPN203D) 
Cell Scraper (Corning 3008) 
Cryovials  (Fisher Scientific FB74414) 
Histobond Glass Slides 75x25x1mm  (RALamb E27.5HB) 
Low Profile 96 well unskirted PCR plates (BioRad MLL-9651) 
Minisart plus Syringe Filters 0.2µm  (Sartorious Stedim Biotech 17823--Q) 
Super Rx Medical X-ray film  (FujiFilm 4741008389) 
T25 flasks  (NUNC TKT-130-150L) 
T75 flasks  (NUNC TKT-130-190W) 
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2.1.6 KITS 
Amaxa Mouse Neural Stem Cell Nucleofection kit (Lonza VPG 1004) 
BCA Protein Assay kit (Thermo Scientific 23227) 
DNAase (QIAGEN 79254) 
Endofree Maxi Prep kit (10) (QIAGEN 12362) 
Gene Clean Gel Extraction (MP BIO 1001-400) 
RNEasy mini (50) Kit (QIAGEN 74104) 
SuperSignal West Dura Extended Exposure Kit (Thermo Scientific 34076) 
 
2.1.7 EQUIPMENT 
Centrifuges Rotanta 460R (Hettich Zentrifugen) 
Biofuge Pico (Heraeus) 
Electrophoresiss Tank Electrophoresis Tank (Flowgen) 
Power Supply Power Pac 200 (BioRad) 
Water Bath BS5 with ET100 controller (Fisher Scientific) 
Incubators CB 150 (Binder) 
Jeio Tech SI-900 (Medline Scientific UK) 
Laminar Flow Hood MicroFlow Peroxide Advanced BioSafety Cabinet ClassIII 
(BioQuell) 
Microscopes AMG (EVOS) 
IX71 (Olympus) 
IX81 (Olympus) 
BX61 (Olympus) 
pH Meter pH Meter 240 (Corning) 
QPCR Thermocycler CFX Connect Real Time System (Bio-Rad) 
Thermocycler TC-412 (Techne) 
TC-512 (Techne) 
Vortex Vortex Genie-2 (Scientific Industries) 
FACS Machine FACS Canto (BD Biosciences) 
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Western Blot Rig Mini-Protean III (Bio Rad) 
Cytocentrifuge CYT04 (Centurion Scientific) 
 
2.1.8 SOFTWARE 
Analysis 3.2 (Soft Imaging System GmbH) 
BD FACs DIVA (BD Biosciences) 
Cyflogic (CyFlo LTD) 
FlowJo 7.6.4 (Tree Star) 
Mendeley (Glyph & Cog) 
Microsoft Office 2007 (Microsoft) 
Photoshop 7 
GraphPad Prism v6 
(Adobe) 
(GraphPad Software Ltd) 
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2.2 MEFI FEEDER LAYER 
2.2.1 GROWING AND IRRADIATING MEFS 
B16 mouse embryos were harvested at 12 to 13 days post-coitum. The uterus, 
containing the embryos, was then removed into 1x PBS. The head and internal 
organs of the embryos were removed and transferred to a sterile petri dish. The 
embryos were then minced using a sterile blade and incubated in 0.05% trypsin for 5 
minutes at 37oC. Following trypsinisation, MEF medium (See Section 2.1.1) was 
added and the mixture vigorously homogenized with a pipette before centrifugation 
at 1000rom for 5 minutes. The supernatant was removed by aspiration and the pellet 
was re-suspended in MEF medium (containing 1% Antibiotic-Antimycotic (GIBCO 
15240062)) and plated as one embryo per 14cm plate. The cells were fed with fresh 
MEF medium every other day until they reached confluence. At this stage the cells 
were split (1:5) using 0.05% trypsin as passage 1. When these plates reached 
confluence 80% were used for irradiation, the remaining 20% were split with trypsin 
to give rise to passage 2. At passage 2 confluence all plates were irradiated and 
frozen. Irradiation was achieved by centrifugation of the trypsinised cells at 1000rpm 
for 5 minutes, followed by aspiration of the supernatant and the combination of all 
cell pellets to a single 50ml tube in 20ml of MEF media. These cells were irradiated 
for 30 minutes at 216 Rads/min. The cells were frozen at -1oC/minute overnight in 
cryovials at a density of 1x106 cells/vial  in 1ml of freezing medium (MEF medium + 
10% DMSO) and stored at -80oC. 
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2.2.2 PLATING IRRADIATED MEFS 
Irradiated Mouse embryonic Fibroblasts (MEFi) were thawed and plated in MEF 
Media (See Section 2.1.1) at a density of 12.5x104 cells onto 6cm culture dishes, 
that were pre-coated with EmbryoMax 0.1% gelatin solution (Millipore ES-006-B) for 
30 minutes, and allowed to attach for a minimum 24 hours prior to use as a feeder 
layer. 
2.3 MAINTENANCE OF ES CELLS 
Human Embryonic Stem Cells (hESCs), H9 cell line, were maintained on feeder 
plates of MEFi, in H9 Media (See Section 2.1.1). The medium was changed daily, by 
aspiration, and the cells were passaged with 1mg/ml collagenase type IV (GIBCO 
17104019) in KO-DMEM (GIBCO 10829018), every three days (or at 80% 
confluence) onto a MEFi feeder layer, as above in H9 medium with 10µM Rho 
Kinase inhibitor (Abcam ab120129) 
2.4 GENERATION AND MAINTENANCE OF HSCS 
H9 cells on a feeder layer of MEFi in a 6cm dish (Nunc TKT-110-0105) at a 
confluence of 70-80% were scored into a 10x10 grid using a 14 gauge needle 
(Monoject 200011) and lifted from the plate using a cell scraper (Corning 3008). 
Cells were allowed to settle by gravity before aspirating the supernatant medium and 
resuspending in fresh H9 medium with 10ng/ml bFGF to a 6cm low attachment plate 
to form embryoid bodies. At day 2 there was a 50% medium change with the addition 
of fresh H9 medium + 10ng/ml bFGF. The EBs were plated 15 EBs per well of a 6-
well tissue culture plate in XVIVO 15 factory medium (See Section 2.1.1) with M-CSF 
and IL-3 at day 4. The medium was changed every 5 days or when the medium 
began to yellow and the supernatant cells were collected by centrifugation at 
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1500rpm for 3 minutes. The pellet of cells was resuspended, assayed for viability 
through trypan blue staining and plated at a maximum density of 1x106 cells per well 
of a 6-well tissue culture plate in XVIVO complete factory medium (See Section 
2.1.1). 
2.5 MAINTENANCE OF THP-1 MONOCYTES 
THP-1 monocytes (a cell line obtained from an acute monocytic leukemia patient) 
were acquired from Dr. Dipak Ramji (Cardiff University). The cells were maintained 
in non-adherent culture in a T75 flask (Nunc TKT-130-190W) in monocyte 
maintenance medium (MMM) (See 2.1.1). Every fourth day the cells were recovered 
from the medium by centrifugation (1500rpm for 3 minutes), re-suspended in MMM 
and split in a 1:2 ratio into T75 flasks (Nunc TKT-130-190W). 
2.6 NEURAL PROGENITOR CELL CULTURE 
H9 cells, at 80% confluence, were dissociated from the plate and Mefi feeder layer 
with 1mg/ml collagenase type IV (GIBCO 17104019) in KO-DMEM (GIBCO 
10829018) and the resulting cells were centrifuged for 3 minutes at 1000rpm. The 
colonies were dissociated into smaller aggregations of cells by manual passaging 
with a pipette. Embryoid bodies (EBs) were created by plating the cell suspension in 
10cm non-adherent culture plates (Sterelin PDS-140-050F) in ADF/SB/LDN medium 
(See Section 2.1.1) for 8 days. The medium was replaced every other day and on 
the eighth day the EBs were dissociated with Accutase (PAA L11-007) for 5 minutes 
at 37oC and centrifuged (1000rpm for 3minutes) to recover the cells. The cells were 
dissociated to a single cell suspension by repeat pipetting and plated onto Poly-L-
Lysine (Sigma P5899)/Laminin (Stemgent 06-0002) coated glass cover slips (VWR 
631-0153) in a 24 well plate (Nunc TKT-190-010Y) at a density of 5x104 cells per 
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well in ADF/FGF medium (See Section 2.1.1). The medium was changed every other 
day until neural precursor formation, with characteristic rosette morphology. At day 
12 the neural precursors were nucleofected (See Section 2.7). 
2.7 NUCLEOFECTION 
2.7.1 CREATING THE PCAGG-PU.1-IRES-GFP CONSTRUCT  
The vector backbone was pIRES2-EGFP which was, through four steps; (1) 
Amplifying human PU.1 by PCR, (2) Inserting a CAG promoter from pCAGIG, (3) 
Inserting PU.1 and (4) Removing the CMV promoter, converted the plasmid into a 
PU.1 expression vector (for vector maps and PU.1 sequence, see Appendix I). 
PU.1 was amplified from human primary macrophage cDNA, using primers that were 
specifically designed to amplify with BamHI restriction sites to the ends of the gene. 
The PCR was carried out using Platinum high fidelity DNA polymerase (See Section 
2.1.2) with the addition of DMSO to aid strand separation.  
The PCR product was inserted into a Zero Blunt TOPO PCR vector (Invitrogen 
K2875-20), which was transformed into the supplied TOP10 competent cells and 
streaked onto 50mg/ml kanamycin sulfate agar plates (See Section 2.1.2). The 
resulting colonies were grown in LB medium containing 50mg/ml kanamycin sulfate 
(See Section 2.1.2) and mini-preped using the alkaline lysis procedure (as decribed 
in Maniatis et al. 1982). The DNA was analysed by BamHI restriction digest for the 
presence of the PU.1 insert and those colonies found to contain the gene were 
sequenced to ensure proper gene amplification and true replication. 
The original CMV promoter from pIRES2-EGFP was then removed and replaced 
with the CAG promoter from pCAGIG. Compatible restriction sites within the MCS of 
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pIRES2-EGFP (XhoI, EcoRI) and surrounding the CAG promoter in pCAGIG (SalI, 
EcoRI) were used to give directionality to the promoter on ligation of the fragments. 
The plasmid DNA preparations were digested with the required enzymes for 
30minutes at 37oC in the appropriate buffer, before running the digest on a 1% TAE 
agarose gel containing 1mM guanosine (See Section 2.1.2) to protect DNA from UV 
damage. The fragments were extracted from the gel using gene clean II kit (MP Bio 
1001-400) and the concentration and purity (260/280 value) of the sample was 
determined by spectrophotometry (Nanodrop). The fragments were ligated in a 3:1 
ratio of insert to plasmid based on molecular weight using the formula;  
((𝑉𝑒𝑐𝑡𝑜𝑟 (𝑛𝑔))(𝐼𝑛𝑠𝑒𝑟𝑡 (𝐾𝑏)))
((𝑉𝑒𝑐𝑡𝑜𝑟 (𝐾𝑏))(𝑟𝑎𝑡𝑖𝑜))⁄ = 𝐼𝑛𝑠𝑒𝑟𝑡 (𝑛𝑔)  
T4 DNA ligase was used for the ligatation (See Section 2.1.2), which occurred at 
25oC for 2 hours. The ligated product was then transformed into Sub Cloning 
Efficiency DH5α E. coli cells (Invitrogen 18265-017), which were streaked onto agar 
plates containing 50mg/ml kanamycin sulfate (See Section 2.1.2). The colonies were 
selected and grown in LB medium with 50mg/ml kanamycin sulfate (See Section 
2.1.2) and were subsequently used in alkaline lysis to extract the DNA. Restriction 
digest reactions were run using several combinations of enzymes to ensure correct 
ligation of the fragments had occurred. 
The PU.1 gene (with verified sequence) was removed from the TOPO vector by Bam 
HI (NEB) digestion along with the newly formed pCAGG-IRES-GFP vector and both 
were gel extracted, ligated and transformed as above. The resulting colonies were 
grown in LB medium containing 50mg/ml kanamycin sulfate (See Section 2.1.2), 
alkaline lysed to extract the DNA and screened for both the presence and correct 
orientation of PU.1 insert by multiple restriction digestions.  
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Finally, the redundant CMV promoter within pCAGG-PU.1-IRES-GFP was removed 
by digestion with AseI (NEB) and BglII (NEB) followed by Klenow (NEB M0210) blunt 
ending of the non-compatible ends, gel extracting and re-ligating the vector (as 
above). The ligation was again transformed into sub cloning efficiency DH5α cells, 
colonies were picked, grown and lysed to extract DNA (as above) before restriction 
digest analysis to ensure proper removal of the CMV promoter and correct re-ligation 
of the vector. 
2.7.3 AMAXA NUCLEOFECTION 
Neural rosettes, created from H9 cells (described in Section 2.6) were dissociated 
from the plate with Accutase (PAA Laboratories L11-007) and washed in PBS pH7.4 
(GIBCO 10010015); cells were centrifuged for 3 minutes at 1000rpm and re-
suspended in Mouse Neural Stem Cell nucleofection solution (Lonza VPG-1004) 
with either 10µg of pCAGG-PU.1-IRES-GFP or control (pCAGG-IRES-GFP) and 
gently mixed before they were transferred to a transfection cuvette. The cells were 
transfected using the Amaxa Nucleofection machine and program A-023. Post 
transfection the cells were re-suspended in 1ml of pre-warmed ADF medium (See 
Section 2.1.1) and removed from the cuvette with the provided plastic Pasteur 
pipette and counted, using a haemocytometer, prior to plating on matrigel (BD 
Biosciences 354230) coated glass cover slips in a 24 well plate at a density of 5x104 
cells per well. 
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2.7.3 SELECTION 
Expression of the GFP marker is evident in the positively nucleofected cells 48 hours 
post nucleofection this was observed under the Olympus IX71 microscope using the 
FITC filter. Selection of the GFP+ cells was achieved by the addition of 200μg/ml 
G418 (GIBCO 1011-027) to the culture medium, which was changed every other 
day, until only GFP+ cells remained. 
2.7.4 DIFFERENTATION TO MONOCYTIC PRECURSORS 
On presence of only GFP+ cells, the G418 (GIBCO 1011-027) was removed from 
the medium and cells were fed every other day in ADF/FGF medium (See Section 
2.1.1). The supernatant was collected and the non-adherent cells were recovered by 
centrifugation at 1000rpm for 3 minutes. The non-adherent cells were re-suspended 
in MMM, cell viability was assessed by trypan blue exclusion and they were plated 
on to 5μg/cm2 fibronectin (Millipore FC010-10MG) coated glass cover slips (VWR 
631-0153)  in a 24-well plate (NUNC TKT-190-010Y). 
2.8 MONOCYTE DIFFERENTIATION TO MICROGLIAL-LIKE CELLS 
2.8.1 ASTROCYTE CONDITIONED MEDIA 
ACM was produced as according to Rushton et al. (2013) and all animal work was 
carried out by Professor Nick Allen. Striata from newborn C57B1/6J mice were 
dissected into cold Hank’s Buffered Salt Solution (HBSS, Life Technologies 
14025092) and digested by incubation with Accutase (PAA Laboratories L11-007) 
and DNAse1 (0.1mg/ml, Sigma D7291) for 30 minutes at 37oC. The digestion was 
terminated and the cells were resuspended by the addition of MEF media (See 
Section 2.1.1). The cells were washed twice and plated into T75 culture flasks 
(NUNC TKT-130-190W) in MEF media. Upon confluence astrocytes were passaged 
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1:6 and confluent cultures from P1 and P2 were used to condition the base medium 
(DMEM/F12 (1:1), 2% Neurobrew 21, 1% L-Glutamine, 1% Penicillin/Streptomycin).  
After the 48h of conditioning the medium was collected filtered and frozen, whilst the 
astrocytes were washed in PBS and cultured in MEF medium for 24h for recovery 
before conditioning re-started. 
2.8.2 MONOCYTE DIFFERENTIATION TO MICROGLIAL-LIKE CELL 
The monocytes were plated at a density of 1x105 onto coverslips that were coated 
with 5µg/cm2 fibronectin (Millipore FC010-10MG) as a 100µl droplet and allowed to 
attach for several hours prior to flooding the wells with 250µl of Astrocyte 
Conditioned Media (ACM) (See Section 2.1.1). The medium was changed every third 
day for up to 14 days, until differentiation to a ramified microglial-like cell. Assays 
took place on day 7 of the differentiation.  
2.8.3 ADDITION OF AΒ 
Prior to addition to cultures Aβ(1-42) (Tocris 1428) and rAβ(42-1) (Tocris 3391) were 
prepared by a 1 hour incubation at 37oC. Aβ(1-42) or rAβ(42-1)  were then added to day 
7 microglial-like cells resulting from culture in ACM, or the control cells cultured in the 
unconditioned base medium at a final concentration of 5µM. Phenotypic and 
immunological studies preceeded after a 2 hour incubation, studies involving gene 
expression resulted from cultures 8 hours post incubation.   
2.11 IMMUNOCYTOCHEMISTRY 
Cells on glass cover slips were fixed in 4% PFA (See Section 2.2.1), or cytospin on 
to glass slides (See Section 2.13.1) and washed in PBS pH7.4 (GIBCO 10010-015) 
before being blocked in the appropriate solution for the marker, either internal or 
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external (See Section 2.9.1). The primary antibodies (See Section 2.3) were diluted 
in the appropriate block (+/- Triton X) and incubated overnight at 4oC. After washing 
with PBS pH7.4 (GIBCO 10010015) the fluorescent secondary antibodies (See 
Section 2.3) were added and incubated for an hour at room temperature before 
washing and counterstaining the nucleus with 0.1μg/ml Hoechst and mounting in 
PBS:Glycerol (1:1) onto glass microscope slides. 
2.12 FACS 
2.12.1 SINGLE COLOUR STAINING 
Live non-adherent cells were washed in 0.1% BSA (Sigma A9418) in PBS (GIBCO 
10010015) and centrifuged at 300rpm for 1 minute. The cell pellet was re-suspended 
in 100μl 0.1% BSA in PBS with 5ul of the appropriate conjugated antibody (See 
Section 2.1.4) for the test samples, and 100μl 0.1% BSA in PBS without any 
antibody for the control sample, for 20 minutes at room temperature in the dark. This 
was followed by gentle centrifugation (300rpm for 1 minute) and a final wash in 0.1% 
BSA in PBS. The cells were then transferred to 5ml round bottom tubes (BD Falcon) 
in an appropriate volume 0.1% BSA in PBS. The samples were then run using a BD 
Bioscience FACS Canto machine and analysed using FlowJo (Version 6.3.2; 
www.FlowJo.com)  
 2.12.2 TRIPLE COLOUR STAINING 
As for the single staining above, with the addition of single stained samples and an 
unstained sample for controls and to allow for any compensation. The triple stained 
sample was then incubated with 0.1% BSA (Sigma A9418) in PBS (GIBCO 
10010015) with 5ul of three antibodies conjugated to fluorophores (See Section 
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2.1.4) chosen to limit spill over into adjacent channels and thus the need for 
compensation and for their intensity compared to the expression level of the marker.  
2.13 HISTOLOGY 
2.13.1 CYTOCENTRIFUGATION 
Non-adherent cells were collected and spun at 800rpm for 1 minute through pre-wet 
filters onto glass slides using a Centurion CYT04 cytocentrifuge. 
2.13.2 STAINING  
Slides were incubated with 5% Giemsa stain (See Section 2.1.2) or haematoxylin for 
10 minutes. Giemsa stained samples were then washed in Sorenson’s buffer pH6.8 
(See Section 2.1.2) followed by washes in tap water to remove the excess stain 
before viewing. Haematoxylin stained samples were washed for 5minutes under a 
running tap to remove the excess stain. Both were viewed on an Olympus IX61 
microscope. 
2.14 PHAGOCYTOSIS ASSAY 
Optimal time and temperature were determined by FACS analysis using fluorescent 
Alexa Fluor® 594 labelled E.coli bioparticles (Invitrogen E23370) and staining the 
non-adherent cells with CD45. The optimal results were then used to chart 
phagocytosis by time-lapse microscopy. For time lapse monocytes were plated at a 
density of 2x104 per well of a 24 well plate and allowed to attach to the tissue culture 
plastic for several hours. On initiation of microscopy the medium was changed by 
aspiration and washing to an extracellular solution to enable cells to maintain 
function outside of a gas controlled incubator and 40ng/µl of beads were added. An 
Olympus IX61 fluorescent microscope was used in conjunction with SimplePCI 
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software to capture an image in both brightfield and using the TRITC filter to 
visualise the beads every 15 seconds for 90 minutes.  
2.15 QPCR 
Cells were washed and lysed in RLT buffer (QIAGEN 74104, as part of RNEasy  
Mini Kit) containing 10μl/ml β-Mercaptoethanol (Sigma A9418) and stored at -80oC. 
On thawing the RNA was extracted using an RNEasy Mini Kit (QIAGEN 74104), the 
lysate was diluted (1:1) in 70% ethanol (Fisher Scientific E0650DF17) and loaded on 
to the provided column. The column was centrifuged for 15 seconds; the column was 
washed with the provided buffer and re-centrifuged for 15 seconds and on-column 
DNAse digestion was performed by incubating the sample on the column in 80μl of 
DNAse in RDD buffer (QIAGEN 79254) for 20 minutes at room temperature. Then 
column was then washed and centrifuged before the sample was eluted in RNAse 
free dH2O. The concentration of the sample and its purity (260/280 value) were 
assessed by Spectrphotometry (Nanodrop). 
cDNA was created by the addition of the collected RNA, random primers (Invitrogen 
48190011), first strand buffer and the reverse transcriptase SuperScript III 
(Invitrogen 18080044), as described in section 2.1.2, before being placed in a 
thermocycler (Techne TC-512 ) with the program detailed below. 
 
 
 
To enable quantification of gene expression QPCR was carried out on the cDNA. 
This was achieved by using primers specifically designed for QPCR with a Tm close 
Temperature  Time 
 25oC  10 minutes 
 42oC  50 minutes 
 70oC  15 minutes 
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to 60oC, which resulted in a product of between 80 and 120bp, optimal for the QPCR 
program (below). The primer efficiencies were first established by serial dilution of 
cDNA using the formula %𝐸 = ((10(−
1
𝑀
)) − 1)𝑥 100. Only primers with efficiencies 
between 90 and 105% were used in the downstream reactions (for primer efficiency 
data see Appendix II). 
The QPCR mix, described above in section 2.1.2, was added to a 96 well plate 
(BioRad MLL-9651) before being centrifuged for 1 minute at 1500rpm and was 
cycled through the program below. For analysis the ΔΔCt Livak method was used on 
3 biological replicates, where each biological sample was analysed in triplicate as 
technical replicates (Livak and Schmittgen 2001). To further define, in this case 
biological replicates are identical cells grown separately but treated in the same 
manner to ascertain that the difference witnessed is representative of a biological 
difference. Technical replicates are defined as the same biological replicate analysed 
multiple times, in this case run in triplicate, to establish technical variability.  
 
Step  Temperature  Time Repeat 
Initial 
Denaturation 
 
 
 
95oC  15 minutes 1X 
Denaturation 
 
 
 
95oC  30 seconds 40X 
Annealing 
 
 
 
60oC  30 seconds  
Extension 
 
 
 
72oC  30 seconds  
                    
 
 
Plate Read 
 
 
- 
1X 
Melt Curve 
 
 
 
53-95oC (+0.5oC/Plate Read)  2 seconds/ +0.5oC       1X 
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2.16 WESTERN BLOT 
Samples were collected in lysis buffer (See 2.13.1) for 30 minutes at 4oC before 
being centrifuged at high speed for 20 minutes. The supernatant was then assayed 
for protein concentration by using a BCA Protein Assay kit (Thermo Scientific 23227) 
and colorimetric analysis.  
Stacking and resolving (10%) Acrylamide gels (See Section 2.1.2) were made and 
allowed to set before the samples were diluted, to the concentration determined in 
the BCA assay, in loading buffer (See Section 2.1.2). The samples were then 
denatured and loaded onto the gel along with a Novex Sharp protein standard 
(Invitrogen LC5800). The gel was run at 100V for an hour in 1x running buffer. After 
which the glass plates were removed, the stacking gel cut away and the gel carefully 
placed onto the membrane (GE Healthcare RPN 203D), in a bath of transfer buffer. 
The transfer cassettes were then constructed using pre-soaked sponges and filter 
paper along with the gel and membrane. The tank was filled with transfer buffer (See 
Section 2.1.2), set on a magnetic stirrer and run overnight at 25V at 4oC. After the 
transfer, the membrane was removed from the cassette washed in 0.1% PBS/Tween 
(See Section 2.1.2) and blocked (See Section 2.1.2) for 1 hour before incubating for 
1 hour in primary antibody diluted in block (See Section 2.1.4). Following the 
incubation, the membranes were washed in 0.1% PBS/Tween then the membrane 
was incubated with the secondary antibody (See Section 2.1.4) for 1 hour. The 
membrane was then washed in 0.1% PBS/Tween before placing in the developing 
cassette and adding SuperSignal West Dura Exposure solutions (Thermo Scientific 
34076) onto the membrane for 5 minutes in the dark before placing the 
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chemiluminescent detection film (Roche 11666916001) on top of the membrane for 
the desired length of time and then developing the image. 
2.17 ELECTROPHYSIOLOGY  
Whole cell voltage clamp was performed by Dr. J. Griffiths on H9 derived cells 
perfused with a HEPES- buffered solution containing, in mM: 135 NaCl; 5 KCl; 5 
HEPES; 1.2 MgCl2; 1.25 mM CaCl2; 10 Glucose; pH 7.4. The pipette solution 
contained, in mM: 117 KCl; 10 NaCl; 2 MgCl2; 1 CaCl2; 11 EGTA; 2 Na.ATP; 11 
HEPES; pH 7.2. Filled with this solution, borosilicate pipettes pulled on a Narishige 
(PP-81) 2-stage puller, demonstrated resistances of 5-7 MΩ. Following capacitance 
and series resistance compensation, cells were voltage clamped at -70 mV and 
currents were evoked by a voltage step protocol (from -170 to +60 mV in 10 mV 
increments, each 200ms, at  2Hz Hz, P/N = 4 on-line subtraction). All 
electrophysiology experiments were conducted at ambient room temperature. All 
current recordings were made using an Axopatch 200A amplifier and Digidata 13320 
A/D interface (Axon Instruments, Forster City, CA, USA). Currents were digitized at 
10 kHz and Bessel low-pass filtered at 5 kHz. 
2.18 CYTOKINE/CHEMOKINE ARRAYS 
Cell culture supernatants were collected 8h post incubation with Aβ(1-42) or rAβ(42-1) 
and centrifuged to remove particles and debris. The membranes (as part of the 
cytokine array (RnD Systems ARY005) or the chemokine array (RnD Systems 
ARY017)) were blocked for 1 hour in 2ml Array Buffer 4 (Included in ARY005 and 
ARY017). During the incubation the samples were prepared as follows; 250µl 
supernatant, 500µl Array Buffer 4 and 750µl Array Buffer 5, finally the antibody 
cocktail was added and incubated for 1 hour. Array Buffer 4 was then removed from 
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the membranes and the supernatant/antibody mix was added and incubated 
overnight at 4oC on a rocking platform. The membranes were then washed 3 times 
with 1x Wash Buffer (Included in ARY005 and ARY017) for 10 minutes per wash, 
after the final wash 2ml Streptavidin-HRP (Included in ARY005 and ARY017) was 
added to each membrane and incubated for 30 minutes on a rocking platform. 
Following the incubation the membranes were washed a further 3 times in 1xWash 
Buffer. The membranes were then removed from the wash and the excess buffer 
was allowed to drain from the membrane before placing it onto a plastic sheet within 
a developing cassette and adding 1ml Chemi Reagent Mix (Included in ARY005 and 
ARY017). The top plastic sheet was placed over the membranes and the air bubbles 
were smoothed out and the Chemi Reagent Mix was evenly spread out over each 
membrane before incubating for 1 minute, after which the excess Chemi Reagent 
Mix was removed. Chemiluminescent detection film (Roche 11666916001) was 
placed on top of the membranes and exposed for the desired length of time. The 
developed image was analysed using ImageJ for the pixel density.  
 
2.19 STATISTICS 
Statistical analysis of QPCR data was carried out using GraphPad Prism 6.05. The 
means were compared using ANOVA and significant differences were compared 
using the Bonferroni Post-Hoc test at a 95% confidence interval, which were also 
denoted on graphs as asterics representing the significance summary provided by 
GraphPad Prism and are defined as follows; * ≤0.05, ** ≤ 0.01, *** ≤ 0.001, **** ≤ 
0.0001. 
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3 .  GENERATION OF MONOCYTES 
BY ECTOPIC OVER-EXPRESSION 
OF PU.1  
3.1 INTRODUCTION 
Terminal differentiation to monocytes is dependent on the timely expression of 
lineage restricted transcription factors and release of cytokines that regulate a 
haematopoeitic niche (Figure 2; Section 1.1.3). One essential transcription factor in 
this regard is PU.1, which is required in a dose-dependent manner throughout 
hematopoiesis and at high levels for the final differentiation of haematopoietic 
precursors to monocytes. Since microglia are derived from a monocytic lineage, 
PU.1 is also vital for microglial differentiation. This was proven in PU.1 knock-out 
mouse models, where a lack of both circulating monocytes and CNS microglia were 
observed (Walton et al. 2000).  
Work by Forsberg et al. (2008) showed that murine adult neural stem cells could be 
reprogrammed easily into monocytes, an unrelated lineage, by introducing an 
exogenous source of PU.1 through lentiviral transduction. When these cells were 
transplanted into the brain in vivo they migrated and differentiated into microglia, 
which were indistinguishable, with the exception of GFP expression, from the native 
microglia. Beutner et al. (2010) have also used a modified five step method for the 
production of neuronal cells as the basis of their differentiation strategy of mESCs to 
microglia. 
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PU.1 is the 270 amino acid, 31kDa protein product from the SPI1 gene. It exists in 
two isoforms due to alternative splicing; (1) the canonical form and (2) the alternative 
form, which has a glutamine insertion at position 15 (Ray et al. 1990). PU.1 is a 
transcription factor of the E-twenty six (Ets) family, which binds to the purine rich 5’-
GAGGAA-3’ sequence (Klemsz et al. 1990). It is a key regulator of haematopoeisis 
with downstream targets that include; c-fms (M-CSF receptor), CD45, CD11b, GM-
CSFRα and CEBP/α and is regarded as the main director of myelo- and lympho-
genesis.  
PU.1 is required both for a cell to enter haematopoiesis, as PU.1 is under the control 
of RUNX1, and also throughout the haematopoietic process in a dose-dependent 
manner (Huang et al. 2008). PU.1 expression levels are low at the onset of 
haematopoeisis, enabling self-renewal of HSCs but levels increase to induce 
differentiation toward Granulocyte Monocyte Precursors (GMPs) (Dakic et al. 2007). 
PU.1 is also accredited as the transcription factor in neutrophil or monocyte fate 
determination. High levels of PU.1 in the granulocyte myeloid precursor (GMP) stage 
repress Gif-1 the neutrophil transcription factor, leading to monocyte differentiation, 
conversely low PU.1 levels allow full Gif-1 function and subsequent neutrophil 
differentiation (McIvor et al. 2003).  
3.2  AIM 
Work described in this chapter aimed to construct a human PU.1 expression vector 
to drive overexpression of PU.1 in hES-derived neural progenitors, for the purpose of 
inducing a lineage switch to either a monocyte or microglial-like fate, in a similar 
means to Forsberg et al. (2008).  
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3.3  VECTOR CONSTRUCTION 
The exogenous source of PU.1 was amplified by PCR from Human monocyte cDNA 
with primers designed specifically to introduce flanking BamHI restriction sites to 
enable ligation into the mammalian expression vector, pIRES2-EGFP. pIRES2-
EGFP drives gene expression from the cytomegalovirus (CMV) promoter. It also 
provides GFP reporter gene expression to visualise the positively transfected cells, 
and a Neomycin/Kanamycin resistance cassette to allow bacterial (Kanamycin) and 
mammalian (Neomycin/G418) selection. Since the CMV promoter has been shown 
to be susceptible to transcriptional inactivation by cytosine methylation in human 
stem cells (Prosch et al 1996), this was replaced with a more robust CAGG promoter 
(a CMV enhancer combined with a chicken β-actin promoter), from pCAGIG 
(Addgene). The CAGG promoter has been shown to increase gene expression by 
almost 10-fold when compared to the CMV alone and to be less susceptible to 
epigenetic silencing (Xu et al. 2001). The strategy for vector construction is shown 
below in Figure 3.1. 
 
 
 
Figure 3.1. Vector Construction (Overleaf) 
(A) The vector bone was created by removing the CAGG promoter region from pCAGIG via 
digestion with SalI and EcoRI. This was ligated into pIRES2-EGFP, which had been digested with 
XhoI and EcoRI, creating pCMV-CAGG-IRES-GFP. The CMV promoter was removed through 
digestion with AseI and BglII and the re-ligated vector generated was pCAGG-IRES-GFP, the 
control vector. 
 
(B) To insert the PU.1 sequence, PU.1 was amplified from monocyte cDNA with BamHi sticky ends 
and cloned into pCR-BluntII-TOPO. The PU.1 sequence was excised from pCR-BluntII-TOPO and 
inserted into pCAGG-IRES-GFP, which had been linearised by BamHI digestion. The ligated vector 
produced was pCAGG-PU.1-IRES-GFP. 
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3.4 NEURAL PRECURSOR DIFFERENTIATION 
In a similar means to the Forsberg et al. (2008) protocol the created vectors; 
pCAGG-PU.1-IRES-GFP or the control pCAGG-IRES-GFP, were transfected into 
neural progenitors to initiate a lineage switch to a monocytic fate (Figure 3.2).  
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Schematic Representation of the Differentiation Protocol 
(A) Embryoid bodies were formed from H9 hES cells in ADF medium with dual SMAD inhibition using 
SB (SB431542) and LDN (LDN193189) for 8 days. (B) hES-derived neural precursors were cultured 
to day 12 (D12) in ADF medium with FGF2. The neural progenitor cells were then transfected with 
either PU.1 or control constructs (C/D). The positively transfected cells GFP+ and neomycin resistant 
and were selected using G418 (E/F) until only GFP+ cells remained at D19 (G). Post selection non-
adherent cells are formed and harvested from D26 (H).  
  3. Over-expression of PU.1 
78 
 
Neurogenic cultures were established from H9 hESCs by forming EBs in serum and 
TGF/BMP-free chemically defined medium (ADF) using a protocol of dual SMAD 
inhibition (Figure 3.3 A) (Chambers et al. 2009). Day 8 neuralised EBs were then 
dissociated to a single cell suspension and re-plated to form neural rosettes in 
adherent monolayer culture (Figure 3.3 B). Neural precursor formed rosette 
structures that stained positively for nestin with centrally localised ZO-I staining at 
day 12, markers for neuron specific intermediate filament and tight junctions 
respectively (Figure 3.3 C and D).  
 
  
Figure 3.3. Neuronal Precursor Differentiation 
(A) Phase contrast image of the embryoid bodies produced from H9 cells in ADF media. (B) Phase 
contrast image of the neural precursor cells at D12. (C) Immunocytochemistry of the D12 neural 
precursors stained with ZO-1 (red). (D) Immunocytochemistry of the D12 neural precursors at D12 
stained with Nestin (red).  
Scale bar represents 50μm 
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3.5 NUCLEOFECTION OF NEURAL PROGENITORS 
The neural rosette cultures nucleofected with either the pCAGG-PU.1-IRES-GFP 
construct (Figure3.4 A) or the control construct pCAGG-IRES-GFP (Figure3.4 D), 
exhibited GFP expression 48h post-transfection (Figure 3.4 C and F).  
   
Figure 3.4. pCAGG-PU.1-IRES-GFP and Control Vectors Express GFP Post-
Transfection 
(A) The pCAGG-PU.1-IRES-GFP construct with a CAG promoter, EGFP and 
Kanamycin/Neomycin resistance cassette and PU.1. (B) Phase contrast image of the neural 
progenitors 48h post transfection (PT). (C) The corresponding GFP expression in the neural 
progenitors 48h PT. (D) The control pCAGG-IRES-GFP construct. (E) Phase contrast image of the 
neural progenitors 48h PT. (F) GFP expression in the neural progenitors 48h PT with the control 
construct. 
Scale bars represent 200µm 
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Post-nucleofection the survival rates of the cells and the %GFP+ cells were 
calculated for several available Amaxa nucleofection programs. The maximal 
transection efficiencies achieved were a 23% survival rate with 31% of the surviving 
cells expressing GFP for those transfected with pCAGG-PU.1-IRES-GFP with similar 
results (25% and 36%, respectively) obtained for the control construct (Figure 3.5). 
Following seven days of G418 selection all remaining cells expressed GFP at a level 
that remained high throughout the differentiation from its onset 24h post 
nucleofection (Figure 3.5). 
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Figure 3.5. pCAGG-IRES-GFP Nucleofection  
The efficiency of nucleofection was determined through cell survival and GFP expression, which 
show similar values in both the PU.1 construct transfection and the control. The neural precursors 
24h post transfection using program A023 with the Pu.1 construct, shows GFP+ cells with a 31% 
transfection efficiency.  
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PU.1 protein expression from the pCAGG-PU.1-IRES-GFP vector was initially 
confirmed by western-blotting following transient transfection and expression in 
HEK293 cells (Figure 3.6 A). PU.1 expression in H9-derived neural precursor cells 
(NPCs) transfected with pCAGG-PU.1-IRES-GFP was also confirmed by QRTPCR 
(Figure 3.6 B and C). ANOVA was conducted to compare the effect of pCAGG-PU.1-
IRES-GFP transfection on PU.1 expression to non-transfected cells, which revealed 
that there was a significant increasein PU.1 expression at the 95% confidence level 
[F(3,8)=263.3, p<0.001]. Post-hoc comparisons using the Bonferroni test indicated 
that the mean for the non-transfected NPCs (M=0.0003, SD=7.497e-005) was 
significantly different to the mean of the transfected samples (PU.1 PT (M=4.469, 
SD=0.1088), PU.1 PS (M=2.788, SD=0.4073)).  
When the control vector, pCAGG-IRES-GFP, was analysed by ANOVA there was no 
significant difference in PU.1 expression when the NPCs were transfected with the 
control construct [F(2,6)=2.362, p=0.1751]. The increase in PU.1 expression 
observed is thus deemed to represent the effect of transfection with the pCAGG-
PU.1-IRES-GFP vector.  
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Figure 3.6. PU.1 Expression is Up-regulated Post-Transfection with 
pCAGG-PU.1-IRES-GFP 
(A)  Western blot showed PU.1 expression in HEK293 cells, when transfected with pCAGG-
PU.1-IRES-GFP and no expression in the control transfection 
(B) PU.1 Expression in Neural Precursor Cells (NPCs) was shown to be increased 4.5-fold 
compared to THP1 cells post-transfection (PT) and almost 3-fold in cells post-selection (PS). 
ANOVA showed that these increases were significant [F(3,8)=263.3, p<0.001]. Post Hoc 
Bonferrroni test revealed significant differences between the means of the NPCs (M=0.0003, 
SD=7.497e-005) and PT (M=4.469, SD=0.1088) and PS (M=2.788, SD=0.4073) samples. 
(C) PU.1 expression in NPCs transfected with pCAGG-IRES-GFP was shown to be similar both 
PT and PS to the un-transfected NPCs. There was no significant difference in the means after 
ANOVA [F(2,6)=2.362,p=0.1751] 
QRTPCR data was normalised to -Actin and taken from 3 technical replicates of 3 biological 
replicates 
Asterisks denote statistical significance;  * ≤0.05, ** ≤ 0.01, *** ≤ 0.001, **** ≤ 0.0001 
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Immunocytochemistry was carried out to show that PU.1 expression originated from 
only GFP+, successfully transfected cells. This showed that PU.1 and GFP 
expression and co-localised in the NPCs transfected with pCAGG-PU.1-IRES-GFP 
48h post-transfection, but no PU.1 expression was evident in the NPCs transfected 
with the control construct (Figure 3.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. PU.1 and GFP Co-Localisation in Neural Progenitors 
(A) NPCs transfected with pCAGG-PU.1-IRES-GFP were stained with PU.1 (red), (B) GFP (green) 
and (C) DAPI. The images were merged (D) to show co-localisation and expression of PU.1 and 
GFP. (E) NPCs transfected with the control construct were stained with PU.1 (red), (F) GFP (green) 
and DAPI (G). Co-localisation via the merged image is shown in H. 
 
Scale bars represent 50 µm  
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3.6 DIFFERENTIATION OF TRANSFECTED CELLS 
To confirm the loss of neuronal identity post transfection during differentiation.  
QRTPCR was performed for the neural intermediate filament, Nestin, both pre- and 
post- transfefction (Figure 3.8). One way ANOVA was carried out to compare nestin 
expression the pCAGG-PU.1-IRES-GFP transfected cells over time. This showed 
that the difference between the means was statisitically significant [F(2,6)=176.6, 
p<0.0001]. Post-hoc comparisons with the Bonferroni test showed that there was a 
statistically significant decrease in nestin expression both post-selection (M=1.087, 
SD= 0.3224) and once integrated at D60 (M=0.9679, SD=0.0711) compared to the 
level of nestin expression in the post-transfected cells at D14 (M=14.17, 
SD=1.6827). This indicated that the cells were undergoing a lineage switch from their 
neural precursor origins during differentiation. Whether this is due to time in culture 
or transfection with PU.1 or both is not clear. 
 
 
 
 
Figure 3.8. Nestin Expression is down-regulated upon transfection with 
pCAGG-PU.1-IRES-GFP 
48h post-transfection at differentiation D14 there was a 14-fold increase in Nestin expression 
relative to undifferentiated H9 hESCs. ANOVA showed that there was a significant decrease in 
nestin expression [F(2,6)=176.6, p<0.001]. Post-selection at D21 and later on at differentiation 
D60, when the PU.1 construct has integrated, there is a statistically significant down-regulation of 
nestin (PU.1 PS (M=1.087, SD=0.3224), PU.1 Int (M=0.9679, SD=0.0711)). 
QRTPCR data was normalised to β-Actin and taken from 3 technical replicates of 3 biological 
replicates. 
Asterisks denote statistical significance;  * ≤0.05, ** ≤ 0.01, *** ≤ 0.001, **** ≤ 0.0001 
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Since there was a loss of expression of the nestin and thus neuronal identity post-
transfection, the effect of PU.1 overexpression in transfected neural progenitors (Day 
14 and Day 21 post-transfection) on the regulation of developmental haematopoietic 
genes was monitored by Q-RTPCR. This was carried out using primers for genes 
involved in haematopoietic induction; both primitive (FLK1) and definitive (RUNX1), 
and haematopoiesis via PU.1, CD34 and CD45 (Figure 3.9). Where CD34 is a 
marker for the apex of haematopoeisis, the HSC and early haematopoeitic 
progenitors, whilst CD45 is the leukocyte common antigen found in more committed 
leukocyte cells and is situated downstream of PU.1.  
A comparison of the means via ANOVA showed that transfection with PU.1 resulted 
in a statistically significant difference [F(3,30)=906.3, p<0.0001]. Bonferroni’s 
multiple comparison test revealed several differences between the NPCs and the 
PU.1 transfected cells. 
PU.1 expression is increased when cells are transfected with the pCAGG-PU.1-
IRES-GFP construct at both D14 and D21 (PU.1 PT (M=3.996, SD=0.686), PU.1 PS 
(M=2.513, SD=0.103)) compared to NPCs at D12 (M=0.00027, SD=0.00006). PU.1 
transfected cells also showed an increase in FLK1 expression of around 3-fold in 
post-transfected cells (M=3.057, SD=0.375) and a 12-fold increase in post-selected 
cells (M=12.47, SD=0.375). FLK1 expression in NPCs remained negligible 
(M=0.1165, SD=0.01595). RUNX1 was not significantly different in the post-
transfected cells (M=0.08115, SD=0.017) but was significantly up-regulated in the 
post-selected cells (M=0.7771, SD=0.072) compared to the NPCs (M=0.01513, 
SD=0.00293). The haematopoietic stem cell marker, CD34, showed no significant 
difference at either of the transfected cell time points (PU.1 PT (M=1.597, 
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SD=0.154), PU.1 PS (M=1.866, SD=0.297)) when compared to the NPCs (M=1.637, 
SD=0.09464). QRTPCR finally revealed that transfection of neural precursors with 
the PU.1 construct resulted in an increase in expression of CD45, to a level 
comparable to THP1 monocytes,  in both post-transfected cells (M=0.9688, 
SD=0.217) and the post-selected cells (M=1.031, SD=0.026) compared to NPCs 
(M=0.03157, SD=0.00238). 
Post-selection, at day 21, the QRTPCR showed that there is an increase in the 
expression of all the haematopoietic markers of interest, with the obvious exception 
of PU.1. This indicates that there is a lineage switch towards a monocytic or 
microglial-like fate occurring upon PU.1 overexpression. 
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To investigate the consequences of ectopic PU.1 expression immunocytochemistry 
was performed post G418 selection. This showed that all selected cells were positive 
for CD45. Groups of CD11b+ cells were also visible but there were very few visible 
CD34+ (Figure 3.10). CD34+ cells would lead to the conclusion of the presence of 
HSCs or early, non-committed, haematopoeitic progenitors found at the beginning of 
haematopoeisis. The presence of CD45+ and CD11b+ cells suggests that the cells 
are more committed leukocytes with at least some of which being committed 
CD11b+ monocytes.  
 
 
 
 
 
 
 
 
 
Figure 3.10. Hematopoietic Marker Localisation in the Adherent Population 
Post-selection (D29) the adherent population, resulting from transfection with pCAGG-PU.1-IRES-
GFP were stained for CD34 (A), CD45 (B) and CD11b (C).  
 
Scale bars represent 100µm  
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3.7 NON-ADHERENT CELL CHARACTERISATION 
With extended culture the transfected adherent cells gave rise to a phase-bright non-
adherent cell population. It is expected that this non-adherent population would 
contain the desired monocytic cell type. The non-adherent cells that were generated 
post-selection were assayed for cell viability using trypan-blue exclusion to ensure 
that these were not a result of increased cell death. The number of viable cells 
steadily increased post-selection in the PU.1 transfected cells, peaking at day 25 at 
over 9x105 cells/ml (Figure 3.11 A). This was compared to the viability of the non-
adherent cells produced from the cells that were transfected with the CAG control, 
which produced significantly fewer viable non-adherent cells (Figure 3.11 B). This 
showed that PU.1 overexpression generated in a greater number of viable, phase 
bright, non-adherent cells. 
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Figure 3.11. Viability of non-adherent cells 
Subsequent to the removal of the selective pressure at D18 the viability of non-adherent cells 
harvested from culture medium was determined. Cells over-expressing PU.1 generated >9x105 
cells/ml at D25 before beginning to decline (A). For the control sample, the viability of cells never 
exceeds 3.5x104 cells/ml (B). 
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The viable non-adherent cells collected at day 30 from the nucleofected samples 
were examined immunologically for markers of haematopoiesis; CD45 and CD11b 
(Figure 3.12). This revealed that forced expression of PU.1 induced expression of 
CD45 and CD11b in non-adherent cells, whilst little staining was evident in cell 
transfected with the CAG only control vector, which would indicate that it is PU.1 
overexpression rather than culture conditions that is the driving force behind the 
differentiation. 
 
 
 
Figure 3.12. Hematopoietic Marker Expression In the Non-Adherent Cells 
(A) Day 30 supernatant cells from cultures transfected with pCAGG-PU.1-IRES-GFP stained for 
CD45 and (B) CD11b. CD45 (C) and CD11b (D) in day 30 supernatant cells harvested from 
cultures transfected with control vector pCAGG-IRES-GFP  
Scale bars represent 100µm 
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The non-adherent cell populations from both transfections, with the PU.1 containing 
construct and the control, were also analysed by flow cytometry to quantify CD11b 
expression as a marker of myelopoiesis and also of microglia along with its co-
expression of GFP.  
Flow cytometry revealed that there was a small population of ~5%. CD11b+ cells in 
control transfected cultures, whilst the population was 6 times larger in cells 
differentiated following pCAGG-PU.1-IRES-GFP transfection, where over 33% of the 
non-adherent cells were CD11b+ (Figure 3.13).  
The GFP+ cells were similar in both the control pCAGG-IRES-GFP and pCAGG-
PU.1-IRES-GFP supernatant cells whether stained or isotype control. The histogram 
for GFP+ cells shows two clear peaks and so two distinct populations of cells. This is 
potentially due to the integration of one or two copies of the GFP expressing plasmid 
into the genome. Cells were also analysed for their co-expression of GFP and 
CD11b, as shown in the quadrant plots where CD11b+/GFP+ cells are seen in the 
upper right quadrant. This showed that only 1.6% of the control transfected cells 
resided within this quadrant, whilst over 13% appeared in the quadrant when 
transfected with pCAGG-PU.1-IRES-GFP, which also equates to around half of the 
CD11b+ population. This confirms that the expression of CD11b is largely due to 
transfection and subsequent expression of PU.1, rather than culture conditions.  
 
 
 
 
 
Figure 3.13. Quantification of GFP and CD11b Expression in PU.1 and 
control vector transfected cells (Overleaf) 
(A) The supernatant cells arising from transfection with the control construct showed only 5.49% of 
the cells were CD11b+. (B) The GFP+ cells were also similar in both the isotype control and the 
test sample but show two distinct populations. (C) Co-expression of CD11b and GFP in the 
unstained control was only 0.61%, which remained low (D) at 1.60% CD11b+/GFP+ cells in the 
stained test sample.(E) Supernatant cells resulting from the transfection of the pCAGG-PU.1-IRES-
GFP construct showed a population of over 33% CD11b+. (F) The isotype control and the stained 
sample showed the same population of GFP+ cells, again with two distinct populations. (G) Co-
expression of CD11b and GFP in the isotype control was 0.18% whilst (H) the co-expression was 
markedly increased in the PU.1 transfected cells with 13.4% CD11b+/GFP+ cells.  
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PU.1 overexpression yielded cells that express both CD45 and CD11b, markers 
commonly used to identify monocytes. The functionality of these cells were assayed 
using time lapse microscopy for the phagocytosis of opsonised E. coli bioparticles 
(Figure 3.14). This showed that over a 60 minute incubation period with the particles, 
none of the cells were shown to have taken up the particles as would have been 
expected by functional monocytes. 
 
 
 
Figure 3.14. Time Lapse Microscopy of E. coli Bioparticle Phagocytosis  
Non – adherent cells that arose from transfection with pCAGG-PU.1-IRES-GFP were incubated 
with fluorescent E.coli bioparticles (red) for 60 minutes, with images taken at 3 minute intervals. 
This shows that, although the bioparticles contact the surface of the cells they are not 
phagocytosed. 
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3.8 DATA SUMMARY 
Neuronal precursor cells differentiated from hESCs formed characteristic neural 
rosette structures, the in vitro 2D equivalent to the neural tube, and were positive for 
both nestin and ZO-1. 
A reproducible transfection protocol was established and both the control and PU.1 
containing plasmids functioned to express GFP. Transfection with pCAGG-PU.1-
IRES-GFP was also shown to lead to expression of PU.1, which was not expressed 
in the cells prior to transfection nor in those cells transfected with the control plasmid. 
Transfection of the PU.1 construct lead to a down-regulation of the neuronal 
intermediate filament Nestin, and thus a loss of neuronal identity. Differentiation of 
cells transfected with PU.1 derived an adherent population of principally CD45+ 
cells, with little or no CD34 expression, but with some pockets of CD11b expression 
post selection. This indicates that PU.1 promotes the differentiation of cells to 
express markers associated with leukocytes (CD45) and monocytes (CD11b) rather 
than those of primitive HSCs (CD34). 
With extended culture, non-adherent cells shed into the culture supernatant stained 
for both CD45 and CD11b when transfected with the PU.1 vector. Cells transfected 
with control vector showed little or no staining for CD45, although a small population 
of CD11b+ cells was detected when analysed by flow cytometry. Although the cells 
that resulted from the transfections were not deemed to be functional monocytes due 
to their lack of ability to phagocytose E.coli bioparticles. Their lack of functionality 
was also confirmed through their inability to differentiate in the presence of astrocyte 
conditioned medium (data not shown). 
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3.9 DISCUSSION 
PU.1 has various roles in hematopoiesis, from cell-cycle regulation to avoid 
exhaustion of the HSC niche and the onset of hematopoiesis to fate determination 
between monocytes and neutrophils. It has been shown previously that the over-
expression of this transcription factor alone is able to ‘re-programme’ a neural stem 
cell to a lineage, far removed from their ectodermal origins, to monocyte and 
ultimately a microglial cell, which would naturally arise from the mesoderm. Neural 
stem cells or progenitors are attributed with significant nuclear plasticity and potential 
for reprogramming, requiring only exogenous Oct4 to enable them to be 
reprogrammed to IPSCs (Kim et al. 2009). It is for this reason that neural stem cells 
were chosen by Forsberg et al. (2008) to be ‘re-programmed’ to monocytes by 
overexpression of exogenous PU.1. A five step protocol for the differentiation of 
neuronal cells can also be adapted for the formation of microglia by Beutner et al. 
(2010). Since neural precursors have been used successfully in the differentiation of 
microglia in murine cells and a robust protocol is established for the formation of 
neural precursors from hESCs these were used in place of the adult neural stem 
cells in the publication by Forsberg et al. (2008).  
The transfection protocol established is one that is reproducible and has maximal 
efficiency for neural progenitors. Efficiencies of transfection using the Amaxa 
nucleofection system in Human neural stem cells has been shown to be 35% by 
Marchenke and Flanagan (2007). Amaxa transfection can be more efficient as 
shown by Maasho et al. (2004) were efficiencies were 40% with viability reaching 
85%, but these figures were gained in natural killer cells, rather than the delicate 
neural progenitors required for the current protocol. This not only confirms the 
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functionality of the protocol used for transfection, but also the functionality of the 
vector through its expression of GFP.  
Under the control of the CAG promoter PU.1 expression was increased over 3-fold in 
G418 selected cells, whilst cells transfected and selected using the control plasmid 
showed little expression of PU.1 when compared to THP1 monocytes.  The co-
expression and thus localisation of PU.1 and GFP was shown but in some cases 
only GFP expression was evident, although not ideal this is not unexplainable, the 
GFP gene is part of the IRES-GFP cassette, which has been shown to interfere with 
the translation of certain small genes (Mansha et al. 2012). At just over 800bp PU.1 
is small and could be a target for such translational interference in some cells, hence 
the GFP only cells found after selection. 
PU.1 expressing cells showed a significant increase in the levels of FLK1 both post-
transfection and post-selection. FLK1 can be upregulated depending on cellular 
activation and proliferation (Yang et al. 2004). PU.1 is able to increase the level of 
proliferation via the expression of MCSFR, so it is unsurprising that cells that 
overexpress PU.1 also have increased FLK1 expression. These cells also show a 
significant increase in the expression of the leukocyte common antigen, CD45, 
expression, evidenced by immunostaining and QRTPCR. CD45 is a receptor 
tyrosine phosphatase vital for leukocyte function. The same techniques showed that 
there was little expression of CD34 and only some CD11b expression. This is most 
likely due to the PU.1 binding sites within the CD45 promoter region, making CD45 a 
downstream target of PU.1 (Anderson 2000). Although likely that the lineage switch 
is due, at least, in part to PU.1 overexpression the length of time in the differentiation 
and the differentiation conditions can not ne overlooked. Since post-selection cells 
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are cultured with IL-3, M-CSF and GM-CSF in a media similar to that used in the 5-
step protocol for mouse ES to microglia differentiation. As mentioned previously 
PU.1 also targets the M-CSF and GM-CSF receptor genes along with CD11b. 
CD11b is an integrin that regulates the adhesion and migration of monocytes as well 
as serving a role in the complement system as the C3bi receptor. Since all of these 
induce monocytic commitment it is unsurprising that the resultant cells are 
expressing largely leukocytic markers. M-CSFR, levels of which increase during 
monocyte differentiation, has a binding site for PU.1 upstream of the 5’ promoter 
elements and functions to increase proliferation of monocytic cells through actions 
on cyclin D and E to induce the transition from G1 to S-phase in the cell cycle 
(Rhoades et al. 1996). This is consistent with the finding that those cells transfected 
with PU.1 produce over 20-fold more viable supernatant cells than those transfected 
with the control construct. 
The non-adherent supernatant cells were shown to be haematopoietic in the 
presence of PU.1, expressing both CD45 and CD11b, whilst the control cultures 
were largely negative for these markers. This is again unsurprising since PU.1 is 
able to bind to the CD45 gene promoter region and influence transcription of CD45. 
As mentioned PU.1 is also able to influence CD11b expression, accounting for the 
CD11b+ cells seen within the supernatant of the cultures transfected with the PU.1 
construct.  Another major difference between the cultures lies in the number of 
supernatant cells produced, due to the proliferative action of PU.1.  
Improvements to the system though could be made in an effort to increase the 
efficiency of the differentiation. The vector, once integrated, is susceptible to 
silencing so PU.1 would no longer be expressed. Although not hugely problematic 
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since the lineage switch to leukocytes, through the initial overexpression of PU.1, the 
high levels of PU.1 required for terminal monocyte differentiation could be assisted 
further by the contribution of endogenous PU.1. To combat this potential problem the 
vector could be supplemented with insulator sequences to prevent transgene 
silencing. Also it is known that transgene expression is most effective when under 
selection, which was not the case here (Alexopoulou et al. 2008). Seven days of 
selection was sufficient to enable stable transfection, after which G418 was 
removed. Increased PU.1 expression after stable transfection could be induced by 
the addition of a minimal concentration of G418 within the culture medium 
throughout the differentiation protocol.  
The monocyte-like cells produced via this protocol were deemed non-functional 
since they were unable to undergo phagocytosis and differentiate to microglial-like 
cells. PU.1 can be bound by various factors including; CBP, HDAC1, RUNX1, which 
under the conditions of PU.1 overexpression could lead to sequestration of these 
and other genes required for differentiation and phagocytosis (Takahashi 2011). An 
important factor in the differentiation of microglia is the interferon requlatory factor 8 
(IRF8), which heterodimerises with PU.1 and leads to the differentiation of microglia 
and the formation of mature phagocytes (Kierdorf et al. 2013; Marquis et al. 2011). 
PU.1 overexpression in hES derived neural progenitors shows much promise for 
switching the lineage to a monocytic one, although there is still room to improve the 
protocol for increased monocyte production. 
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4.  M-CSF/ IL -3  DIRECTED 
DIFFERENTIATION 
4.1 INTRODUCTION 
Microglia are the immune cells of the brain, which are derived from haematopoietic 
precursors during embryogenesis. They infiltrate the brain prior to the formation of 
the BBB and proliferate in situ until birth. These infiltrating cells are initially ameboid 
cells, which function in the phagocytosis of excess apoptotic neurons produced 
during development to help shape the developing brain, whilst also having the ability 
to provoke cell death of developing cells via a superoxide-dependent mechanism 
(Vilharat, 2005).  A sub-population of microglia are suggested to derive from bone 
marrow cells that migrate into the CNS during pathogenesis throughout postnatal 
and adult life. To this extent it is plausible to hypothesise that in vitro differentiation of 
hESCs to monocytes and subsequent differentiation to microglia poses an attractive 
route to producing Human ES-derived microglial-like cells.  
Generation of hematopoietic cells from hESCs has been established using many 
protocols (reviewed in (Orlovskaya et al. 2008)). Evseenko et al. (2010) utilized an 
adherent method to create hematopoietic cells by culturing in the presence of 
multiple growth factors (SCF, FLt3, TPO, VEGF, IL-3, Epo) and a small molecule 
TGFβ antagonist (SB-431542) supplemented with the use of murine bone marrow 
stromal OP9 feeder layers. Although the focus of their work was tracking and 
mapping the process of epithelial to mesenchymal transition (EMT), they were able 
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to produce CD34+ hematopoietic precursors, which could be further cultured to 
derive monocytes and microglial-like cells. Chadwick et al. (2003) created 
hematopoietic cells through an embryoid body based protocol by culturing for 15 
days, again in the presence of a similar set of growth factors; SCF, FLt3, IL-3, IL-6, 
G-CSF and BMP4. They showed a mechanism for mimicking the events of early 
differentiation of hematopoietic precursors in the embryo resulting in the production 
of a CD34+CD45+ population of cells.  
Both methods, and many of the other protocols discussed by Orlovskaya et al. 
(2008), use multiple growth factors in order to achieve haematopoietic differentiation. 
A more recent report published in PLOS One by van Wilgenburg et al. (2013) and its 
predecessor published in Experimental Haematology by Karlsson et al. (2008) 
showed that hESCs could be differentiated into monocytes  utilising only two growth 
factors,  M-CSF and IL-3, throughout the differentiation. Due to the smaller number 
of growth factors required and the lack of possible feeder layer contamination, this 
protocol is the most attractive and as such is replicated in this chapter with H9 
HESCs in order to achieve hematopoietic differentiation, the foundation of microglial 
differentiation.  
Macrophage – Colony Stimulating Factor (M-CSF) is a haematopoietic cytokine 
whose actions are directed specifically towards macrophages (Rambaldi et al. 1987). 
It was found to be a homodimeric protein, with its two subunits linked via disulphide 
bonds with different isoforms produced through alternative splicing (Cerretti et 
al.1988). M-CSF can also induce differentiation of haematopoeitic stem cells (HSCs) 
to macrophages through synergising with other cytokines, in particular those of the 
the interleukin family, but its main role remains closely connected to macrophages by 
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extending the growth and survival rate of the macrophage precursor, the monocyte 
(Metcalf et al. 1992). 
The other growth factor used in the differentiation protocol described by van 
Wilgenburg et al (2013) is IL-3. Interleukins are a large family of cytokines that are 
defined as being produced by leukocytes; mainly T-cells and macrophages. 
Interleukins have been shown to promote growth and differentiation of cells within 
the haematopoietic system and also play key roles in inflammation (Frendel 1992). 
IL-3 is a small protein that supports the differentiation of HSCs due to its interactions 
with colony stimulating factors, such as M-CSF, resulting in colony forming 
granulocytes, macrophages, erythroid, megakaryocyte and mast cells, whilst also 
being able to signal and effect non-haematopoietic stromal cells in the bone marrow 
(Ihne 1992). 
Hematopoiesis, is a complex process that involves successive loss of multipotency 
and self-renewal of HSCs, the derivation of lineage-restricted progenitors and 
subsequent terminal differentiation to the various blood cells. Amongst the defined 
progenitor populations the Granulocyte Monocyte Progenitor (GMP) is the first to 
form within the AGM of the embryo. GMPs are characterised by expression of both 
CD34 and CD45 and can ultimately give rise to granulocytes, monocytes and 
microglia (Manz et al. 2002). Monocyte-like precursors are the foundation for 
microglial formation and prior to birth microglia proliferate in situ, undergoing 
differentiation from a monocyte-like cell due to the environmental cues secreted from 
the surrounding glial and neuronal cells. Microglial engraftment to the brain during 
pathogenesis in adult life is likely to result from bone marrow derived cells crossing a 
compromised BBB and also differentiating based on the similar cues that signal to 
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embryonic precursors with regard to their subsequent differentiation to microglia, 
although the type of microglial cell produced, whether pro-inflammatory or 
phagocytic is dependent on the inflammatory status of the tissue. Environments rich 
in IL-4 will lead to cells with a greater capacity for phagocytosis, whilst environments 
that have high levels of TNF-a yield a greater proportion of neurotoxic, inflammatory 
microglia.   
4.1 AIM 
The aim of this chapter was to direct the differentiation of hESCs into monocytic 
precursors through the application of the growth factor combination utilised by van 
Wilgenburg and colleagues (2013) namely M-CSF and IL-3 (Figure 3.1). With both 
the GMP (CD34+/CD45+) and monocyte (CD34low/CD45+/CD11b+) cells being further 
differentiated into microglial-like cells in chapter 5. Figure 4.1 provides an overview 
of the differentiation strategy used and illustrates the time course, the stepwise 
changes in culture conditions as well as the transformation in cell morphology within 
these cultures as differentiation proceeds. 
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4.2 THE NON-HAEMATOPOIETIC NATURE OF HESCS 
Since pluripotent cells are prone to spontaneous differentiation to derivatives of the 
three germ layers, endoderm, ectoderm and mesoderm the outcome of directed 
differentiation is dependent on maintaining a high standard of pluripotency in the 
starting hESC population. The quality of the H9 hESCs was assayed through 
immunocytochemistry for the expression of the standard pluripotency markers 
OCT4, SSEA4, NANOG and SOX2 (Figure 4.2). Staining was evident for all markers 
over the whole of all colonies, confirming that conditions were optimal for maintaining 
a pluripotent stem cell state. Staining for the transcription factors OCT4, SOX2 and 
NANOG was restricted to the nucleus, and staining for the surface antigen SSEA4 
was constrained to the plasma membrane.  
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Figure 4.2. The pluripotency of H9 Human Embryonic Stem Cells 
H9 colonies (A and B) had the morphology of pluripotent cells, compact colonies of uniform 
cells with a defined perimeter. The pluripotency of the H9 cells was examined through 
immunocytochemistry using Oct4 (C), SSEA4 (D), Sox2 (E) and Nanog (F). All cells were 
positive for these markers over the entire colony and are thus deemed to be pluripotent. 
Scale bars represent 50um  
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Markers used to follow haematopoietic lineage commitment during hESCs 
differentiation were also analysed by flow cytometry and were confirmed to be 
negative in the starting H9 population. These included CD34, CD45 and CD11b. 
CD34 is a marker for HSCs, CD45 is a marker for leukocytes and CD11b is a marker 
for lineage committed monocytes (Figure 4.3). The data showed that hESCs are not 
innately haematopoietic with the percentage positive cells for each antibody being; 
1.27% CD34+, 1.58% CD45+ and 2.41% CD11b+. The low percentages of positively 
stained cells could be due to background as no staining was evident when 
immunocytochemistry was carried out with the same antibodies. These data 
substantiate that the cells are pluripotent and not committed to a haematopoietic fate 
prior to the onset of differentiation. 
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  Figure 4.3. The non-haematopoietic nature of H9 Human Embryonic Stem 
Cells 
Undifferentiated hESCs were assayed for their expression of the haematopoeitic markers by flow 
cytometry. A and D show the unstained control and the CD34 stained sample respectively.  CD45 
staining was carried out (B) alongside its unstained control (E). The final marker assayed was 
CD11b (C) against its unstained control sample (F). A graph showing the average percentage 
positive cells in three biological replicates is shown in G.  
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4.3 THE MONOCYTE PRODUCING COLONIES 
Directed differentiation of H9 hESCs to monocytes was achieved in two stages; (1) 
the formation of cystic EBs and (2) the adherence of the cystic EBs to tissue culture 
plastic for the production of monocytes into the culture supernatant (factory 
colonies). The commitment of the EB and factory colony cells to the mesoderm 
lineage from their pluripotent precursors was monitored through QRTPCR using 
markers of pluripotency, mesoderm and neural filament; Nanog, Brachyury and 
Nestin, respectively (Figure 4.4). ANOVA for the comparison of the means showed 
that there was a statistically significant difference between them [F(2,18)=199.3, 
p<0.0001]. The post hoc Bonferroni test showed that Brachyury was increased in the 
EB (M=75.95, SD=6.908) compared to the factory colonies (M=0.3981, SD=0.026). 
Both Nestin and Nanog were similar, with no significant difference, in both EBs 
(Nestin (M=1.293, SD=0.292), Nanog (M=0.03401, SD=0.029)) and factory colonies 
(Nestin (M=0.3321, SD=0.103), Nanog (M=0.0003523, SD=0.0000418). 
This means that there is a loss of pluripotency on EB formation, which is sustained 
throughout the culture of the factory colonies. The mesoderm marker brachyury is 
increased during the day 4 EB stage, where production of all three grem layers is 
expected, but decreased in the factory colony stage where there should be the loss 
of general germ layer markers and the expression of the more specific 
haematopoietic ones.   
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Figure 4.4. Commitment of EBs and Factory Colonies to the Mesoderm 
Lineage 
Day 4 EBs are committed to the mesoderm lineage, revealed by a 76-fold increase in Brachyury 
expression compared to the undifferentiated hESCs. Nanog expression was decreased by 96.5% 
of that in hESCs revealing a loss of pluripotency and self-renewal capacity. Nestin, neural filament 
marker, expression remained unchanged. Day 12 factory colonies were shown to have around 
0% less expression of the general mesoderm marker, Brachyury and nestin, whilst expression of 
nanog was decreased by 99.9% compared to the hESCs.  
QRTPCR data is normalised to -Actin over 3 technical replicates of 3 biological replicates 
Asterisks denote statistical significance;  * ≤0.05, ** ≤ 0.01, *** ≤ 0.001, **** ≤ 0.0001 
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To assess the developmental changes that occur in the EB and factory colonies 
expression of both early and late haematopoietic genes were also analysed by 
QRTPCR relative to both hESCs and THP1 monocytes, as shown in Figure 4.5 (A 
and B, respectively). Relative to hESCs there is a statistical difference between the 
means of EB and factory colony gene expression [F(1,24)=233.0, p<0.0001]. 
Bonferroni multiple comparisons test showed that although decreased in the factory 
colonies, FLK1 and RunX1 expression was not statisitically different to that of the 
EBs. The increased expression of PU.1 and CD34 in the factory colonies was also 
shown to not be statistically significant. There were significant increases in the 
expression of CD45 and CD11c in factory colonies (CD45 (M=55.43, SD=4.438), 
CD11c (M=15.32, SD=0.403)) compared to the levels in the EBs (CD45 (M=8.804, 
SD=3.780), CD11c (M=0.7188, SD=0.0645). A comparison of the mean gene 
expression of EBs and Factory cells relative to THP1 monocytes was analysed by 
ANOVA and showed a significant difference between the fold change of the 
expressed genes at the two time points [F(2,36)=6.258, p=0.0046]. Post hoc 
comparisons of the means by the Bonferroni test showed that, with the exception of 
FLK1, the expression of all other genes were not significantly different in the EB 
stage compared to the facotory stage. For FLK1, expression was increased in the 
factory stage (M=5.262, SD=0.177) compared to the EB stage (M=4.131, 
SD=0.664). Although the remaining genes were not statistically different the trend 
implies an increasein expression in the day 12 factory colonies compared to the day 
4 EBs. This indicates that the factory colonies are beginning to differentiate towards 
leukocyte production.  
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Figure 4.5. Haematopoietic Gene Expression in EBs and Factory Cells 
(A) Gene expression relative to hESCs reveals a significant increase in the expression of CD45 
and CD11c in the factory cells (CD45 (M=55.43, SD=4.438), CD11c (M=15.32, SD=0.403)) 
compared to the EBs (CD45 (M=8.804, SD=3.780), CD11c (M=0.7188, SD=0.0645)). 
(B) Relative to THP1 monocytes there is an increase in the expression of FLK1 in the factory 
stage (M=5.262, SD=0.177) compared to the EB stage (M=4.131, SD=0.664). 
QRTPCR data is normalised to -Actin over 3 technical replicates of 3 biological replicates 
Asterisks denote statistical significance;  * ≤0.05, ** ≤ 0.01, *** ≤ 0.001, **** ≤ 0.0001 
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The adherent factory colonies were assayed for the presence of PU.1, FLK1 and 
RUNX1, markers of early haematopoietic precursors along with later markers of 
haematopoiesis; CD34 and CD45 (Figure 4.6). The adherent factory colony cells 
showed evidence of staining for PU.1 from day 8 through to day 20, although the 
location of the staining trafficked between the cytoplasm and the nucleus, which 
would be a way of controlling the dose response required for haematopoiesis. 
Nuclear staining for PU.1 was evident at day 12, which corresponded with the onset 
of the downstream marker CD45 staining the membrane. Upstream of PU.1 is the 
definitive haematopoietic marker, RUNX1, staining for which was high from day 8 
and maintained throughout the differentiation. Maintenance of RUNX1 was expected 
as in vivo RUNX1 is expressed at some level in all haematopoitic cells, with the 
exception of erythrocytes (North et al. 2004). FLK1, a marker of primitive 
hematopoiesis and the haemangioblast, stained most positively between day 8 and 
day 12, after which the presence of staining decreased. CD34 expression was also 
shown to occur only to day 12. This could indicate a ‘budding off’ of CD34+ cells in a 
similar fashion to those of the embryonic blood islands. 
 
 
 
 
 
Figure 4.6. Primitive and definitive haematopoiesis in EBs and Factory 
colonies (Overleaf) 
Haematopoietic markers analysed every 4 days from day 8 (D8) to day 20 (D24).  PU.1 staining 
was evident from D8 and maintained to D20 at low levels, where it cycled from cytoplasm to 
nucleus. Samples were positively stained for FLK1 from D8 onwards. High levels of RUNX1 
staining were observed throughout the time course. The haematopoietic stem cell marker, CD34, 
was only observed by immunohistochemistry to D12. CD45; leukocyte marker, expression is seen 
truly as a membrane bound receptor from D12, after which expression is decreased. The right 
panel shows a schematic representation of the differentiation of haematopoietic cells from the 
Haemangioblast (HMGB) or FLK1+ primitive haematopoietic precursor to the RUNX1+ definitive 
haematopoietic cell (haemogenic endothelium (HMGE). The cells then enter haematopoiesis as the 
CD34+ heamatopoeitic stem cell (HSC) and proceed through to a CD45+ myeloid cell. 
Scale bars represent 50μm 
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4.4 ES-DERIVED MONOCYTES 
The non-adherent cells shed into the culture supernatant from the monocyte 
factories were harvested and examined microscopically using both histological and 
immunological techniques to assay cell morphology and the expression of CD34, 
CD45 and CD11b (Figure 4.7 a-c). Haematoxylin staining of the ES-derived 
monocytes (ESdM) revealed a uniform population of large cells (~20m) with a large 
nuclei and nucleoli, and abundant granular cytoplasm.  Immunocytochemistry 
revealed cells positive for all three haematopoietic markers CD34, CD45 and CD11b. 
The level of CD34 staining inferred of the presence of GMP cells, whilst the CD11b 
staining indicated that monocytes were also present, meaning that the ESdM 
cultures comprised mixed populations of cells at various stages in myeloid 
haematopoiesis.  
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Figure 4.7. Haematopoietic Marker Expression and Morphology 
Immunocytochemistry was carried out on cytocentrifuged cells for the haematopoeitic markers 
CD34 (A), CD45 (B) and CD11b (C) and they were stained histologically with Haematoxylin for 
morphological analysis (D – F).   
Scale bars represent 100µm (A-C), 200µm (D), 100µm (E), 50µm (F) 
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Haematopoietic gene expression in ESdM cells was examined by QRTPCR (Figure 
4.8), and the levels compared to those seen in THP1 monocytes and through 
ANOVA were shown to have no significant difference between the means 
[F(1,2)=3.065, p=0.221]. The only significant difference between the ESdM and 
THP1 lays with the expression of CD11c, which is increased in the ESdM (M=1.371, 
SD=0.114). Although expressed in monocytes, CD11c is more highly expressed in 
microglia and dendritic cells and this marginal increase om expression could indicate 
that the cells have a more microglial nature. 
 
 
  
 
Figure 4.8. Comparison of haematopoietic Gene Expression in ESdM and 
THP1 cells 
Overall comparison of the means by ANOVA, showed no statistical difference [F(1,2)=3.065, 
p=0.221]. A statistically significant difference was seen in the levels of CD11c with expression 
increased in ESdM cells (M=1.371, SD=0.114).  
QRTPCR data was normalised to -Actin and taken from 3 technical replicates of 3 biological 
replicates 
Asterisks denote statistical significance;  * ≤0.05, ** ≤ 0.01, *** ≤ 0.001, **** ≤ 0.0001 
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The non-adherent cells were also characterized by flow cytometry using the same 
three markers to quantify the percentage of cells that were haematopoeitic, 
leukocytic and monocytic. To optimize the FACs protocol and antibodies a primary 
blood mononuclear cell sample was used (Figure 4.9).  
 
 
 
 
Figure 4.9 Optimisation of the FACs protocol 
Control primary blood mononuclear cells (PBMCs) were used to optimise the FACs protocol for the 
conjugated antibodies, CD34 (A/B), CD45 (C/D) and CD11b (E/F). This showed a population of CD34+ 
cells of 23.2%, 17.5% of the cells were CD45+ and CD11b+ cells accounted for 13.5% of PBMCs 
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When the non-adherent cells, produced from the adherent factory colonies were 
stained and analysed by flow cytometry it revealed a small population of CD34+ 
(<5%) early haematopoietic progenitors, and a larger population of CD45 (16.4%) 
and a population of 7% of CD11b positive cells, indicating differentiation to yield 
more committed monocyte-like cells (Figure 4.10).  
Triple staining the supernatant with antibodies against CD34, CD45 and CD11b and 
assessing their co-staining by flow cytometery (Figure 4.11), showed that there was 
a CD34+/CD45+ population of over 47.6% and a committed monocyte, 
CD45+/CD11b+, population of 37.6%. Co-staining of the early HSC marker, CD34, 
and the late monocyte marker, CD11b, resulted in a smaller population of around 
17%. 
This suggests that there is again a mixed population of GMP (CD34+/CD45+) 
precursors as well as committed monocytes (CD45+/CD11b+). From the single 
staining experiments is also appear that the supernatant also contain cells 
transitioning through haematopoiesis and as such fall outside of these defined 
stages, only CD34+ or just CD45+.   
 
 
 
 
  
  4. M-CSF/IL-3 Directed Differentiation  
119 
 
  
Figure 4.10. Quantification of the Haematopoietic Population of Supernatant 
Cells 
Flow cytometry of the supernatant cells using the haematopoietic markers; CD34 (A/B), CD45 
(C/D) and CD11b (E/F) and their dot plots for the unstained (left) and stained (right) samples, 
representative of three individual experiments, show that there is a mixed population of GMP cells 
(4.44% CD34+) and monocytes (16.4% CD45+/ 7.77% CD11b+) within the supernatant.  
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Figure 4.11. Quantification of the Co-Expression of Haematopoietic Markers 
in Supernatant Cells 
Co-expression of CD34/CD45 (A/B), CD45/CD11b (C/D) and CD11b/CD34 (E/F) for the unstained 
(left) and stained (right) supernatant samples, representative of two individual experiments, show 
that there is a GMP CD34+/CD45+ population (upper right quadrant) of 47.6%, a 37.6% population 
of CD45+/CD11b+ cells and a large CD11b+/CD34+ (16.9%).  
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4.5 FUNCTIONALITY OF ES-DERIVED MONOCYTES 
The functionality of the ES-derived cells was examined using a phagocytosis assay. 
Time-lapse microscopy and flow cytometry were used to visualize and quantify the 
uptake of fluorescent E.Coli bioparticles (Figure 4.12). For time lapse microscopy the 
suspended monocytes were first attached to glass coverslips using fibronectin for 
several hours prior to onset of the experiment. Cells were visualised by live staining 
with Cy5-conjugated anti-CD45 antibody to mark the perimeter of the cells and 
Hoescht 33342 to track cell nuclei and were analysed for uptake and cytoplasmic 
localisation of Alexa Fluor® 594-labelled E.Coli beads.  
 
 
 
 
 
 
 
 
Time lapse microscopy (Figure 4.13a/b) of ESdM showed that after eighteen minutes 
of incubation with the opsonised E.Coli bioparticles, the ESdM began to send out 
cytoplasmic extensions to surround the labeled bioparticles, twenty minutes later 
these projections would meet to encapsulate the particles and around 5 minutes post 
encapsulation the extended cytoplasmic processes began to retract followed by 
Figure 4.12 Phagocytosis of E.coli Bioparticles 
Two examples of live CD45 immunofluorescent (green), Hoescht 33342 (blue) stained ES-derived 
monocytes, with uptake and  cytoplasmic concentration of Alexa Fluor® 594 E.coli bioparticals 
(red) following a 60 minute monocyte/E.Coli biopartical co-culture 
Scale Bars represent 100m 
 
Hoescht/E.coli 594/ CD45 Hoescht/E.coli 594/ CD45 
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internalisation of the beads approximately 40 minutes after addition of the particles, 
which then moved to a more central location within the cell after 60 minutes of 
incubation.  
 
 
 
 
 
 
 
Figure 4.13a. Time Lapse Microscopy of E.coli Bioparticle Phagocytosis in 
ESdM (Example 1) 
Images shown are taken every 3 minutes over a period of a 60 minute incubation, starting at 6 
minutes. The arrow highlights the movement of a specific bead during the time course. This 
shows that after 18 minutes cytoplasmic extensions form to surround the bead, which retract upon 
internalisation after around 40 minutes. The bead then moves within the cell to a central location 
by the end of the incubation period.   
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Figure 4.13b. Time Lapse Microscopy of E.coli Bioparticle Phagocytosis in 
ESdM (Example 2) 
Images shown are taken every 3 minutes over a period of a 60 minute incubation, starting at 6 
minutes. The arrow highlights the movement of a specific bead during the time course. This shows 
that after 18 minutes cytoplasmic extensions form to surround the bead, which retract upon 
internalisation after around 40 minutes. The bead then moves within the cell to a central location 
by the end of the incubation period.   
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Flow Cytometry of the resting, unstimulated, cells showed that there was a basal 
capacity of around 35% for phagocytosis in the control THP1 monocyte cell line and 
27% in the ES-derived monocytes after a 60 minute incubation with opsonized Alexa 
Fluor® 594-labelleld E.Coli beads (Figure 4.14).  
 
 
 
 
Figure 4.14. Time Lapse Microscopy of E.coli Bioparticle Phagocytosis in 
ESdM 
Flow cytometry showed that when resting the THP1 cell line (A and B) were showed a phagocytic 
capacity of around 35% which compared well to the ES-derived monocytes (C and D) with a 27% 
capacity 
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4.6 DATA SUMMARY 
We have shown that H9 hESCs expressing the pluripotency markers Oct4, SSEA4, 
nanog and Sox2 do not express markers used to signify commitment to a 
haematopoietic fate. H9 cells underwent hematopoietic differentiation under the 
direction of the cytokines M-CSF and IL-3. Cultures progressed through 
differentiation of mesoderm cells in the EB stage, followed by PU.1 expression in the 
monocyte producing factories and ultimately produce a non-adherent cells positive 
for CD45 and CD11b, characteristic of monocytes. These ESdMs were also shown 
to be functional through their ability to successfully phagocytose E.coli bioparticles in 
a capacity that was similar to those of the human monocytic cell line THP-1. As such 
the method described here is capable of producing ES-derived monocytes from a H9 
cell line as well as for the cell lines used during publication of the protocol by van 
Wilgenburg et al. (2013). 
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4.7 DISCUSSION 
FLK1 and RUNX1 are classic markers for the haemangioblast and primitive or 
definitive embryonic hematopoietic cells prerequisites for the hematopoietic stem cell 
(Lacaud et al. 2002). Downstream of RUNX1 is the transcription factor PU.1 that is 
vital for both the onset of hematopoiesis and the terminal differentiation of 
monocytes (Huang et al. 2008). RUNX1 is also able to bind to CD34 downstream 
regulatory elements, increasing CD34 expression (Levantini et al. 2011). Although 
the presence of RUNX1 and PU.1 in the factory cells concurs with the proposed 
differentiation scheme for monocyte development, the lack of CD34 in the factories is 
unexpected since CD34 precursors are required for the onset of haematopoiesis. 
However, CD34+ cells do subsequently appear in the non-adherent population, 
which is in keeping with the accepted differentiation scheme proposed for monocyte 
development; namely that RUNX1 expression in definitive haematopoietic cells 
results in an increase in PU.1 expression and the onset of haematopoiesis, leading 
to the formation of CD34+ HSCs. PU.1 expression is evident only at low levels at the 
HSC stage but increases as the cells progress through haematopoiesis and become 
committed to a monocytic fate. 
The observation that the adherent factory colony cells, even at late stages, do not 
show significant expression of CD34, but the non-adherent population do, suggests 
that the factory cells act in a similar way to the embryonic blood islands where the 
CD34+ HSCs ‘bud off’ from the islands into the primitive circulatory system, 
explaining their absence in the adherent culture. The factory colonies are composed 
of cells of several different morphologies, which could be explained through their 
formation. The factory colonies arise from the attachment of an EB to the tissue 
culture plastic. Although EB differentiation in the protocol used is biased towards 
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mesoderm, EBs are nevertheless complex developmental entities composed of cell 
derivatives from all three germ layers; the outer primitive endoderm, the mesoderm 
and the inner ectoderm and it is from the mesoderm cells that blood islands are 
formed and subsequently give rise to the non-adherent myeloid cells (Dang et al. 
2002).  
Positivity for CD34+ and CD11b+ expression on cells within the non-adherent 
population is suggestive of both GMP and monocyte differentiation, representing 
cells that are at different stages of haematopoieitic commitment. This could be due to 
asynchrony in differentiation resulting from differential exposure of cells within EBs to 
cytokines. In three dimensional EB cultures cells in the centre respond to signal from 
a different microenvironment than those at the exterior. As such this may account for 
asynchrony in differentiation as well as some diversity in lineage specification.  
Changes in the profile of marker expression map well onto changes expected for 
monocyte differentiation. As cultures progressed through haematopoiesis CD34 
expression was lost and CD45 and CD11b were up-regulated. This progression was 
seen by flow cytometry and corroborated by QRTPCR. 
A hallmark function of monocytes is phagocytosis. Importantly, time-lapse 
microscopy showed that differentiated CD45+ monocytes showed efficient 
phagocytosis of aggregated E.Coli particles. This was proven by flow cytometry, 
which showed that the phagocytic capacity of the ESdMs was similar to that of the 
THP-1 monocytic cell line.  When un-stimulated, approximately 30% of both ESdM 
and THP1 populations showed phagocytosis.  
5.Differentation of ESdM to Microglia 
 
 
 
5.  DIFFERENTIATION OF ES-
DERIVED MONOCYTES TO 
MICROGLIAL-LIKE CELLS 
5.1 INTRODUCTION 
Microglia infiltrate the CNS early in development where they proliferate in situ 
expressing an ameboid phenotype, visible from the second trimester until birth, 
where they then differentiate into the immune dampened ramified phenotype 
(Cuadros and Navascués 1998). It has been suggested that there is a microglial 
niche that enables self-renewal since the BBB, in young healthy individuals, provides 
an obstacle to recruitment of new microglia from their haematopoieitc precursors 
(Davoust et al. 2008). 
In cases where microglial load and thus apoptosis increases, due to infection and 
inflammation, the compromised BBB allows recruitment of new cells from the blood. 
This phenomenon was illustrated by Djukic et al. (2006), who showed that under 
pathological conditions monocytes are recruited to the CNS by secretion of CXCL2 
and CXCL8 from the CNS resident microglia. These infiltrating monocytic cells were 
observed to integrate into the pool of brain microglia gaining both microglial 
morphology and functionality and eventually becoming indistinguishable from the 
established ramified microglia. 
Monocyte descendants range from common macrophages to more specialised 
dendritic cells and microglia. The reason for their diverse differentiation potential is 
due to the constitution and mileu of their target organ, macrophages differentiate 
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within the majority of tissues, whereas dendritic cells are found only in tissues that 
contact the external environment and microglia only differentiate once a monocyte 
crosses the blood brain barrier and is within the CNS.  
Much work has been carried out into the soluble or non-diffusable factors that play a 
role in microglial development. The focus of this work has been on the release of 
cytokines from surrounding astrocytes. The spotlight has fallen on M-CSF as a key 
cytokine in the maturation of microglia. It was shown by Liu et al. (1994) that 
obstructing the c-fms receptor with an antibody there was a complete inhibition of 
microglial ramification, which they corroborated by the use of Hebimycin A, a 
tyrosine kinase inhibitor, which blocked the c-fms cascade and thus cell ramification. 
Depletion of the CSF-1 receptor, the product of the c-fms gene, but not the loss of M-
CSF lead to a decrease in almost 50% of microglia meaning that there must be an 
alternative ligand for CSF-1R in the brain (Greter et al. 2012). This was identified as 
IL-34 by Greter et al. (2012) and work by Ohgidani et al. (2014) showed that IL-34, 
which is released from neurons, in combination with GM-CSF was more successful 
at differentiating microglial-like cells from human peripheral blood cells than GM-CSF 
together with the original ligand, M-CSF.  
Another key difference between monocytes and microglia is the presence of 
outwardly rectifying K+ channels. Schilling et al. (2001) showed that TGF signaling 
was required for the increase in these channels which, along with M-CSF, is 
released from astrocytes. The proliferation of microglia is also under the control of 
astrocytes. It was found that soluble GM-CSF results in the formation of a rod 
shaped cell, which is indicative of proliferation (Suzumura et al. 1991).  
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Microglial differentiation from hESCs proves to be problematic and, as of yet, 
remains unaccomplished. More publications have, however, been made regarding 
the successful differentiation of human microglia from their primary haematopoietic 
precursor cells. Microglia were successfully differentiated from human primary 
monocytes by Etemad et al. (2012) by culture in the presence of MCSF, GMCSF, 
NGF and CCL2 for 14 days, many of which are soluble factors released from 
astrocytes in vivo,. The resultant cells were comparable to those of the HMC3 
microglial cell line based on expression of surface markers, phagocytic ability and 
antigen presentation. 
The reason for the differentiation observed by Djukic et al. (2006) could be explained 
by the work of Sievers et al. (1994), where monocytes from the spleen and liver were 
cultured both in the presence of astrocytes and in astrocytes conditioned media. 
They found that culturing monocytes on an astrocyte monolayer produced a ramified 
microglial cell. The same result was achieved in cells only exposed to astrocyte 
conditioned medium, which suggests that astrocytes orchestrate differentiation 
through the secretion of diffusible factors, most importantly M-CSF, GM-CSF and 
TGF-β, into their surroundings leading to monocyte to microglial differentiation both 
in vitro and in vivo within the brain (Sievers et al. 1994). As such this is a route that 
can be exploited for in vitro differentiation of monocytes to microglial-like cells. 
 
 
 
 
 5.Differentiation of ESdM to Microglial-Like Cells 
130 
 
5.2 AIM 
The previous chapters aimed to produce hES- derived monocytes for their ultimate 
differentiation to microglial-like cells. As described, the overexpression of PU.1, 
although still a possible route to monocyte differentiation, is not as well developed, 
nor as productive for monocyte production as the MCSF/IL-3 directed differentiation 
protocol described in chapter 4. Further work is required to increase the 
reproducibility and yield of monocytic cells using the PU.1 overexpression method. 
As such the monocyte to microglial-like cell differentiation in this chapter will utilise 
hES-derived monocytes (ESdM) from chapter 4. 
Work in this chapter tested the hypothesis that astrocyte conditioned medium or 
astrocyte co-culture would progress the differentiation of ESdMs derived from the 
MCSF/IL-3 directed differentiation protocol to microglial-like cells, characterised by a 
combination of marker expression (IBA-1, Glut5 and CD45) and electrophysiological 
properties that distinguish between macrophages and microglia. Figure 5.1 
summarises the differentiation strategy.
 
 
Figure 5.1. Schematic Representation of the Differentiation Protocol 
ESdM (a) from the XVIVO factories (Chapter 4) were plated onto fibronectin coated coverslips (b) 
and cultured for seven days in medium conditioned by astrocytes, where they differentiate into 
microglia of the ramified morphology (c). 
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5.3 MONOCYTE DIFFERENTIATION TO MICROGLIAL-LIKE CELLS 
Since brain microglia are thought to differentiate from bone marrow derived 
monocytes in response to signals from astrocytes (Sievers et al., 1994) we 
investigated the responses of ESdMs and control THP1 cells to astrocyte 
conditioned medium (ACM). 
THP-1 cells and ESdMs were grown in fibronectin coated plates and transferred from 
monocyte maintenance medium to a DMEM/F12/Neurobrew21 base medium (See 
Section 2.1.1) that is routinely used for neural and astroglial cell culture, with or 
without conditioning from primary mouse astrocytes. After 7 days a dramatic 
difference in the appearance of cells cultured in ACM compared to those cutured in 
control medium was observed. Treatment with ACM transformed both the THP1 and 
ESdM monocytes to display a ramified morphology with elongated processes. 
Furthermore, ACM induced expression of the microglial marker IBA-1, phenotypes 
that were not observed in cells cultured for the same period in unconditioned control 
medium (Figure 5.2 A - H).  Upon quantification of the IBA-1+ cells, it was shown that 
88.9% of EsdMs cultured in ACM were IBA-1+ compared to just 22% in the 
unconditioned media. Similarly 80% of the THP-1 monocytes were IBA-1+ when 
cultured in ACM, whilst only 25.7% were positive for IBA-1 in the unconditioned 
media control.  
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It was also observed that ACM provided an apparent selection for the IBA-
1+/ramified cells.  Compared to the number of cells plated, approximately 17%  were 
present at day 7 post-plating in ACM, compared to approximately 80%  in 
unconditioned medium. It is interesting to note that the percentage survival is similar 
to the percentage of CD11b+ cells that were originally present within the ESdM 
population derived from the MCSF/IL-3 directed differentiation protocol (Figure 5.3).   
 
 
 
Figure 5.3. Culture with ACM Leads to a Decrease in Cell Number in the 
ESdM Population 
When cultured in unconditioned media, there was maintenance of ~80% of the plated cells by day 
7, none of which were IBA-1+. Conversely culturing in ACM led to a reduction in cell number, to 
around 17% of the starting cell number. 
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The loss of cells on culturing with ACM and the apparent selection for CD11b+ cells 
that differentiated into IBA-1+ ramified microglial-like cells led to the hypothesis that 
the ramified cells stopped proliferating and thus ACM promoted terminal 
differentiation of the cells. Evidence suggests that in order to proliferate ramified 
microglia must re-activate to the ameboid form, and that such activation can be 
achieved by stimulation with GM-CSF (Zielasek and Hartung 1996). 
Immunocytochemistry for Ki67, a marker of the active phases of the cell cycle and so 
proliferation, was carried out on EsdM cultured in ACM for 7 days supplemented with 
either 5µg or 50µg GM-CSF and compared to the unstimulated cells (Figure 5.4). It 
was found that in the unstimulated cells, only 3% of the IBA-1+ cells stained for Ki67 
(Figure 5.4 A). Upon stimulation with 5µg GM-CSF there was staining within the 
nuclei of the 69% of the IBA-1+ cells, and some were seen to be in the process of 
mitosis (Figure 5.4 B). Stimulation with 50µg GM-CSF also resulted in Ki67+/IBA-1+ 
cells, but less frequently with only 18% of the total number of cells staining positively 
for both markers (Figure 5.4 C). 
  
Figure 5.4. GM-CSF promotes proliferation in ESdM Cultured in ACM 
(A) Unstimulated, IBA-1+, cells lacked nuclear Ki67 staining, whilst (B) stimulation with 5µg GM-CSF 
led to the re-entry of the IBA-1+ cells to the cell cycle and the presence of Ki67. (C) Addition of 50µg 
GM-CSF led Ki67 staining within the nuclei of the IBA-1+ cells. Arrow heads indicate Ki67+ cells, 
Arrows indicate mitotic cells. 
Scale Bars represent 100µm 
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Since IBA-1 can be expressed in both microglia and activated macrophages, the 
resultant cells from the ACM and control cultures were also stained at day 7 for 
CD45 and Glut5. CD45 is a marker of leukocytes, it is highly expressed in 
monocytes and macrophages but is only expressed at very low levels in microglia 
with the ramified phenotype (Sedgwick et al. 1991). Glut5 is a highly selective 
marker for microglia and can be used to discriminate against even perivascular 
macrophages (Kettenmann et al. 2011). Thus ramified microglia can be defined as 
CD45low/Glut5+. Use of CD45 and Glut5 confirmed the microglial-like phenotype of 
the IBA-1+ cells induced by treatment with ACM (Figure 5.5). After treatment with 
ACM both ESdM and control THP1 cells showed robust Glut5 staining (88.5% and 
88.9% of total cells, respecitvely), with only 32.5% of EsdMs and 37% of THP-1 
monocytes positive for CD45 (Figure 5.5 A - D). This contrasted with the reciprocal 
pattern of high CD45 and low Glut5 staining seen in cells cultured in unconditioned 
medium (Figure 5.5 E - H). In detail, unconditioned media resulted in 13.6% of 
EsdMs and 8.3% of THP-1 monocytes staining for Glut5, whilst 95.3% of EsdMs and 
90.5% of THP-1 monocytes were positive for CD45. The staining also illustrates the 
morphological changes associated with ACM culture. In unconditioned medium the 
membrane staining of CD45 shows that both ESdM and THP1 cells are, without 
exception, round with low complexity. Whereas Glut5 staining in ACM treated 
cultures shows more complex cell morphologies that are elongated with process 
formation, typical of microglia.  
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The microglial-like cells generated from culture in ACM were also analysed by 
QRTPCR for the expression of microglial genes, with gene expression levels  
compared to those in unconditioned media and relative to those present in THP-1 
monocytes (Figure 5.6 A and B). ANOVA was used to compare the gene expression 
of cells cultured in ACM for 7 days to those cultured in the unconditioned media and 
it showed a significant difference for both the control cell line, THP1 monocytes, 
[F(1,12)=1203, p<0.0001] and for the EsdM [F(1,12)=60.71, p<0.0001].  
Bonferroni’s multiple comparison test for THP1 monocytes in ACM compared to 
those in unconditioned media showed that there was no significant change in the 
levels of CD45 or IBA-1 although the trend implied that CD45 expression had 
decreased in ACM culture and IBA-1 expression had increased. There was also no 
significant difference in the expression of TREM-2 or CD11c between the culture 
conditons. Surprisingly there was deemed to be no significant decrease in the 
expression of the monocyte specific marker NG2 upon culture in ACM 
(THP1(M=1.337, SD=0.371), THP1MG (M=49.86, SD=0.0001)).  As expected the 
microglial specific marker CD80 was increased upon culture in ACM (THP1 
(M=0.9323, SD=0.091), THP1MG (M=49.86, SD=2.2410)).  
When the same comparison was carried out to compare EsdM cultured in ACM to 
those cultured in unconditioned media it showed that there was a similar, 
insignificant, trend for decreased CD45 and increased IBA-1. Here there was, as 
expected, a significant decrease in the levels of the monocyte marker NG2 when 
cells were cultured in ACM (EsdM (M=32.68, SD=1.218), EsdMG (M=0.7646, 
SD=0.093)). This corresponded with an increase in CD80 expression post culture in 
ACM (EsdM (M=0.1785, SD=0.099), EsdMG (M=29.00, SD=4.880)). CD11c is 
expressed on both monocytes and microglia, with the greatest expression observed 
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in the latter. After 7 days in ACM there was an increase in CD11c expression (EsdM 
(M=0.06338, SD=0.056), EsdMG (M=8.352, SD=0.049)). TREM2, being a myeloid 
receptor, is apparent on all myeloid cells but in this case culture in ACM caused a 
large increase in expression of over 42-fold (EsdM (M=16.82, SD=0.977), EsdMG 
(M=59.04, SD=9.026)).   
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Figure 5.6. Expression of Microglia Specific Genes 
(A) THP1 cells were cultured for seven days in either astrocyte conditioned medium (THP1MG) or 
unconditioned base medium (THP1). The microglial gene CD80 was shown to be significantly 
increased upon culture in ACM (THP1 (M=0.9323, SD=0.091), THP1MG (M=49.86, SD=2.241)). The 
changes in expression for the other measured genes did not show a significant difference between 
culture media. The trend did indicate that there was a decrease in monocytic genes (NG2 and CD45). 
(B) EsDM cells were also cultured for seven days in either astrocyte conditioned medium (EsdMG) or 
unconditioned base media (EsdM). There was a significant decrease in NG2 expression upon ACM 
culture (EsdM (M=32.68, SD=1.218), EsDMG (M=0.7646, SD=0.093)), and an increase in CD80 
(EsdM (M=0.1785, SD=0.099), EsDMG (M=29.00, SD=4.880)), CD11c (EsdM (M=0.06338, 
SD=0.056), EsDMG (M=8.352, SD=0.049)) and TREM2 (EsDM (M=16.82, SD=0.977), EsDMG 
(M=59.04, SD=9.026)) expression.  
QPCR data is normalised to -Actin with data obtained from 3 technical replicates of 3 biological 
replicates 
Asterisks denote statistical significance;  * ≤0.05, ** ≤ 0.01, *** ≤ 0.001, **** ≤ 0.0001 
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5.4 ELECTROPHYSIOLOGICAL PROFILE OF ES-DERIVED MICROGLIAL-
LIKE CELLS 
Previous work has determined that microglia express a distinctive profile of 
electrophysiological activity (Kettenmann et al. 1993; Kettenmann et al. 2011). The 
most characteristic and distinctive channel possed by microglia is an inwardly 
rectifying K+ channel, which is not present in any other myeloid lineage cell 
(Kettenmann et al. 1993). The presence and activity of the Kir channel can be 
induced in monocytes and macrophages by co-culture with astrocytes and astrocytic 
factors released into conditioned medium (Schmidtmayer et al. 1994). Attachment of 
microglia to a substratum also induces a change in the ion channel profile, with the 
appearance of voltage gated K+ channels (McLarnon et al. 1997). The presence of a 
voltage-gated sodium channel is also expected, this is suggested to be due to the 
expression of NaV1.5 or NaV1.6 channels (Black and Waxman 2012). 
Na+ and K+ channel expression was investigated using whole-cell patch clamp 
electrophysiology (Figure 5.7). By utilising a voltage step protocol from -170mV to 
+60mV after clamping at -70mV and using whole cell patch clamps to record the 
data, the family of currents generated show the presence of large inward currents 
with the addition of some outward or voltage gated events (Figure 5.7B). 
When these data were investigated via mean current density versus voltage plots, 
there was evidence to suggest that the majority of cells possessed inwardly rectifying 
K+ channels, confirmed by the reversal potential of around -80mV (Figure 5.7C). The 
lack of plateau subsequent to this, expected if only Kir channels were present, would 
suggest that there was also the presence of voltage-gated K+ channels in the 
EsdMG when attached to coverslips with fibronectin and cultured in ACM. As 
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mentioned, attachment to a substrate has been shown to induce the activity of KV 
channels (McLarnon et al. 1997). 
 NaV channels are also thought to be present in microglia, and are to be linked to the 
activation state of the cell.  Of the cells investigated, around 50%, showed a mean-
current density versus voltage plot that resembled that of voltage-gated sodium 
channels (Figure 5.7 D). The reversal potential in this case was around +20mV, 
although large error bars were present,  possibly due to a highly variable intracellular 
sodium concentration between the tested cells. 
The membrane capacitance of cells is relative to the cell surface area and thus size 
of the cell. Microglia are thought to have smaller membrane capacitance than 
neurons but a similar capacitance to macrophages. The capacitance of the EsdMG 
subsequent to culture in ACM for 7 days (Table 5.1) was, on average, 34.34 ± 
2.48pF (n=14), an expected value for microglial cells. If we assume 1µF/cm², this 
means that the average area under the patch clamp was 3434.26 ± 247.94µm².  
  
Table 5.1 EsDMG Membrane Capacitance Values 
The membrane capacitance of the ESdMG was on average 34.34 ± 2.48pF. Assuming 1µF/cm², 
the average area under patch clamp was 3434.46 ± 247.94µm². 
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To quantify the expression of selected ion channels, QRTPCR was performed for 
Kir2.1, NaV1.5 and NaV1.6 and expression was compared in ACM and in the 
unconditioned base medium relative to THP1 monocytes (Figure 5.8). ANOVA 
showed that there was a significaant difference in the means depending on culture 
media [F(3,24)=94.65, p<0.0001]. For THP1 monocytes, culture in ACM promoted 
the expression of both Kir2.1 (THP1 (M=0.1600, SD=0.053) THP1MG (M=2.770, 
SD=0.665)) and NaV1.6 (THP1 (M=0.2533, SD=0.029), THP1MG (M=1.983, 
SD=0.340)). Culture conditions seemed to not have an effect on the levels of NaV1.5, 
as there was no significant difference in expression.  
The same was true of the EsDM, ACM culture lead to an increase in both Kir2.1 
(EsdM (M=0.2267, SD=0.006), EsdMG (M=6.843, SD=0.930)) and NaV1.6 (EsdM 
(M=1.953, SD=0.741), EsDMG (M=4.320, SD =0.902)). Again culture in ACM had no 
effect on the expression of NaV1.5.  
Kir2.1 channels are prevelant in microglia and is expressed less in monocytes and 
macrophages, and as such is a good marker for microglial functionality. Thus the 
increase in their expression after culture in ACM is indicative of the formation of 
microglial-like cells. Voltage gated Na+ channels are also expressed in microglia, of 
the two most likely candidates found within the literature, NaV1.6 was most highly 
expressed in cells cultured in ACM for seven days, whilst NaV1.5 expression was 
illustrated to be down-regulated in all cells regardless of conditioning relative to the 
maintained THP1 monocytes and thus not responsible for the NaV-type traces 
witnessed by the electrophysiology.  
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Figure 5.8. Expression of Ion Channels in Microglia 
ES derived monocytes (ESdM) and THP1 cells were cultured for seven days in either 
conditioned medium (-MG) or unconditioned medium. Kir2,1is upregulated in both THP1MG 
and EsdMG after culture in ACM, similarly Nav1.6 is also increased after seven days in ACM. 
Nav1,5 remains constant, regardless of conditioning, and is downregulated relative to THP1 
monocytes in maintenance media.  
QPCR data is normalised to -Actin with data obtained from 3 technical replicates of 3 
biological replicates. 
Asterisks denote statistical significance;  * ≤0.05, ** ≤ 0.01, *** ≤ 0.001, **** ≤ 0.0001 
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5.5 FUNCTIONALITY OF ES-DERIVED MICROGLIAL-LIKE CELLS 
To determine whether the microglial-like cells produced by culture of ESdMs in ACM 
were could be activated, cultures were incubated with amyloid A or the reverse 
control peptide rA(42-1) for 120 minutes. The results were consistent with the 
hypothesis that ramified microglia on Aβ(1-42) incubation would re-activate to the 
ameboid form and phagocytose the peptide (Figure 5.9 A-D). This was not seen to 
the same extent when incubated with the control. Although the cells do not become 
ameboid and are not activated there is staining for Aβ on the membrane of the cell. 
In the unconditioned control, Aβ staining is seen around the nucleus, which could 
indicate phagocytosis by the CD45+ cells that this culture produces. There is no 
such staining evident on the rAβ treated cells. Preliminary sholl analysis of the ACM 
cultured cells (Figure 5.9 E) shows that ramified cells are around 200µm in length 
prior to Aβ treatment. Upon treatment of these cells with rAβ(1-42) has little effect on 
the cell length, but there is a trend for a decreased number of processes. Conversely 
treatment of ACM cultured cells with Aβ(1-42) resulted in a dramatically reduced cell 
length, by 35%, due to the retraction of processes as the ramified quiescent cell is 
re-activated to the phagocytic ameboid form.  
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Figure 5.9. Activation of ES-derived Microglia by Amyloid β 
The ES-derived monocytes cultured in unconditioned medium and subjected to incubation with 
either Aβ(1-42) (A) or the control peptide (B) remain IBA-1 negative, with no morphological changes. 
Monocytes cultured in ACM for 7 days and subjected to a 120 minute incubation with Aβ(1-42) show 
IBA-1 positivity with a rounded, ameboid, phenotype and internalization of Aβ (C). When incubated 
with the control peptide, the cells remain IBA-1 positive but do not take on the ameboid form (D). 
Preliminary sholl analysis shows that treatment of ACM cultured cells with rAβ(42-1) makes little 
difference in the length of the microglial-like cells when compared to untreated cells ACM cultured 
cells (E). Incubation of ACM cultured cells with Aβ(1-42) reduces cell length by over a third as 
processes retract (E). 
Scale bars represent 50μm 
 
E 
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The morphological changes witnessed through the immunocytochemistry, should be 
accompanied by changes in the expression and release of cytokines. To corroborate 
this, EsdMG and EsdM were collected post incubation with either Aβ(1-42) or the 
control rAβ(42-1) and tested for changes in mRNA levels of cytokines through 
QRTPCR relative to THP1 monocytes in maintenance media (Figure 5.10). ANOVA 
was used to compare the means, which showed a significant difference between 
them [F(3,12)=259.1, p<0.0001]. Bonferroni multiple comparison test showed that 
there was no significant difference in the expression of TNFα regardless if cell type 
or Aβ(1-42) addition.  
IL-1β expression in EsdM treated with Aβ(1-42) was increased compared to EsdMG 
treated with Aβ(1-42) (EsdM (M=17.37, SD=1.556), EsdMG (M=9.268, SD=0.279)). IL-
1β was decreased in EsdMG when treated with the reverse peptide rAβ(42-1) 
(EsdMG+Aβ (M=9.268, SD=0.279), EsdMG+rAβ (M=1.368, SD=0.080)). IL-1β was 
similarly reduced in the EsdM when treated with the reverse peptide compared to 
treatment with Aβ(1-42) (EsdM+Aβ (M=17.37, SD=1.556), EsdM+rAβ (M=3.128, 
SD=0.490)). Comparing the effect of rAβ(42-1) on EsdMG and EsdM there was an 
increase in expression of IL-1β in EsdM + rAβ(42-1)  (EsdMG+Aβ (M=1.368, 
SD=0.080), EsdM+rAβ (M=3.128, SD=0.490)). 
Between both the cell types, the EsdM monocytes show the greatest increases in 
cytokine levels when Aβ(1-42). There was a less pronounced effect on the levels of 
cytokines in EsdMG when treated with Aβ(1-42).  
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Figure 5.10. Levels of Cytokine mRNA Post Incubation with Aβ 
ES derived microglia (ESdMG) or ES derived monocytes (ESdM) were incubated with either 
5μg/ml AB(1-42) or an equal concentration of the control rAB(42-1). There was no statistical difference 
in the expression of TNFα on addition of AB(1-42). IL-1β was increased in EsdM+Aβ compared to 
EsdMG+Aβ (EsdM (M=17.37, SD=1.556), EsdMG (M=9.268, SD=0.279)). When treated with the 
reverse peptide both EsdMG and EsdM were decreased compared to the AB(1-42) treated cells. The 
effect of treatment with rAB(42-1) on the cells resulted in the decreased IL-1β, but of the two cell 
types the greatest expression was observed in the EsdM monocytes. 
QPCR data is normalised to -Actin with data obtained from 3 technical replicates of 3 biological 
replicates 
Asterisks denote statistical significance;  * ≤0.05, ** ≤ 0.01, *** ≤ 0.001, **** ≤ 0.0001 
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Figure 5.11. Cytokine Secretion post AB Incubation 
The dot blot was carried out for ESdMG in ACM or ESdM in unconditioned media. All cells were 
treated with either Aβ(1-42) or rAβ(42-1). Major differences are highlighted by white rectangles; IL-13 
(I),  IL-17 (II), IL-27 (III), MIF (IV) and SERPINE1 (V) in cells cultured with ACM on addition of Aβ 
and CD154 (VI), IFN-ү (VII), IL-1α (VIII), IL-1ra (IX), IL-2 (X), IL-16 (XI), and IL-32a (XII) in cells 
cultured in unconditioned media with the addition of Aβ. 
 
The cytokine release from the cells was also assayed by collecting the supernatant 
post incubation with both Aβ(1-42) and the control, rAβ(42-1), and analysing through 
immunoblotting techniques (Figures 5.11-5.14).  
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The cytokine array (Figure 5.11/5.12) showed that when ESdMG in ACM are 
incubated with Aβ(1-42) , there was an increase in the levels of MIF and SERPIN E1 
along with increases in the levels of several interleukins; IL-13, IL-17 and IL-27. 
When EsdM, cultured in the unconditioned base media, were treated with Aβ(1-42) 
there was an increase in the levels of CD154, IFN-γ, IL-1α along with IL-1rα, IL-2, IL-
16 and IL-32α. This shows that the EsdMG were behaving in a anti-inflammatory 
manner, whilst the EsdM, being monocytic, were pro-inflammatory. 
The chemokine array (Figure 5.13/5.14) showed that post incubation with Aβ(1-42) , 
there was an increase in the levels of secreted CCL21 and CCL19 in EsdMG 
cultured in ACM. There was also an increase in CXCL4 levels along with an increase 
in IL-8 secretion seen in these cells. Secretion of CXCL5 and IL-16 was increased in 
those cells cultured in unconditioned medium and incubated with Aβ. Again 
suggesting an anti-inflammatory nature in the EsdMG and a pro-inflammatory nature 
in the EsdM monocytes. 
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Figure 5.13. Chemokine Secretion post AB Incubation 
The dot blot was carried out for ESdMG in ACM or ESdM in unconditioned media. All cells were 
treated with either Aβ(1-42) or rAβ(42-1). Major differences are highlighted by the black rectangles; 
CCL21(I), IL-8 (II), CCL19 (II), CXCL4 (IV) in cells cultured with ACM and on the addition of Aβ 
and CCL26 (V), IL-16 (VI) in cells cultured in unconditioned media upon the addition of Aβ. 
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5.6 DATA SUMMARY 
We showed that EsdMs that were cultured in ACM for seven days differentiated into 
ramified microglial-like cells. This resulted in the formation of IBA-1+/Glut5+/CD45low 
cells, which were not produced when culturing in unconditioned control medium 
(IBA-1-/Glut5-/CD45high). These ramified microglial-like cells were susceptible to 
stimulation by GM-CSF, which increased the rate of proliferation.   
The microglial-like cells were further characterised by QRTPCR for microglial and 
monocytic genes, which showed low expression of monocytic genes NG2 and CD45, 
but increased expression of microglial gene, CD80, whilst there was also expression 
of TREM2 and IBA-1 in all cell types.  
Electrophysiological experiments showed that there was the presence of both 
inwardly rectifying and voltage gated potassium channels and voltage gated sodium 
channels in the resting H9-derived cells. The membrane capacitance, and thus cell 
surface area, was consistent with values gained in prior published experiments. 
Together this data reveals that the cells differentiated in ACM are of a microglial-like 
nature.  
Further functional experiments showed that the ramified cells were capable of 
becoming activated to the ameboid form on incubation with AB(1-42), which was not 
seen when incubated with the reverse control peptide. Under these conditions the 
ESdMG also secreted cytokines and chemokines, although here the profile would 
suggest that the EsdMG were anti-inflammatory in nature, rather than the pro-
inflammatory nature expected in the case of AD. 
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5.7 DISCUSSION 
This work showed that monocytes derived from H9 hESCs are able to differentiate 
into microglial-like cells in the presence of astrocytes but we also see the same 
differentiation with only astrocyte conditioned media. 
Since monocytes can differentiate into microglia in medium only conditioned by 
astrocytes and do not require a physical astrocyte presence, this shows that 
monocytes require cues from their surrounding mileu to differentiate. As mentioned 
previously and in the works of Sievers et al. (1994) these factors are likely to be M-
CSF, GM-CSF and TGF-β. The differentiation shown here occurs within just seven 
days, whereas protocols using a defined medium with additional growth factors, such 
as that of Etemad at al. (2012), takes twice as long. This is most likely due to the 
astrocytic secretion of all the required cytokines at the correct concentration, 
initiating an efficient differentiation.  
Clearly microglia and macrophages are intricately linked and thus specific markers to 
differentiate between both populations are difficult to find. Even the routinely used 
IBA-1 falls short in this application since it is also expressed by activated 
macrophages. Here we used a combination of IBA-1, the more specific Glut5 and 
CD45. This showed that under the influence of ACM monocytes differentiate into 
microglial-like cells. It was noted that only around 17%, the level of CD11b+ cells in 
the ESdM supernatant, remained after 7 days of ACM culture. This suggests that 
only committed monocytes (CD11b+) and not their GMP precursors (CD34+/CD45+) 
are able to differentiate into microglial-like cells. 
To ultimately distinguish between these cell types electrophysiology was used to 
show the presence of inwardly rectifying K+ channels with the absence of outward 
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currents, this observation concurs with the published findings from Kettenman et al. 
During the recording there was also evidence of the presence of a voltage gated 
sodium channel, such channels seen in the work of Anderson et al. (2006). 
Membrane capacitance is proportional to the surface area of the cell under the patch 
clamp. Reports of microglial capacitance range from, 46 ± 2pF and 18 ± 6pF and 
culture in ACM has been shown to lead to increases in membrane capacitance in the 
order of around 9pF, due to increased ramification (Toulme and Khakh 2012; 
Boucsein et al. 2000; Klee et al. 1999). The average capcitance of the EsdMG was 
34.34 ± 2.48pF, and thus a value expected for microglial cells.  
Activation of microglia from the immune dampened ramified cell to the phagocytic 
ameboid cell in the presence of Aβ is determined by engagement of the fAβ receptor 
complex along with the activation of ion channels and transporters. The fAβ receptor 
complex is comprised of CD36, CD47 and integrin α6 β1, which is able to initiate a 
cascade involving the Src kinases Lyn and Syk, followed by ERK and then p38 map 
kinase to lead to the secretion of IL-1β and phagocytosis of the Aβ (Bamberger et al. 
2003; Koeingsknecht-Talboo and Landreth 2005). De-ramification is in part due to 
the osmotic potential of the cell, which is tightly regulated by ion channels and 
transporters. Non-selective cation channels within the cell body enable the entry of 
cations that results in the entry of water and the swelling of the cell body. Conversely 
there is an efflux of KCl through Cl-/K+ co-transporters localized on the processes, 
which causes efflux of water and their retraction to the ameboid phenotype. Aβ itself 
is regarded by many as a regulator of voltage-gated potassium and calcium 
channels in neurons. Plant et al. (2006) show that AB acts as a chaperone of KV4 
subunits to the plasma membrane to result in an increased A-type current. Although 
this work is focused upon neurons, microglia also possess KV channels, which are 
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up-regulated during activation with Aβ. Upon staining ESdMG for Aβ after incubation 
there is evidence of intra-membrane staining, which could be linked to the 
chaperoning role proposed by Plant et al. (2006). 
The ESdMG show the presence of Kir2.1 and NaV1.6 whilst they have very little 
expression of NaV1.5 channels. NaV1.5 has been the focus of voltage gated sodium 
channel work in human microglia in recent years but it has been noted that their 
appearance is activation dependent (Nicholson and Randall 2009). Since the 
microglial-like cells cultured here are of the immune dampened ramified form, it is 
perhaps fitting that there is little activity from these channels.  
Associated with IL-1β is the NFκB pathway, where a positive feedback system is 
instigated with NFκB acting as the transcription factor for the production of yet more 
IL-1β. In this pathway TNF-α also plays a role, through a very similar positive 
feedback mechanism. Both IL-1β and TNF-α can, through this signaling cascade, 
lead to the degradation of the cell. TNF-α production is also stimulated by IFN-ү 
secretion, which effects the cell through a JAK/STAT mediated pathway involving 
STAT1a and inducing several genes, not just TNF-α, but also IL-1, IL-3, G-CSF and 
GM-CSF along with a positive feedback system for IFN-ү expression (Benveniste 
and Benos 1995). 
Secretion of all three of these cytokines can have detrimental effects on the survival 
of surrounding cells, causing the initiation of their own NFκB pathway and cell 
degradation, a vicious cycle that leads to a region of inflammation and in the case of 
microglia and the brain, loss of the surrounding neuron population. This is seen in 
neurodegeneration and in particular AD, where the decrease in brain volume is 
substantial. 
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Activation of microglia is dependent upon the level of tPA, an enzyme required for 
the conversion of Plasminogen to plasmin. In this regard the increased levels of MIF 
and SERPIN E1 witnessed in the array would suggest that the Aβ(1-42) is not acting in 
a neurotoxic manner, but instead is in the case of MIF retarding neuronal death and 
enhancing axonal regeneration whilst transforming ramified microglia to the ameboid 
form. Infusion of MIF into mouse brain prior to excitotoxin – induced neuronal death 
was shown to protect neurons against the damage. SERPIN E1, an inhibitor of both 
tPA and uPA increases the migratory ability of microglia and modulates 
phagocytosis, whilst inhibiting microglial activation through the tPA pathway. 
Plasmin, a broad spectrum protease, is able to degrade Aβ and promote non-
amyloidogenic cleavage to sAPPa. Thus tPA inhibition through SERPIN E1, which is 
increased in both AD patients and through direct AB injection in murine models, 
results in AB accumulation and the formation of senile plaques and ghost tangles. 
Several interleukins were shown to be increased in the ESdMG cultures on addition 
of Aβ. IL-13 secretion was increased on addition of Aβ and has been shown to 
induce death of activated microglia through the enhancement of COX-2 expression 
and PGE(2) production. This fits with the degradation of microglia that have 
phagocytosed Aβ, to prevent further inflammation. IL-17 was shown to be increased 
dramatically in ESdMG cultures on addition of Aβ. IL-17 was shown to be increased 
in the ESdMG cultures with Aβ addition, whilst very little was released by the ESdMG 
stimulated with the reverse peptide. This increase is similar to published results, 
where unstimulated microglia produced no IL-17, whilst the increase in the 
stimulated microglia also lead to the increased expression of anti-inflammatory 
proteins, NGF, BDNF and GDNF. Finally IL-27 secretion was up-regulated in cells 
treated with Aβ. IL-27 inhibits Aβ degradation and enhances its retention once 
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phagocytosed by microglia. It has also been shown that IL-27 inhibits OSM-mediated 
TNF-α and iNOS expression in microglia. 
This reveals that the ESdMG although functional are not neurotoxic, from their 
activation being inhibited, the increased anti-inflammatory proteins that result from 
the secretion of the specific interleukins that were up-regulated, to the increase in 
cell death that results from increased COX-2 expression.  
This could be due to the Aβ incubation time being too short, so that there was little 
time for neurotoxic behaviours to develop, the microglial-like cells were not pre-
conditioned to react in a cytotoxic manner or it could be due to the ESdMG being 
immature and acting more like fetal microglia than the aged microglia that are found 
in AD brains. 
The second array highlighted several differences in chemokines secreted by ESdMG 
when treated with AB compared to those secreted by ESdM. Of note are the 
chemokines that are involved in homing and chemotaxis; CCL21 and MIP-3b 
(CCL19). These are up-regulated in ESdMG after incubation with AB and microglia 
have been shown to have increased migration to these chemokines when TREM2 is 
stimulated. TREM2, a risk factor gene in AD, controls phagocytosis and the 
production of pro-inflammatory mediators. Stimulation increases phagocytosis and 
decreases pro-inflammatory mediators.  CXCL4 has also been shown to be involved 
in chemotaxis of microglia, which requires CXCR3. CXCL4 has also been shown to 
decrease facial nerve regeneration and increase the severity of disease in stroke 
models when exogenously applied. In monocytes there is an increase in phagocytic 
ability in response to CXCL4 but it was shown to be decreased in microglia, along 
with a decrease in NO production.  CXCL4 is not found in ramified microglia and is 
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not found within neurons or astrocytes. IL-8 was shown to be increased in ESdMG 
incubated with AB. Studies suggest that IL-8 causes an increase in COX-2 and is 
produced in response to pro-inflammatory stimuli, such as LPS or Aβ. IL-8 is also 
functional in microglial chemotaxis. Together this again suggests that the ESdMG, 
although functional, are not centres of inflammation when incubated with Aβ.  
There are four proteins that are present on both the cytokine and chemokine array, 
but their expression differs between each array. IL-8 is only present in the EsdM 
cultured in ACM and incubated with Aβ. It has a pixel density of around 250 in the 
cytokine array, whereas the chemokine array showed IL-8 pixel density to be 
doubled. IL-16 is present in all conditions in the cytokine array but only present in 
EsdM cultured in unconditioned media and treated with Aβ in the chemokine array, 
but all densities are less than 1000. IP-10 is not present in the unconditioned media 
group treated with rAβ in the cytokine array but is present in all other conditions. In 
the chemokine array IP-10 is absent from the ACM + Aβ group. For both arrays the 
pixel densities are less than 600. Finally SDF-1 is present only in the unconditioned 
+ Aβ group in the cytokine array, but is present in all conditions in the chemokine 
array, with densities far below 1000.  
This could be attributed to many factors including; the supernatants being taken from 
different wells. We know that the EsDM population is a mixed one and although ACM 
seemingly provides a selection for IBA-1+ cells, there could be different cell types, at 
various stages of differentiation contained within each well that could lead to 
differences in protein secretion. The differences between arrays could also be 
attributed to potential differences in the protein concentration within each sample, 
although a constant volume, 250µl, of supernatant was added to each array 
membrane it does not necessarily follow that there is a consistent protein 
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concentration and there is no way in which to normalise for such differences. Finally 
the differences in the density of these spots are small and they arise from weak 
spots that could result in less accuracy during the analysis, especially after 
background subtraction.  
The levels of GM-CSF from the cytokine array were similar for both treatments with 
both cell types. GM-CSF is considered to be one of the major factors released by 
astrocytes that directly influences microglial phenotype and proliferation. To enable 
the true effect of Aβ(1-42) stimulation to be deduced a media only control would need 
to be included for both arrays. But from the data currently available we concluded 
that the microglial-like cells resultant from the differentiation in ACM are anti-
inflammatory in nature, whereas those in unconditioned media have a pro-
inflammatory nature.  
Thus we have shown a method for the differentiation of functional microglial-like cells 
from an ES-derived monocyte, which is displays the correct phenotype and gene 
expression, ion channel activation and cytokine secretion can be induced through 
the incubation of such cells with Aβ.  
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6.  GENERAL DISCUSSION 
The work presented here focused upon the development of an efficient, reproducible 
protocol for the generation of microglial-like cells from hESCs. At the time of onset of 
the study there were no published protocols available for hESC differentiation to 
microglia, but innovative work in mouse models had yielded several routes; namely 
‘reprogramming’ adult neural stem cells by Forsberg et al. (2008) and growth factor 
directed differentiation from mESCs (Napoli et al. 2009). We show that functional 
microglial-like cells can be produced in relatively large numbers without the need of 
feeder layers or large quantities of growth factors from hESCs. These ES-derived 
cells can then be used in in vitro modelling of disease or utilised in functional and cell 
therapy experiments.  
6.1 MONOCYTE DIFFERENTIATION 
6.1.1 PU.1 OVEREXPRESSION 
Exogenous over-expression of PU.1 in hESC-derived NSCs produced 
GFP+/CD11b+ cells. CD11b is required as a component of the leukocyte adhesion 
and migration complex and as such is a marker for myeloid cells and in particular 
monocytes, macrophages and microglia (Strauss-Ayali et al. 2007). This would 
suggest that PU.1 does promote the differentiation of neuronal precursors to a 
myeloid lineage, however, the resulting cells lacked the ability to phagocytose E. coli 
bioparticles nor did they possess the ability to respond to secreted factors in the 
ACM and differentiate to microglia. 
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 At physiological levels PU.1 is vital throughout haematopoiesis to promote terminal 
differentiation to monocytes (see Figure 1.2). PU.1 antagonises GATA-1 to enable 
myeloid lineage fate determination over a lymphoid fate, and high doses of PU.1 are 
required to promote the formation of CFU-M over CFU-G (Mak et al. 2011). 
Overexpression of PU.1 in haematopoietic precursors would override the 
antagonistic unbias of haematopoiesis and would favour the differentiation of 
monocytes. In terms of the ‘re-programming’ carried out in chapter 3; neural 
precursors, with their substantial nuclear plasticity, hold great potential for re-
programming to any cell type including iPSCs and monocytes with the introduction of 
only one important exogenous gene, Oct4 or PU.1 respectively (Kim et al. 2009).  
PU.1 is bound by and targets many other proteins, including CBP, HDAC1, RUNX1 
and PU.1 itself (Takahashi 2011). CBP is required for early phagocytosis and 
activation of macrophages to the M1 state (Yamamoto et al. 1999). Overexpression 
of PU.1 could lead to the sequestration of CBP leading to a reduction in both 
phagocytosis and classical activation. PU.1 is able to form a complex with HDAC1 
which has been shown to have a down regulating effect on the expression of other 
TFs, including c-MYC (Kihara-Negishi et al. 2001). This could be extended to enable 
us to theorise that other genes, required for phagocytosis and differentiation to 
microglia, could also be affected. RUNX1 has been shown to be in a negative 
feedback loop with PU.1 and RUNX1 expression is required for both myeloid and 
microglial development. If the level of overexpression is the root cause of the lack of 
function witnessed, the fact that PU.1 is able to bind to itself to increase expression 
would mean that any inhibition caused would be exacerbated.  
Expression of interferon regulatory factor 8 (IRF8) could be used to address their 
lack of differentiation to microglia. Kierdorf et al. (2013) reported that 
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microgliogenesis is a process that requires expression of both PU.1 and IRF8 and 
the heterodimeric complex that they form. IRF8 has also been implicated in 
mononuclear phagocyte development from myeloid precursors as such lack of IRF8 
expression in the produced cells could explain both their lack of phagocytic capacity 
and their inability to differentiate to microglia (Marquis et al. 2011). 
To combat these issues the vector could be re-designed to include a Cre/LoxP 
system to enable exogenous PU.1 expression to be stopped subsequent to the 
lineage switch allowing endogenous expression to continue and thus permit 
downstream processes to occur as intended. 
Although the lack of function could also be explained through the integration of 
plasmid DNA into a gene vital for phagocytosis and or differentiation to microglia. 
This could be avoided by targeting the vector to integrate into the genome by 
recombination. On the whole this protocol, with slight alterations in the plasmid 
design could show promise for the production of monocytes through lineage 
switching or from IPSCs without the need for numerous growth factors. 
6.1.2 MCSF/IL3 DIRECTED DIFFERENTIATION 
The protocol set out in chapter 4 resulted in the formation of a mixed haematopoietic 
population consisting of cells positive for the haematopoietic stem cell marker CD34 
as well as more committed myeloid lineage cells, CD45+, and monocytes; CD11b+. 
These latter, differentiated cells were also deemed functional through their ability to 
phagocytose E. coli microbeads.  
Monocytes are classified as CD45+/CD11b+, whilst lymphocytes are CD45+/CD11b- 
and microglia can be described as CD45low/CD11b+. QPCR of both the factory 
colonies and the resultant supernatant cells also showed expression of CD11c at 
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similar levels to the THP1 control. CD11c expression is most common in non-
lymphoid tissues in particular dendritic cells of the small intestine and skin but it is 
also expressed in monocytes and macrophages. Dendritic cells and monocytes do 
have a common precursor, but have strikingly different morphologies. Dendritic cells 
have branched projections that function to increase the surface area of the cell to 
enable antigen processing and presentation (Patterson et al. 1991). Monocytes on 
the other hand, do not bear such processes and are on the whole spherical, with few 
membrane ruffles. It is based on this morphological difference that we can confirm 
that the cells that result from this protocol are indeed monocytic rather than dendritic.  
Phagocytosis, is a function of many white blood cells including monocytes. As such 
phagocytosis was used as a marker of functionality of the ES-derived monocytes 
(ESdM). It was shown that the percentage of cells that had phagocytosed the E.coli 
biobarticles were similar to that of the monocytic cell line THP-1. Although the 
percentage was only around 30% this was slightly greater than a characteristic value 
for unstimulated cells (Baqui et al. 1998). Stimulation with LPS or IFN-ү would have 
shown an increase in phagocytosis (Suzumura et al. 1991), which if the process was 
repeated, could be included to further reveal the functionality of the cells produced in 
response to interferons and endotoxins.  
Van Wilgenburg and colleagues (2013) have previously used this protocol, with 
some variations, to generate monocytes from the Hues2 hES cell line along with 
multiple IPSC lines. We now show that the protocol is also functional with the H9 cell 
line. The resultant ESdM are numerous, express the correct profile of markers and 
most importantly are shown to be functional through their ability to phagocytose. 
Thus this protocol has the potential to function with AD IPSCs to produce patient and 
or disease specific cells.  
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6.2 MONOCYTE DIFFERENTIATION TO MICROGLIAL-LIKE CELLS 
6.2.1 ASTROCYTE CONDITIONED MEDIA (ACM) 
Upon culturing the ESdM in ACM for seven days, there was down regulation of the 
leukocyte marker, CD45, with the appearance of IBA-1, GLUT5 and CD80 and a 
resultant ramified morphology. The resultant cells were able to phagocytose Aβ(1-42), 
which also resulted in a morphological adaptation to the ameboid phenotype. 
Functionality of these cells was also shown through their cytokine expression and 
release along with their electrophysiological properties. The differentiation of these 
cells in ACM is suggested to be due to the simultaneous presentation of M-CSF, 
GM-CSF and TGF-β secreted by astrocytes (Schilling et al. 2001).  
Ramification of microglia results in a down regulation of markers associated with 
immunity, instead focus is transferred to their surveying functions. The use of IBA-1 
as a marker for microglia is useful when confined to the parameter of the brain but, 
outside of the CNS IBA-1 expression is seen in other cells such as activated 
macrophages (Imai et al. 1996). Thus the use of other markers for microglia are 
required to endorse the differentiation scheme for microglial-like cell production. 
Another marker of interest in microglial identification is GLUT5, which is able to 
distinguish even peripheral macrophages from the target microglial cells (Sasaki et 
al. 2003; Kettenmann et al. 2011). CD80, although not exclusively expressed in 
microglia, is only expressed at low levels in monocytes. Differential expression can 
thus be utilised along with the additional markers to enable a confirmation upon cell 
type. The marker profile of the ESdM subsequent to culture with ACM is thus 
comparable to that of microglia. 
Under normal physiological conditions ramified microglia survey the environment and 
are activated upon uncovering a stimulus; cell debris, protein or foreign body. 
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Activation results in a retraction of cytoplasmic processes to the cell body and the 
formation of the characteristic ameboid cell, capable of engulfing and removing 
potentially toxic bodies. Such a process occurs on detection of Aβ fibrils, resulting in 
their phagocytosis. Phagocytosis of Aβ was shown to occur when incubated with the 
ESdM subsequent to their culture in ACM. Along with their capacity for phagocytosis 
the ramified cells were also shown to undergo a morphological change to an 
ameboid phenotype, where the processes had retracted and the cells were largely 
spherical. This indicates that resultant ESdMGs would be functional in the desired 
AD model as they possess the ability to recognise and engulf Aβ(1-42).  
Microglia have a unique electrophyiological profile, most pronounced in murine and 
rodent cells. There is an absence of outwardly rectifying K+ currents with only 
inwardly rectifying Kir currents visible, microglia are the only myeloid lineage cell to 
display such electrophysiology (Kettenmann et al. 1993). This is the polar opposite to 
the profile of macrophages and as such serves as an ideal marker to differentiate 
between the two closely related cell types. The profile for human microglial cells is 
more complicated as they show both inward and outward K+ currents as well as 
voltage-gated Na+ currents and these currents can be induced through the presence 
of astrocytes (Schmidtmayer et al. 1994). The currents recorded in the ESdMG were 
comparable with those recorded by Schmidtmayer and colleagues (1994), when 
differentiating monocytes and macrophages to microglia through astrocyte co-
culture. Schilling et al. (2001) also showed that culture of the BV-2 murine microglial 
cell line in ACM led to an up-regulation of outward K+ channels, which would also 
explain the activity from the outward K+ channels witnessed within the patch clamp 
experiments with the ESdMG cells.  
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Chemokine and cytokine secretion from ESdMG after incubation with Aβ(1-42) showed 
that these, non-AD microglial-like cells would promote axonal regeneration and 
reduce cell death, instead of acting in a neurotoxic manner, which is likely to be the 
case in AD-derived cells. As such these ESdMG are not classically activated (M1), 
but are of the M2 phenotype, which is neuroprotective (Lewis et al. 2012). TREM2 is 
an AD risk factor gene that is expressed on microglia, its physiological function 
inhibits inflammation and promotes phagocytosis, it would follow that TREM2 could 
promote M2 activation over the neurotoxic M1 activation (Guerreiro et al. 2013). Its 
loss of function in AD could result in a greater number of classically activated M1 
microglia and inflammation. If the protocol was repeated with IPSCs from patients 
with an AD TREM2 variant, it may be expected to show the opposite cytokine profile 
and thus M1 activation. 
6.3 LEGITIMACY OF STUDY 
6.3.1 DIFFERENTIATION STRATEGY 
Is the differentiation of hESCs to microglial-like cells, via monocytes, a valid 
differentiation strategy?  
Microglia are derived from myeloid precursors in early development which infiltrate 
the CNS prior to the formation of the BBB proper. These cells proliferate in situ and 
further differentiate to the immune dampened ramified cells to form the resident 
microglial population (Perry et al. 1985; Davis et al. 1994).  
Monocytes can also be recruited from the bone marrow under pathological stresses, 
where the BBB loses integrity. The in vivo differentiation of microglia during 
development would suggest that they are of myeloid origin and as with all monocyte 
  6.Discussion 
168 
 
derived cells, the environment within which the cells reside impact on further 
differentiation (Cuadros and Navascués 1998).  
Monocytes in the bone marrow become tissue macrophages with very different 
properties dependent on location from osteoclasts in the bone to Kupffer cells in the 
liver. Dendritic cells are specialised for mucosa and epidermis, whilst microglia are 
generated from the same precursors but are specialised for the CNS, the 
differentiation of which occurs subsequent to crossing the BBB. As such the only 
scheme suitable for microglial differentiation would require a monocytic step, 
followed by a period of time in an environment similar to that of the CNS to enable 
final differentiation to microglia. 
Aside from the in vivo differentiation scheme, there have been previous studies in 
published works that are able to create microglia from monocytes, using 
environmental stimuli to direct differentiation. Forsberg et al. (2008) were able to 
create murine monocytes and transplant them into the brain, where they 
differentiated and became indistinguishable from the resident microglial population. 
Sievers et al. (1994) also showed that the presence of factors released from 
astrocytes were capable of differentiating blood and splenic monocytes into 
microglia. Thus to take a two-step approach to the differentiation scheme, hESCs to 
monocytes and then monocytes to microglia is the most feasible option in producing 
hES-derived microglial-like cells.  
6.3.2 MICROGLIAL MARKERS 
As mentioned microglia are closely related and function similarly to monocytes and 
macrophages, which means that specific microglial markers are rare. Microglia are 
still identified using a marker profile rather than the use of an absolute microglial 
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marker. The suggested profile is CD68+, CD45low, CD11chigh, MHC-II+, CD14-, IBA-
1+. There are numerous other markers that show differential expression between 
monocytes/macrophages and microglia, such as; CD80, NG2, LN, peroxidase and 
Ki-67. There is also the use of GLUT5, a marker found to be more specific than IBA-
1 toward microglia in the confines of the brain. Thus the profile used here to 
differentiate between microglial-like cells and monocytes is CD45low, CD11chigh, 
NG2low, CD80high, IBA-1+, TREM2+, GLUT5+. 
It is with the use of these various markers that microglia can be positively identified 
from their close relatives, the monocyte. This study has incorporated the use of 
many of these markers as well as using functional and morphological data to enable 
a satisfactory identification of the cells resulting from the differentiation as microglial-
like cells. 
6.3.3 THP1 MONOCYTIC CELLS AS A CONTROL CELL LINE 
The THP1 cell line was established in 1980 from the culture of a 1-year old 
Japanese boy suffering with acute monocytic leukemia by Tschiya et al. (1980). The 
group showed that the cell line was monocytic in nature via function and marker 
expression, characteristics that remained true when cutltured for over a year. Two 
decades later cytogenetic analysis of the THP-1 cell line by Odero et al. (2000), 
revealed that the cells were near diploid but they were karyotypicallly abnormal, 
including trisomy 8 and monosomy 10. This means that the expression of particular 
genes in THP1 cells, especially those located on chromosome 8 and 10 will differ 
from the expression of those same genes in karyotypically normal cells and thus the 
differentiation potential may also vary. This could be combated by the use of other 
control cell lines together with the THP1 cells to validate the results. 
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6.3.4 THE EFFECT OF NEUROBREW 21 IN THE ACM 
NeuroBrew 21 is an optimised form of B27, a supplement used during neuronal 
differentiations and used here within the ACM (Chen et al. 2008). It should be noted 
that there are several components of NeuroBrew 21 that could, if in the correct 
concentration, have an effect on functionality of both microglia and Aβ upon such 
cells.   
The first component listed is bovine albumin, which has been shown to increase 
expression and secreation of pro-inflammatory cyotkines such as IL-1β and TNF-α 
(Zhao et al. 2009). Microglial activation by albumin is unsurprising since a break-
down in the BBB would lead to the influx of albumin and the resultant microglial 
activation is anticipated in such a situation. There is also high homology between the 
mammalian albumins, so bovine albumin would have a similar effect on human 
microglia as human albumin. Albumin can also play a role in preventing the 
aggregation of Aβ via its physiological chaperone role, decreasing the cytotoxic 
effects since microglia are only able to respond to fibrillary Aβ (Finn et al. 2012).  
Albumin has also been associated with enhancing superoxide production in cultured 
microglia (Si et al. 1997), which leads to the next component of NeuroBrew 21; 
superoxide dismutase (SOD). Extracellular SOD, an enzyme that partitions toxic O2- 
into the less harmful H2O2 or conventional O2 has been implicated in the activation of 
microglia to the cytotoxic phenotype, whilst an excess of SOD1 has been shown to 
protect against Aβ toxicity (Roberts et al. 2013; Celsi 2004). Conversion of H2O2 into 
water and oxygen is catalysed by Catalase, which protects cells from the harmful 
actions of hydrogen peroxide. Catalase can also inhibit the proliferative response of 
microglia to IL-1β and TNF-α since this response is governed by the release of 
hydrogen peroxide from NADPH oxidase (Mander et al. 2006). With regards to Aβ, 
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Aβ is able to bind to catalase and thus inhibit the break-down of H2O2, which is able 
to contribute to Aβ toxicity (Milton et al. 1999).  
The glutathione within the NeuroBrew 21 supplement is an anti-oxidant and plays a 
role in protecting cells from reactive oxygen species, which are produced during cell 
stress (Hirrlinger et al. 2000). Excess glutathione could also lead to an increase in 
the generation of plasmin, since glutathione and tPA are intricately linked. Since 
plasmin degrades Aβ, lessening Aβ load, glutathione provides protection from the 
effects of Aβ (Lasierra-Cirujeda et al. 2013). Oxidative stress due to Aβ can also be 
diminished by L-Carnitine, the precursor to Acetyl-CoEnzyme A and another 
component of NeuroBrew 21, which functions through a buffering system and via the 
maintenance of ATP levels (Dhitavat et al. 2002).  
NeuroBrew 21 also contains steroid hormones, of note are corticosterone and 
progesterone. Corticosterone has the ability to inhibit both the synthesis and 
secretion of TNFα and through this action has an anti-inflammatory effect 
(Jacobsson et al. 2006). Similarly progesterone is deemed an anti-inflammatory 
agent and has been shown to inhibit microglial proliferation in microglial only cultures 
(Ganter et al. 1992).  
Finally, vitamins A and E are also contained within the NeuroBrew 21 supplement. 
Vitamin A, or retinol, supresses the production of IL-6, a plaque promoting cytokine, 
in astrocytes and microglia. Vitamin A also functions to inhibit the nuclear 
translocation of NFκB leading to the suppression of TNF-α and iNOS production in 
activated microglia (Shudo et al. 2009). Vitamin E, α-tocopherol, decreases the 
levels of COX-2 and PGE(2) and through its activation of Protein Phosphatase 2 in 
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microglial cells enables the silencing of the NFκB signalling cascade (Egger et al. 
2003).  
Although these components of NeuroBrew 21 are, on the whole, able to promote an 
anti-inflammatory nature in microglia and decrease the cytotoxicity of Aβ. The 
concentrations of each component are not sufficient to interfere with the 
differentiation of the microglial-like cells nor have an effect on the outcome of Aβ 
treatment, but it is important to be aware of their presence within the ACM. 
6.4 IMPACT OF STUDY 
Prior to the onset of this study there were no published protocols to enable the 
differentiation of microglia from human pluripotent cells although protocols did exist 
for the generation of microglia from mESCs, thus the impact of the study is vast, and 
holds great potential for both AD and many other CNS disorders.  
From hES-derived microglia we can study the function of microglia in response to 
Aβ, in exceptional detail whilst limiting the number of animal models or using 
precious primary cell samples. A plentiful supply of microglial-like cells can be 
produced via this protocol and thus numerous possibilities to study the effect Aβ has 
on cell activation. This can then be extended with the use of AD IPS, with common 
variants of the recently discovered risk factor genes, like TREM2, to enable a better 
understanding of the gene function in the disease.  
The protocol could also be used to create a co-culture model of AD, using AD IPSC-
derived neurons and microglia. Such a model would provide insight into the effect 
microglia have on neurons during disease progression under certain conditions, such 
as Aβ load and hypoxia. The model could provide a good substitute to animal 
models for early drug screening, to lessen the burden on animal usage on drugs that 
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simply will not work. The use of IPSCs could eventually lead to patient specific 
models of the disease and thus tailor made treatments dependent on their genetic 
constitution.  
Microglia are not just implicated in the progression of AD, but also play a role in 
multiple sclerosis (MS), Parkinson’s Disease (PD), HIV associated neurocognitive 
disorder (HAND) and even OCD. The development of a protocol to differentiate 
numerous numbers of microglia and microglia from patient specific cells will 
inevitably lead to progress being made in these other CNS diseases. For these 
diseases, as in AD, IPS models of the brain could be developed for use in both 
understanding the disease and drug discovery. In HAND for example, there have 
been moves made to try and target microglia to protect them from HIV. The 
techniques and genes required for protection could thus be optimised on ES-derived 
cells, without the need to sacrifice animals or again use valuable primary cells. 
One of the underlying mechanisms of AD disease progression is neuroinflammation 
caused by microglia that, through the process of aging and the accumulation of risk 
factors, become neurotoxic and deregulated. Age will also increase the permeability 
of the BBB enabling easier entry for cells, and as such cell therapy could be a useful 
route for AD treatment. Although there will never be ablation of the endogenous 
neurotoxic cells, the incorporation of new, healthy, phagocytic cells could be enough 
to regain control of the inflammation by an increase in phagocytosis of debris and 
plaques.  
Transplantation of microglia has been completed successfully in rat models of stroke 
where there was an improvement in the disease phenotype and behaviour 
(Narantuya et al. 2010). This protocol could be harnessed for said therapy, since 
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there are no contaminants from feeder layers, such as OP9 for haematopoietic 
differentiation, when using IPSCs. Aside from their obvious uses in AD, microglia 
harness the ability to traverse the BBB, which together with the ability to be created 
from patient specific cells, means that they hold great potential to be used for gene 
delivery to the CNS. The future of cell transplantation into human patients is 
uncertain, whether the transplanted cells will do more harm than good is still not fully 
understood, but should cell transplantation be a possibility in the near future this 
protocol could be harnessed to enable transplantation of patient-specific microglia 
that could be genetically modified if necessary to combat disease caused by the 
resident microglial population. 
6.5 FURTHER WORK 
Further work would initially include experiments that focus on the functional aspects 
of microglia in response to Aβ, such as the electrophysiological changes that occur 
on activation, as well as migration experiments towards Aβ, as microglia do toward 
Aβ plaques in vivo, to prove that the differentiated cells are capable of functioning in 
the same way as endogenous microglia.  
Then the focus would be on the conditioned media, and the identification of the 
components secreted by astrocytes that are vital for monocyte to microglial 
differentiation. Would the base media with the addition of TGF-β, M-CSF (or IL-34) 
and GM-CSF alone or in combination promote the same differentiation as witnessed 
by the astrocyte conditioned media? Would this defined media prevent any batch to 
batch variation as is problematic with conditioning? Would neuron conditioned media 
also promote such differentiation and if so would the resultant microglia function in a 
similar manner? 
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The differentiation could then be expanded to include more cell lines, especially 
those from AD patients with genetic variants of the genes involved in immunity 
identified in the recent GWAS studies; TREM2, INPP5D, HLA-DRB1 and HLA-
DRB5. Any loss of function of these genes would result in alterations in the 
behaviour of the endogenous microglial population. Creating IPS derived microglia 
with these mutations would enable a better understanding of the role these 
mutations play in inflammation and thus AD progression.  
The ultimate aim would be to develop an in vitro AD model to enable the effect of 
microglia on all cell types in the brain to be studied in relative ease under numerous 
conditions, without requiring such a dependence on animal models. In vitro brain 
models created with IPSCs containing genetic variants of interest where neurons 
and microglia are able to interact would allow for an insight into how afflicted cells 
behave in a system. It is known that neuronal loss occurs during AD, with such a 
model the loss of neurons could be observed and the mechanism more greatly 
understood through MAP2 staining techniques, live/dead or MTT assays. The 
addition of Aβ is thought to increase the resting calcium level and will give an 
enhanced response to EAAs via Ca2+ homeostasis destabilisation, which could be 
examined through calcium imaging techniques.  
Electrophysiologically, neurons from AD brains show inhibition of both glutamate and 
potassium receptors that could be observed through patch clamping experiments. 
The non-AD microglia in this system would show an increase in Aβ phagocytosis and 
then, to limit inflammation, should undergo apoptosis thus decreasing the viability of 
the microglia in the model. The variant cells would possibly show less phagocytosis, 
less apoptosis and thus more inflammation leading to a greater loss of neuronal 
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cells.  
 
  7.References 
177 
 
7.  REFERENCES 
Alexopoulou, A.N., Couchman, J.R. and Whiteford, J.R. 2008. The CMV early 
enhancer/chicken beta actin (CAG) promoter can be used to drive transgene 
expression during the differentiation of murine embryonic stem cells into vascular 
progenitors. BMC cell biology 9, p. 2.  
Alliot, F., Godin, I. and Pessac, B. 1999. Microglia derive from progenitors, 
originating from the yolk sac, and which proliferate in the brain. Brain research. 
Developmental brain research 117(2), pp. 145–52.  
Bamberger, M.E., Harris, M.E., McDonald, D.R., Husemann, J. and Landreth, G. 
2003. A cell surface receptor complex for fibrillar B-Amyloid mediates microglial 
activation. The Journal of neuroscience : the official journal of the Society for 
Neuroscience 23, pp. 2665–22674. 
Baqui, A.A.M.., Meiller, T.F., Turng, B., Kelley, J.I. and Falker, W.A. 1998. Functional 
Changes In Thp-1 Human Monocytic Cells after Stimulation with Lipopolysaccharide 
of Oral Microorganisms and Granulocyte Macrophage Colony Stimulating Factor. 
Immunopharmacology and Immunotoxicology 20(4), pp. 493–518. 
Black, J. a and Waxman, S.G. 2012. Sodium channels and microglial function. 
Experimental neurology 234(2), pp. 302–15.  
Boucsein, C., Kettenmann, H. and Nolte, C. 2000. Electrophysiological properties of 
microglial cells in nomral and pathologic rat brain slices. European Journal of 
Neuroscience 12(6), pp. 2049–2058. 
Boya, J., Calvo, J. and Prado, A. 1979. The origin of microglial cells. Journal of 
Anatomy 129, pp. 177–186. 
Bronner-Fraser, M. and Fraser, S. 1997. Differentiation of the Vertebrate Neural 
Tube. Current Opinion in Cell Biology 9, pp. 885–891. 
Brustle, O., Jones, K.N., Learish, R.D., Karram, K., Choudhary, K., Wiestler, O.D., 
Duncan, I.D. and McKay, R.D. 1999. Embryonic stem cell - derived glail precursors; 
a source of myelinating transplants. Science 285, pp. 754–756. 
Brustle, O., Spiro, A.C., Karram, K., Choudhary, K., Okabe, S. and McKay, R.D. 
1997. In vitro-generated neural precursors participate in mammalian brain 
development. Proceedings of the National Academy of Sciences of the United States 
of America (94), pp. 14809–14814. 
Bushong, E. a, Martone, M.E. and Ellisman, M.H. 2004. Maturation of astrocyte 
morphology and the establishment of astrocyte domains during postnatal 
hippocampal development. International journal of developmental neuroscience : the 
  7.References 
178 
 
official journal of the International Society for Developmental Neuroscience 22(2), pp. 
73–86.  
Butovsky, O., Talpalar, A.E., Ben-Yaakov, K. and Schwartz, M. 2005. Activation of 
microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II 
expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them 
protective. Molecular and cellular neurosciences 29(3), pp. 381–93. 
Cajal, S.R. 1913. Contribucion al conocimiento de la neuroglia del cerebro human. 
Trab. del Lab. de Invest. Biol 11, p. 254. 
Celsi, F. 2004. Overexpression of superoxide dismutase 1 protects against β-
amyloid peptide toxicity: effect of estrogen and copper chelators. Neurochemistry 
International 44(1), pp. 25–33.  
Cerretti, D.P. 1988. Human macrophage colony stimulating factor: alternative RNA 
and protein processing from a single gene. Molecular Immunology 25, pp. 761–770. 
Chadwick, K., Wang, L., Li, L., Menendez, P., Murdoch, B., Rouleau, A. and Bhatia, 
M. 2003. Cytokines and BMP-4 promote hematopoietic differentiation of human 
embryonic stem cells. Blood 102(3), pp. 906–15.  
Chambers, S.M., Fasano, C. a, Papapetrou, E.P., Tomishima, M., Sadelain, M. and 
Studer, L. 2009. Highly efficient neural conversion of human ES and iPS cells by 
dual inhibition of SMAD signaling. Nature biotechnology 27(3), pp. 275–80.  
Chan, H.. and Bonini, N.M. 2000. Drosophila models of human neurodegenerative 
disease. Cell Death and Differentiation 7(11), pp. 1075 – 1080. 
Chan, W.Y., Kohsaka, S. and Rezaie, P. 2007. The origin and cell lineage of 
microglia: new concepts. Brain research reviews 53(2), pp. 344–54.  
Chen, S.K., Tvrdik, P., Peden, E., Cho, S., Wu, S. and Spangrude, G. 2010. 
Hematopoietic origin of pathological grooming in HoxB8 mutant mice. Cell 141, pp. 
775–785. 
Chen, Y., Stevens, B., Chang, J., Milbrandt, J., Barres, B. a and Hell, J.W. 2008. 
NS21: re-defined and modified supplement B27 for neuronal cultures. Journal of 
neuroscience methods 171(2), pp. 239–47.  
Cleveland, D.W., Hwo, S.Y. and Kirscher, M.W. 1977. Purification of Tau, a 
microtubule-associated protein that induces assembly of microtubules from purified 
tubulin. Journal of molecular biology 116, pp. 207–225. 
Comery, T.A., Martone, R.L., Aschmies, S., Atchison, K.P., Diamantidis, G., Gong, 
X., Zhou, H., Kreft, A.F., Pangalos, M.N., Sonnenberg-Reines, J., Jacobsen, J.S. 
and Marquis, K.L. 2005. Acute Y-Secretase Inhibition Imrpoves Contextual Fear 
Conditioning in the Tg2576 Mouse Model of AD. Journal of Neuroscience 28, pp. 
8898–8902. 
  7.References 
179 
 
Costa, M.R., Gotz, M. and Berninger, B. 2010. What determines neurogenic 
competence in glia? Brain research reviews 63, pp. 47 – 59. 
Cuadros, M. a and Navascués, J. 1998. The origin and differentiation of microglial 
cells during development. Progress in neurobiology 56(2), pp. 173–89. 
Dahéron, L., Opitz, S.L., Zaehres, H., Lensch, W.M., Andrews, P.W., Itskovitz-eldor, 
J. and Daley, Q. 2013. S tem C ells. , pp. 770–778. 
Dakic, A., Wu, L. and Nutt, S.L. 2007. Is PU.1 a dosage-sensitive regulator of 
haemopoietic lineage commitment and leukaemogenesis? Trends in immunology 
28(3), pp. 108–14.  
Dang, S.M., Kyba, M., Perlngeiro, K., Daley, G.Q. and Zandstra, P.W. 2002. 
Efficiency of Embryoid Body Formation and Haematopoeitic Development from ESC 
in Different Culture Systems. Biotechnology and Bioengineering 78(4), pp. 442 – 
453. 
Davis, E.J., Foster, T.D. and Thomas, W.E. 1994. Cellular forms and functions of 
brain microglia. Brain research bulletin 34(1), pp. 73–8. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/8193937. 
Davoust, N., Vuaillat, C., Androdias, G. and Nataf, S. 2008. From bone marrow to 
microglia: barriers and avenues. Trends in immunology 29(5), pp. 227–34. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/18396103 [Accessed: 13 March 2012]. 
Deeks, S.G. 2011. HIV infection, inflammation, immunosenescence and aging. 
Annual Reviews in Medicine 62, pp. 141–155. 
Dhitavat, S., Ortiz, D., Shea, T. and Rivera, E. 2002. Acetyl-l-Carnitine Protects 
Against Amyloid-Beta Neurotoxicity: Roles of Oxidative Buffering and ATP Levels. 
Neurochemical Research 27(6), pp. 501–505. 
Dodart, J.-C., Bales, K.R., Gannon, K.S., Greene, S.J., DeMattos, R.B., Mathis, C., 
DeLong, C. a, Wu, S., Wu, X., Holtzman, D.M. and Paul, S.M. 2002. Immunization 
reverses memory deficits without reducing brain Abeta burden in Alzheimer’s 
disease model. Nature neuroscience 5(5), pp. 452–7.  
Doestsh, F. 2003. The Glial Identity of Neural Stem Cells. Nature Neuroscience 
6(11), pp. 1127–1134. 
Egger, T., Schuligoi, R., Wintersperger, A., Amann, R., Malle, E. and Sattler, W. 
2003. Vitamin E (a-tocopherol) attenuates cyclo-oxygenase 2 transcription and 
synthesis in immortalized murine BV-2 microglia. Biochemical Journal 370, pp. 459–
467. 
Etemad, S., Zamin, R.M., Ruitenberg, M.J. and Filgueira, L. 2012. A novel in vitro 
human microglia model: Characterization of human monocyte-derived microglia. 
Journal of neuroscience methods.  
  7.References 
180 
 
Evans, M.J. and Kaufman, M.H. 1981. Establishment in culture of pluripotential cells 
from mouse embryos. Nature 292(9), pp. 154–156. 
Evseenko, D., Zhu, Y., Schenke-layland, K., Kuo, J., Latour, B., Ge, S. and Scholes, 
J. 2010. Mapping the first stages of mesoderm commitment during differentiation of 
human embryonic stem cells. Proceedings of the National Academy of Sciences of 
the United States of America 107(31), pp. 13742–13747. 
Findeis, M.A. 2007. The role of amyloid beta peptide 42 in Alzhiemer’s disease. 
Pharmacology and Therapeutics 116, pp. 266–286. 
Finn, T.E., Nunez, A.C., Sunde, M. and Easterbrook-Smith, S.B. 2012. Serum 
albumin prevents protein aggregation and amyloid formation and retains chaperone-
like activity in the presence of physiological ligands. The Journal of biological 
chemistry 287(25), pp. 21530–40.  
Flower, R.J. and Rothwell, N.J. 1994. Lipocortin-1: cellular mechanisms and clinical 
relevance. Trends in pharmacological sciences 15(3), pp. 71–6.  
Forsberg, M., Carlén, M., Meletis, K., Yeung, M.S.Y., Barnabé-Heider, F., Persson, 
M. a a, Aarum, J. and Frisén, J. 2008. Efficient reprogramming of adult neural stem 
cells to monocytes by ectopic expression of a single gene. Proceedings of the 
National Academy of Sciences of the United States of America 107(33), pp. 14657–
61.  
Fredoroff, S. 1995. Development of Microglia. In: Kettenmann, H. and Ransom, B. R. 
eds. Neuroglia. Oxford University Press, New York, pp. 162–181. 
Freed, C.R. and Greene, P.E. 2001. Transplantation of Embryonic Dopamine 
Neurons for Severe Parkinson’s Disease. 344(10), pp. 710–719. 
Freed, C.R., Greene, P.E., Breeze, R.E., Tsai, W.Y., DuMouchel, W., Kao, R., 
Dillion, S., Winfield, H., Culver, S., Trojanowski, J.Q., Eidelberg, D. and Fahn, S. 
2001. Transplantation of embrynoic dopamine neurons for severe Parkinson’s 
disease. New England Journal of Medicine 344, pp. 710–719. 
Frendel, G. 1992. Interleukin 3: from colony-stimulating factor to pluripotent 
immunoregulatory cytokine. International Journal of Immunopharmacology 14, pp. 
421–430. 
Ganter, S., Northoff, H. and Mannel, D. 1992. Growth Control of Cultured Microglia. 
230. 
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M.F., 
Conway, S.J., Ng, L.G., Stanley, E.R., Samokhalov, I.M. and M., M. 2010. Fate 
mapping analysis reveals that adult micoglia derive from primitive macrophages. 
Science 330(6005), pp. 841–845. 
Greter, M., Lelios, I., Pelczar, P., Hoeffel, G., Price, J., Leboeuf, M., Kündig, T.M., 
Frei, K., Ginhoux, F., Merad, M. and Becher, B. 2012. Stroma-derived interleukin-34 
  7.References 
181 
 
controls the development and maintenance of langerhans cells and the maintenance 
of microglia. Immunity 37(6), pp. 1050–60.  
Griciuc, A., Serrano-pozo, A., Parrado, A.R., Lesinski, A.N., Asselin, N., Mullin, K., 
Hooli, B., Choi, S.H., Hyman, B.T. and Tanzi, R.E. 2014. Alzheimer’s Disease Risk 
Gene CD33 Inhibits Microglial Uptake of Amyloid Beta. Neuron 78(4), pp. 631–643. 
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., 
Cruchaga, C., Sassi, C., Kauwe, J.S.K., Younkin, S., Hazrati, L., Collinge, J., 
Pocock, J., Lashley, T., Williams, J., Lambert, J.-C., Amouyel, P., Goate, A., 
Rademakers, R., Morgan, K., Powell, J., St George-Hyslop, P., Singleton, A. and 
Hardy, J. 2013. TREM2 variants in Alzheimer’s disease. The New England journal of 
medicine 368(2), pp. 117–27.  
Guillemin, G.J. and Brew, B.J. 2004. Microglia, macrophages, perivascular 
macrophages and pericytes : a review of function and identification. Journal of 
leukocyte Biology 75(3), pp. 388–397. 
Hanisch, U.-K. and Kettenmann, H. 2007. Microglia: active sensor and versatile 
effector cells in the normal and pathologic brain. Nature neuroscience 10(11), pp. 
1387–94.  
Hansen, D. V, Lui, J.H., Parker, P.R.L. and Kriegstein, A.R. 2010. Neurogenic radial 
glia in the outer subventricular zone of human neocortex. Nature 464(7288), pp. 
554–561.  
Hao, C., Richardson, A. and Fedoroff, S. 1991. MACROPHAGE-LIKE CELLS 
ORIGINATE FROM NEUROEPITHELIUM IN CULTURE : CHARACTERISATION 
and PROPERTIES OF THE MACROPHAGE-LIKE cells. International journal of 
developmental neuroscience : the official journal of the International Society for 
Developmental Neuroscience 9(1). 
Heneka, M.T. 2006. Inflammation in Alzheimer’s disease. Clincal Neuroscience 
Research 6, pp. 247–260. 
Heneka, M.T., Rodríguez, J.J. and Verkhratsky, A. 2010. Neuroglia in 
neurodegeneration. Brain research reviews 63(1-2), pp. 189–211.  
Hirrlinger, J., Gutterer, J., Kussmaul, L., Hamprecht, B. and Dringen, R. 2000. 
Microglial cells in culture express a prominent glutathione system for the defense 
against reactive oxygen species. Developmental Neuroscience 22(5-6), pp. 384–
392. 
Huang, G., Zhang, P., Hirai, H., Elf, S., Yan, X., Chen, Y., Koschmieder, S., Okuno, 
Y., Dayaram, T., Grownwy, J.D., Shivdasani, R.., Gilliland, D.G., Speck, N.A., Nimer, 
S.. and Tenen, D.G. 2008. PU.1 is a major downstream target of AML1 (RunX1) in 
adult mouse hematopoiesis. Nature Genetics 40, pp. 51–60. 
Ihne, J.N. 1992. Interleukin-3 and hematopoeisis. Chemical Immunology 51, pp. 65–
106. 
  7.References 
182 
 
Imai, Y., Ibata, I., Ito, D., Ohsawa, K. and Kohsaka, S. 1996. A novel gene iba1 in 
the major histocompatibility complex class III region encoding an EF hand protein 
expressed in a monocytic lineage. Biochemical and biophysical research 
communications 224(3), pp. 855–62.  
Ito, D., Imai, Y., Ohsawa, K., Nakajima, K., Fukuuchi, Y. and Kohsaka, S. 1998. 
Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain 
research. Molecular brain research 57(1), pp. 1–9.  
Jacobsson, J., Persson, M., Hansson, E. and Rönnbäck, L. 2006. Corticosterone 
inhibits expression of the microglial glutamate transporter GLT-1 in vitro. 
Neuroscience 139(2), pp. 475–83.  
James, D., Levine, A.J., Besser, D. and Hemmati-Brivanlou, A. 2005. 
TGFb/activin/nodal signaling is necessary for the maintenance of pluripotency in 
human embryonic stem cells. Development 132, pp. 1273–1282. 
Jordan, F.L. and Thomas, W.E. 1988. Brain macrophages: questions of origin and 
interrelationship. Brain research reviews 13, pp. 165–178. 
Karlsson, K.R., Cowley, S., Martinez, F.O., Shaw, M., Minger, S.L. and James, W. 
2008. Homogeneous monocytes and macrophages from human embryonic stem 
cells following coculture-free differentiation in M-CSF and IL-3. Experimental 
hematology 36(9), pp. 1167–75.  
Kettenmann, H., Banati, R. and Walz, W. 1993. Electrophysiological behavior of 
microglia. Glia 7(1), pp. 93–101.  
Kettenmann, H., Hanisch, U., Noda, M. and Verkhratsky, A. 2011. Physiology of 
Microglia. , pp. 461–553. 
De Keyser, J., Mostert, J.P. and Koch, M.W. 2008. Dysfunctional astrocytes as key 
players in the pathogenesis of central nervous system disorders. Journal of the 
neurological sciences 267(1-2), pp. 3–16.  
El Khoury, J. and Luster, A.D. 2008. Mechanisms of microglia accumulation in 
Alzheimer’s disease: therapeutic implications. Trends in pharmacological sciences 
29(12), pp. 626–32.  
Kierdorf, K., Erny, D., Goldmann, T., Sander, V., Schulz, C., Perdiguero, E.G., 
Wieghofer, P., Heinrich, A., Riemke, P., Hölscher, C., Müller, D.N., Luckow, B., 
Brocker, T., Debowski, K., Fritz, G., Opdenakker, G., Diefenbach, A., Biber, K., 
Heikenwalder, M., Geissmann, F., Rosenbauer, F. and Prinz, M. 2013. Microglia 
emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. 
Nature neuroscience 16(3), pp. 273–80.  
Kihara-Negishi, F., Yamamoto, H., Suzuki, M., Yamada, T., Sakurai, T., Tamura, T. 
and Oikawa, T. 2001. In vivo complex formation of PU.1 with HDAC1 associated with 
PU.1-mediated transcriptional repression. Oncogene 20(42), pp. 6039–47.  
  7.References 
183 
 
Killackey, H.P. 1984. Glia and the elimination of transient cortical projections. Trends 
in neurosciences 7, pp. 2225 – 226. 
Kim, J.B., Sebastiano, V., Wu, G., Araúzo-Bravo, M.J., Sasse, P., Gentile, L., Ko, K., 
Ruau, D., Ehrich, M., van den Boom, D., Meyer, J., Hübner, K., Bernemann, C., 
Ortmeier, C., Zenke, M., Fleischmann, B.K., Zaehres, H. and Schöler, H.R. 2009. 
Oct4-induced pluripotency in adult neural stem cells. Cell 136(3), pp. 411–9.  
Kim, J.H., Auerbach, J.M., Rodrigeuz-Gomez, J.A., Velasco, I., Gavin, D., Lumelsky, 
N., Lee, S.H., Nguyen, J., Sanchez-Pernaute, R., Bankiewicz, K. and McKay, R.D. 
2002. Dopamine neurons derived from embryonic stem cells function in an aminal 
model of Parkinson’s disease. Nature 418, pp. 50–56. 
Kim, S.U. and de Vellis, J. 2005. Microglia in health and disease. Journal of 
neuroscience research 81(3), pp. 302–13.  
Kim, S.W., Fitzgerald, M.L., Kang, K., Okuhira, K., Bell, S.A., Manning, J., Koehn, 
S.L., Lu, N., Moore, K.J. and Freeman, M.W. 2005. Abca7 null mice retain normal 
macrophage phosphatidylcholine and cholesterol efflux activity despite alterations in 
adipose mass and serum cholesterol levels. Journal of Biological Chemistry 280, pp. 
3989–3995. 
Kitamura, T., Miyake, T. and Fujita, S. 1984. Genesis of resting microglia in the gray 
matter of mouse hippocampus. Journal of Comparative Neurology 226, pp. 421–433. 
Klee, R., Heinemann, U. and Eder, C. 1999. Voltage-Gated Proton Currents in 
Microglia of Distinct Morphology and Functional State. Neuroscience 91(4), pp. 
1415–1424. 
Klemsz, M.J., McKercher, S.R., Celada, a, Van Beveren, C. and Maki, R. a 1990. 
The macrophage and B cell-specific transcription factor PU.1 is related to the ets 
oncogene. Cell 61(1), pp. 113–24.  
Koeingsknecht-Talboo, J. and Landreth, G. 2005. Microglial Phagocytosis Induced 
by Fibrillar B-Amyloid and IgGs are Differentially Regulated by Proinflammatory 
Cytokines. The Journal of neuroscience : the official journal of the Society for 
Neuroscience 25, pp. 8420–8249. 
Kroon, E., Martinson, L., Kadoya, K., Bang, A., Kelly, O., Eliazer, S., Young, H., 
Richardson, M., Smart, N., Cunningham, J., Aqulnick, A., D’Amour, K., Carpenter, M. 
and Baetge, E. 2008. Pancreatic endoderm derived from human embryonic stem 
cells generates glucose-reponsive insulin-secreting cells in vivo. Nature 
Biotechnology 26(4), pp. 443–452. 
Lacaud, G., Gore, L., Kennedy, M., Kouskoff, V., Kingsley, P., Hogan, C., Carlsson, 
L., Speck, N., Palis, J. and Keller, G. 2002. Runx1 is essential for hematopoietic 
commitment at the hemangioblast stage of development in vitro. Blood 100(2), pp. 
458–66.  
  7.References 
184 
 
LaFerla, F.M., Green, K.N. and Oddo, S. 2006. Intracellular amyloid-B in Alzheimer’s 
disease. Nature reviews. Neuroscience 8, pp. 499–509. 
Lambert, J.C., Ibrahim-Verbaas, C. a, Harold, D., Naj, a C., Sims, R., Bellenguez, C., 
DeStafano, a L., Bis, J.C., Beecham, G.W., Granier-Boley, B., Russo, G., Thorton-
Wells, T. a, Jones, N., Smith, a V, Chouraki, V., Thomas, C., Ikram, M. a, Zelenika, 
D., Vardarajan, B.N., Kamatani, Y., Lin, C.F., Gerrish, a, Schmidt, H., Kunkle, B., 
Dunstan, M.L., Ruiz, a, Bihoreau, M.T., Choi, S.H., Reitz, C., Pasquier, F., 
Cruchaga, C., Craig, D., Amin, N., Berr, C., Lopez, O.L., De Jager, P.L., 
Deramecourt, V., Johnston, J. a, Evans, D., Lovestone, S., Letenneur, L., Morón, 
F.J., Rubinsztein, D.C., Eiriksdottir, G., Sleegers, K., Goate, a M., Fiévet, N., 
Huentelman, M.W., Gill, M., Brown, K., Kamboh, M.I., Keller, L., Barberger-Gateau, 
P., McGuiness, B., Larson, E.B., Green, R., Myers, a J., Dufouil, C., Todd, S., 
Wallon, D., Love, S., Rogaeva, E., Gallacher, J., St George-Hyslop, P., Clarimon, J., 
Lleo, a, Bayer, a, Tsuang, D.W., Yu, L., Tsolaki, M., Bossù, P., Spalletta, G., Proitsi, 
P., Collinge, J., Sorbi, S., Sanchez-Garcia, F., Fox, N.C., Hardy, J., Deniz Naranjo, 
M.C., Bosco, P., Clarke, R., Brayne, C., Galimberti, D., Mancuso, M., Matthews, F., 
Moebus, S., Mecocci, P., Del Zompo, M., Maier, W., Hampel, H., Pilotto, a, Bullido, 
M., Panza, F., Caffarra, P., Nacmias, B., Gilbert, J.R., Mayhaus, M., Lannefelt, L., 
Hakonarson, H., Pichler, S., Carrasquillo, M.M., Ingelsson, M., Beekly, D., Alvarez, 
V., Zou, F., Valladares, O., Younkin, S.G., Coto, E., Hamilton-Nelson, K.L., Gu, W., 
Razquin, C., Pastor, P., Mateo, I., Owen, M.J., Faber, K.M., Jonsson, P. V, 
Combarros, O., O’Donovan, M.C., Cantwell, L.B., Soininen, H., Blacker, D., Mead, 
S., Mosley, T.H., Bennett, D. a, Harris, T.B., Fratiglioni, L., Holmes, C., de Bruijn, 
R.F., Passmore, P., Montine, T.J., Bettens, K., Rotter, J.I., Brice, a, Morgan, K., 
Foroud, T.M., Kukull, W. a, Hannequin, D., Powell, J.F., Nalls, M. a, Ritchie, K., 
Lunetta, K.L., Kauwe, J.S., Boerwinkle, E., Riemenschneider, M., Boada, M., 
Hiltuenen, M., Martin, E.R., Schmidt, R., Rujescu, D., Wang, L.S., Dartigues, J.F., 
Mayeux, R., Tzourio, C., Hofman, a, Nöthen, M.M., Graff, C., Psaty, B.M., Jones, L., 
Haines, J.L., Holmans, P. a, Lathrop, M., Pericak-Vance, M. a, Launer, L.J., Farrer, 
L. a, van Duijn, C.M., Van Broeckhoven, C., Moskvina, V., Seshadri, S., Williams, J., 
Schellenberg, G.D. and Amouyel, P. 2013. Meta-analysis of 74,046 individuals 
identifies 11 new susceptibility loci for Alzheimer’s disease. Nature genetics 45(12), 
pp. 1452–8.  
Lasierra-Cirujeda, J., Coronel, P., Aza, M. and Gimeno, M. 2013. Beta-amyloidolysis 
and glutathione in Alzheimer ’ s disease. Journal of Blood Medicine 4, pp. 31–38. 
Lee, S.H., Lumelsky, N., Studer, L., Auerbach, J.M. and McKay, R.D. 2000. Efficient 
generation of midbrain and hindbrain neurons from mouse embryonic stem cells. 
Nature biotechnology 18(6), pp. 675–9.  
Lehnardt, S. 2010. Innate immunity and neuroinflammation in the CNS: the role of 
microglia in Toll-like receptor-mediated neuronal injury. Glia 58(3), pp. 253–63.  
Levantini, E., Radomska, H.S., Hetherington, C.J., Alberich-Jorda, M., Amabile, G., 
Zhang, P., Gonzalez, D.A., Zhang, J., Basseres, D.S., Wilson, N.K., Koschmieder, 
S., Huang, G., Zhang, D.E., Ebralidze, A.K., Bonifer, C., Okuno, Y., Gottgens, B. and 
Tenen, D.G. 2011. RUNX1 regulates the CD34 gene in haematopoietic stem cells by 
  7.References 
185 
 
mediating interactions with a distal regulatory element. EMBO 30(119), pp. 4059–
4070. 
Levenberg, S., Golub, J.S., Amit, M., Itskovitz-Eldor, J. and Langer, R. 2002. 
Endothelial cells derived from human embryonic stem cells. Proceedings of the 
National Academy of Sciences of the United States of America 99, pp. 4391–4396. 
Lewis, C.-A., Manning, J., Rossi, F. and Krieger, C. 2012. The Neuroinflammatory 
Response in ALS: The Roles of Microglia and T Cells. Neurology research 
international 2012, p. 803701.  
Liang, J., Takeuchi, H., Jin, S., Noda, M., Li, H., Doi, Y., Kawanokuchi, J., Sonobe, 
Y., Mizuno, T. and Suzumura, A. 2010. Glutamate induces neurotrophic factor 
production from microglia via protein kinase C pathway. Brain research 1322, pp. 8–
23.  
Lim, W.F., Inoue-Yokoo, T., Tan, K.S., Lai, M.I. and Sugiyama, D. 2013. 
Hematopoietic cell differentiation from embryonic and induced pluripotent stem cells. 
Stem cell research & therapy 4(3), p. 71.  
Ling, E.A., Kaur, C. and Wong, W.C. 1982. Light and electron microscopic 
demonstration of non-specific esterase in ameboid microglial cells in teh corpus 
callosum in postnatal rats: a cytochemical link to monocytes. Journal of Anatomy 
135, pp. 385 – 394. 
Link, C.D. 2005. Invertebrate models of Alzheimer’s disease. Genes, brain, and 
behavior 4(3), pp. 147–56.  
Liu, W., Brosnan, C.F., Dickson, D.W. and Lee, S.C. 1994. Short Communication 
Macrophage Colony-Stimulating Factor Mediates Human Fetal Central Nervous 
System Culture. 145(1), pp. 48–53. 
Livak, K.J. and Schmittgen, T.D. 2001. Analysis of relative gene expression data 
using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (San 
Diego, Calif.) 25(4), pp. 402–8.  
Loh, Y.-H., Wu, Q., Chew, J.-L., Vega, V.B., Zhang, W., Chen, X., Bourque, G., 
George, J., Leong, B., Liu, J., Wong, K.-Y., Sung, K.W., Lee, C.W.H., Zhao, X.-D., 
Chiu, K.-P., Lipovich, L., Kuznetsov, V. a, Robson, P., Stanton, L.W., Wei, C.-L., 
Ruan, Y., Lim, B. and Ng, H.-H. 2006. The Oct4 and Nanog transcription network 
regulates pluripotency in mouse embryonic stem cells. Nature genetics 38(4), pp. 
431–40.  
Mak, K.S., Funnell, A.P.W., Pearson, R.C.M. and Crossley, M. 2011. PU.1 and 
Haematopoietic Cell Fate: Dosage Matters. International journal of cell biology 2011, 
p. 808524.  
Mander, P.K., Jekabsone, a. and Brown, G.C. 2006. Microglia Proliferation Is 
Regulated by Hydrogen Peroxide from NADPH Oxidase. The Journal of Immunology 
176(2), pp. 1046–1052.  
  7.References 
186 
 
Maniatis, T., Fritsch, E.F. and Sambrook, J. 1982. Molecular Cloning: A Laboratory 
Manual. Cold Spring Harbor Laboratory. 
Manz, M.G., Miyamoto, T., Akashi, K. and Weissman, I.L. 2002. Prospective 
isolation of human clonogenic common myeloid progenitors. Proceedings of the 
National Academy of Sciences of the United States of America 99(18), pp. 11872–7.  
Marquis, J.-F., Kapoustina, O., Langlais, D., Ruddy, R., Dufour, C.R., Kim, B.-H., 
MacMicking, J.D., Giguère, V. and Gros, P. 2011. Interferon regulatory factor 8 
regulates pathways for antigen presentation in myeloid cells and during tuberculosis. 
PLoS genetics 7(6), p. e1002097.  
Martin, C.., Ingersoll, S.A. and Martin, B.K. 2007. Transcriptional control of the C3a 
receptor gene in glail cells: dependence upon AP-1 but not Ets. Molecular 
Immunology 44, pp. 703–712. 
Martin, G.R. 1981. Isolation of a pluripotent cell line from early mouse embryos 
cultured in medium conditioned by teratocarcinoma stem cells Developmental 
Biology : 78(12), pp. 7634–7638. 
Mattson, M.P. 2000. Apoptosis in neurodegenerative disorders. Nature reviews. 
Molecular cell biology 1(2), pp. 120–9.  
Mcgeer, P.L., Schulzer, M. and McGeer, E.G. 1996. Arthritis and anti-inflammatory 
agents as possible protective factors for Alzheimer’s disease: a review of 17 
epidemiologic studies. Neurology 47(2), pp. 425–432. 
McGrath, K.E. and Palis, J. 2005. Hematopoiesis in the yolk sac: more than meets 
the eye. Experimental hematology 33(9), pp. 1021–1028. 
McIvor, Z., Hein, S., Fiegler, H., Schroeder, T., Stocking, C., Just, U. and Cross, M. 
2003. Transient expression of PU.1 commits multipotent progenitors to a myeloid 
fate whereas continued expression favors macrophage over granulocyte 
differentiation. Experimental hematology 31(1), pp. 39–47.  
McLarnon, J.G., Xu, R., Lee, Y.B. and Kim, S.U. 1997. Ion channels of human 
microglia in culture. Neuroscience 78(4), pp. 1217–28. 
Merkle, F.T. and Alvarez-Buylla, A. 2006. Neural stem cells in mammalian 
development. Current opinion in cell biology 18(6), pp. 704–9.  
Merrill, J.E. 1987. Macroglia : neural cells responsive to lymphokines and growth 
fadors. 8(5), pp. 146–150. 
Metcalf, D. 1992. Synergistic suppression: anomalous inhibition of the proliferation of 
factor-dependent hamopoietic cells by combination of two colony-stimulating factors. 
Proceedings of the National Academy of Sciences of the United States of America 
89, pp. 2819–2823. 
  7.References 
187 
 
Milton, N.G.N., Campus, R.F., Street, R.H. and Nw, L. 1999. Amyloid-B binds 
catalase with highaffinity and inhibits hydrogen peroxide breakdown. Biochemical 
Journal 296, pp. 293–296. 
Min, J.Y., Yang, Y., Converso, K.L., Liu, L., Huang, Q., Morgan, J.P. and Xiao, Y.F. 
2002. Transplantation of emryonic stem cells improves cardiac function in 
postinfarcted rats. Journal of Applied Physiology 92, pp. 288–296. 
Mineur, Y.S., McLoughlin, D., Crusio, W.E. and Sluyter, F. 2005. Genetic Mouse 
Models of Alzheimer’s Disease. Neural Plasticity 12(4), pp. 299–310. 
Moore, M.A.S. and Metcalf, D. 1970. Ontogeny of the haematopoietic system: yolk 
sac origin in vivo and in vitro colony forming cells in the developing mouse embryo. 
British Journal of Haematology 18, p. 279. 
Napoli, I., Kierdorf, K. and Neumann, H. 2009. Microglial precursors derived from 
mouse embryonic stem cells. Glia 57(15), pp. 1660–71.  
Narantuya, D., Nagai, A., Sheikh, A.M., Masuda, J., Kobayashi, S., Yamaguchi, S. 
and Kim, S.U. 2010. Human Microglia Transplanted in Rat Focal Ischemia Brain 
Induce Neuroprotection and Behavioral Improvement. PLoS ONE 5(7), p. e11746. 
Navascués, J., Cuadros, M.A. and Almendros, A. 1996. Development of microglia: 
Evidence from studies in the avain central nervous system. In: Ling, E. A., Tan, C. 
K., and Tan, C. B. . eds. Topical Issues in Microglial Research. Singapore: 
Singapore Neuroscience Assosication, pp. 43–64. 
Neher, J.J., Neniskyte, U., Zhao, J.-W., Bal-Price, A., Tolkovsky, A.M. and Brown, 
G.C. 2011. Inhibition of microglial phagocytosis is sufficient to prevent inflammatory 
neuronal death. Journal of immunology (Baltimore, Md. : 1950) 186(8), pp. 4973–83.  
Neumann, J., Gunzer, M., Gutzeit, H.O., Ullrich, O., Reymann, K.G. and Dinkel, K. 
2006. Microglia provide neuroprotection after ischemia. FASEB journal : official 
publication of the Federation of American Societies for Experimental Biology 20(6), 
pp. 714–6.  
Nicholson, E. and Randall, a D. 2009. Na(v)1.5 sodium channels in a human 
microglial cell line. Journal of neuroimmunology 215(1-2), pp. 25–30.  
Niwa, H., Burdon, T., Chamber, I. and Smith, A. 1998. Self-renewal of pluripotent 
embryonic stem cells is mediated via activation of STAT3. Genes and Development 
12, pp. 2048–2060. 
Odero, M., Zeleznik-Le, N., Chinwalla, V. and Rowley, J. 2000. cytogenetic and 
molecular analysis of the acute monocytic leukemai cell line THP-1 with an MLL-AF9 
translocation. Genes, Chromosomes and Cancer 29(4), pp. 333–338. 
Ohgidani, M., Kato, T. a, Setoyama, D., Sagata, N., Hashimoto, R., Shigenobu, K., 
Yoshida, T., Hayakawa, K., Shimokawa, N., Miura, D., Utsumi, H. and Kanba, S. 
  7.References 
188 
 
2014. Direct induction of ramified microglia-like cells from human monocytes: 
dynamic microglial dysfunction in Nasu-Hakola disease. Scientific reports 4, p. 4957.  
Orlovskaya, I., Schraufstatter, I., Loring, J. and Khaldoyanidi, S. 2008. Hematopoietic 
differentiation of embryonic stem cells. Methods (San Diego, Calif.) 45(2), pp. 159–
67.  
Palis, J., Robertson, S., Kennedy, M. and Al, E. 1999. Development of erythroid and 
myeloid progenitors in the yolk sac and embryo proper of the mouse. Development 
126, p. 5073. 
Palis, J. and Yoder, M.C. 2001. Yolk-sac hematopoiesis : The first blood cells of 
mouse and man. 29, pp. 927–936. 
Parakalan, R., Jiang, B., Nimmi, B., Janani, M., Jayapal, M., Lu, J., Tay, S.S.W., 
Ling, E.-A. and Dheen, S.T. 2012. Transcriptome analysis of amoeboid and ramified 
microglia isolated from the corpus callosum of rat brain. BMC neuroscience 13(1), p. 
64.  
Parpura, V., Basarsky, Trent, A., Liu, F., Jeftinija, K., Jeftinija, S. and Haydon, Philip, 
G. 1994. Glutamate-mediated astrocyte-neuron signalling. Nature 369, pp. 744 – 
747. 
Patterson, S., Gross, J., Bedford, P. and Knight, S.C. 1991. Morphology and 
phenotype of dendritic cells from peripheral blood and their productive and non-
productive infection with human immunodeficiency virus type 1. Immunology 72(3), 
pp. 361–7.  
Perry, V.H., Hume, D.. and Gordon, S. 1985. Immunohistochemical localization of 
macrophages and microglia in the adult and developing mouse brain. Neuroscience 
15(2), pp. 313 – 326. 
Pittman, A.M., Fung, H.-C. and de Silva, R. 2006. Untangling the tau gene 
association with neurodegenerative disorders. Human molecular genetics 15 Spec 
No(2), pp. R188–95.  
Priller, C., Bauer, T., Mitteregger, G., Krebs, B., Kretzschmar, H. a and Herms, J. 
2006. Synapse formation and function is modulated by the amyloid precursor 
protein. The Journal of neuroscience : the official journal of the Society for 
Neuroscience 26(27), pp. 7212–21.  
Priller, J., Flugel, A., Wehner, T., Boentert, M., Haas, C.A., Prinz, M., Fernandez-
Klett, F., Prass, K., Bechmann, I., de Boer, B.A., Frotscher, M., Kreutzberg, G.W., 
Persons, D.A. and Dirnagl, U. 2001. Targeting gene-modified hematopoietic cells to 
the central nervous system: use of green fluorescent protein uncovers microglial 
engraftment. Nature Medicine 7(12), pp. 1356–1361. 
Putnam, A.J. and Mooney, D.J. 1996. Tissue Engineering using synthetic 
extracellular matrices. Nature Medicine 2, pp. 824–826. 
  7.References 
189 
 
Rambaldi, A., Young, D.C. and Griffin, D. 1987. Expression of the M-CSF (CSF-1) 
gene by human monocytes. Blood 69, pp. 1409–1413. 
Ray, D., Culine, S., Tavitain, A. and Moreau-Gachelin, F. 1990. The human 
homologue of the putative proto-oncogene Spi-1: characterisation and expression in 
tumors. Oncogene 5(5), pp. 663–668. 
Reed-Geaghan, E.G., Savage, J.C., Hise, A.G. and Landreth, G. 2009. CD14 and 
toll-like receptors 2 and 4 are required for fibrillar AB-stimulated microglial activation. 
The Journal of neuroscience : the official journal of the Society for Neuroscience 29, 
pp. 11982–11992. 
Rezaie, P. and Male, D. 2002. Differentiation, Ramification and Distribution of 
microglia within the Central Nervous System Examined. Neuroembryology and Aging 
1(1), pp. 29–43. 
Del Rio-Hortega, P. 1919. El “tercer element” de los centros nerviosos. I. La 
microglia en estado normal. II. Intervencion de la microglia an los preocesos 
patologicos (Celulas en bastoncito y cuerpo granulo-adiposos). III. Naturaleza 
probable de la microglia. Bol. Soc. Espan. Biol 9, pp. 68–120. 
Del Rio-Hortega, P. 1932. Microglia. In: Penfield, W. ed. Cytology and Cellular 
Pathology of the Nervous System. New York: Paul B. Hoeber, pp. 483 – 534. 
Roberts, K., Zeineddine, R., Corcoran, L., Li, W., Campbell, I.L. and Yerbury, J.J. 
2013. Extracellular aggregated Cu/Zn superoxide dismutase activates microglia to 
give a cytotoxic phenotype. Glia 61(3), pp. 409–19.  
Rosenthal, S.L. and Kamboh, M.I. 2014. Late-Onset Alzheimer’s Disease Genes and 
the Potentially Implicated Pathways. Current genetic medicine reports 2, pp. 85–101. 
Available at:  
Rushton, D.J., Mattis, V.B., Svendsen, C.N., Allen, N.D. and Kemp, P.J. 2013. 
Stimulation of GABA-induced Ca2+ influx enhances maturation of human induced 
pluripotent stem cell-derived neurons. PloS one 8(11), p. e81031.  
Saijo, K. and Glass, C.K. 2011. Microglial cell origin and phenotypes in health and 
disease. Nature reviews. Immunology 11(11), pp. 775–87.  
Sasaki, A., Horikoshi, Y., Yokoo, H., Nakazato, Y. and Yamaguchi, H. 2003. 
Antiserum against human glucose transporter 5 is highly specific for microglia among 
cells of the mononuclear phagocyte system. Neuroscience letters 338(1), pp. 17–20.  
Sasaki, K. and Matsamura, G.A. 1986. Haematopoietic cells of the yolk sac and the 
liver in mouse embryo: a light and electron microscopical study. Journal of Anatomy 
148, p. 87. 
Schiegelmich, T., Henke, K. and Peri, F. 2011. Microglia in the developing brain: 
from immunity to behavior. Current Opinion in Neurobiology 21, pp. 5–10. 
  7.References 
190 
 
Schilling, T., Nitsch, R., Heinemann, U., Haas, D. and Eder, C. 2001. Astrocyte-
released cytokines induce ramification and outward K+ channel expression in 
microglia via distinct signalling pathways. European Journal of Neuroscience 14(3), 
pp. 463–473. 
Schmidtmayer, J., Jacobsen, C., Miksch, G. and Sievers, J. 1994. Blood monocytes 
and spleen macrophages differentiate into microglia-like cells on monolayers of 
astrocytes: membrane currents. Glia 12(4), pp. 259–67.  
Sedgwick, J.D., Schwender, S., Imrich, H., Dörries, R., Butcher, G.W. and ter 
Meulen, V. 1991. Isolation and direct characterization of resident microglial cells from 
the normal and inflamed central nervous system. Proceedings of the National 
Academy of Sciences of the United States of America 88(16), pp. 7438–42. 
Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=52311&tool=pmcentrez&r
endertype=abstract. 
Shudo, K., Fukasawa, H., Nakagomi, M. and Yamagata, N. 2009. Towards Retinoid 
Therapy for Alzheimer ’ s Disease. , pp. 302–311. 
Si, Q., Nakamura, Y. and Kataoka, K. 1997. Albumin enhances superoxide 
production in cultured microglia. Glia 21(4), pp. 413–418. 
Sievers, J., Parwaresch, R. and Wottge, H.U. 1994. Blood monocytes and spleen 
macrophages differentiate into microglia-like cells on monolayers of astrocytes: 
morphology. Glia 12(4), pp. 245–58.  
Simard, a R., Soulet, D., Gowing, G., Julien, J.P. and Rivest, S. 2006. Bone Marrow-
Derived Microglia Play a Critical Role in Restricting Senile Plaque Formation in 
Alzheimer’s Disease. Neuron 49, pp. 489–502. 
Sporle, R. and Schughart, K. 1997. Neural Tube Morphogenesis. Current Opinion in 
Genetics and Development 7, pp. 507 – 512. 
Strauss-Ayali, D., Conrad, S.M. and Mosser, D.M. 2007. Monocyte subpopulations 
and their differentiation patterns during infection. Journal of leukocyte biology 82(2), 
pp. 244–52.  
Strazza, M., Pirrone, V., Wigdhal, B. and Nonnemacher, M.R. 2011. Breaking down 
the barrier: the effects of HIV-1 on the blood-brain barrier. Brain research 1399, pp. 
96–115. 
Sumi, S.M., Bird, T.D., Nochlin, D. and Raskind, M.A. 1992. Familial presenile 
dementia with psychosis associated with cortical neurofibrillary tangles and 
degeneration of the amygdala. Neurology 42(1), pp. 120 – 127. 
Sun, Y.E., Martinowich, K. and Ge, W. 2003. Making and repairing the mammalian 
brain - signaling toward neurogenesis and gliogenesis. Seminars in Cell and 
Developmental Biology 14, pp. 161–168. 
  7.References 
191 
 
Suzuki, A., Raya, A., Kawakami, Y., Morita, M., Matsui, T., Nakashima, K., Gage, 
F.H., Rodriguez-Esteban, C. and Belmonte, J.C.I. 2006. Nanog binds to Smad1 and 
blocks bone morphogenetic protein-induced differentiation of embryonic stem cells. 
Proceedings of the National Academy of Sciences of the United States of America 
103(27), pp. 10294–10299. 
Suzumura, a, Marunouchi, T. and Yamamoto, H. 1991. Morphological transformation 
of microglia in vitro. Brain research 545(1-2), pp. 301–6.  
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K. and 
Yamanaka, S. 2007. Induction of pluripotent stem cells from adult human fibroblasts 
by defined factors. Cell 131(5), pp. 861–72.  
Takahashi, S. 2011. Myeloid Leukemia - Basic Mechanisms of Leukemogenesis. 
December, . Koschmieder, S. ed. InTech. 
Tanaka, R., Komine-Kobayashi, M., Mochizuki, H., Yamada, M., Furuya, T., Migita, 
M., Shimada, T., Mizuno, Y. and Urabe, T. 2003. Migration of enhanced green 
fluorescent protein expressing bone marrow-derived microglia/macrophage into the 
mouse brain following permanent focal ischemia. Neuroscience 117(3), pp. 531–539.  
Tanzi, R.. and Bertram, L. 2001. New Frontiers in Alzheimer’s Disease Genetics. 
Neuron 32, pp. 181–184. 
Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A., Swiegiel, J.J., 
Marshall, V.S. and Jones, J.M. 1998. Embryonic Stem Cell Lines Derived from 
Human Blastocysts. Science 282, pp. 1145–1147. 
Toulme, E. and Khakh, B.S. 2012. ImagingP2X4 Receptor Lateral Mobility in 
Microglia: REGULATION BY CALCIUM AND p38 MAPK. The Journal of Biological 
Chemistry 287(18), pp. 14734–14748. 
Tschiya, S., Yamabe, M., Yamaguchi, Y., Kobayashi, Y., Konno, T. and Tada, K. 
1980. Establishment and characterisation of a human acute monoctyic leukemia cell 
line (THP-1). International journal of cancer 26(2), pp. 171–176. 
Vilhardt, F. 2005. Microglia: phagocyte and glia cell. The International Journal of 
Biochemistry and Cell Biology 37, pp. 17–21. 
Virchow, R. 1846. uber das granulierte anschen de Wandungen der Gehirnventrikel. 
Allg Z Psychiat 3, pp. 242–250. 
Walton, M.R., Gibbons, H., MacGibbon, G. a, Sirimanne, E., Saura, J., Gluckman, 
P.D. and Dragunow, M. 2000. PU.1 expression in microglia. Journal of 
neuroimmunology 104(2), pp. 109–15.  
Van Wilgenburg, B., Browne, C., Vowles, J. and Cowley, S. a 2013. Efficient, long 
term production of monocyte-derived macrophages from human pluripotent stem 
cells under partly-defined and fully-defined conditions. PloS one 8(8), p. e71098.  
  7.References 
192 
 
Williams, R.L., Hilton, D.J., Pease, S., Wilson, T.A., Stewart, C.L., Gearing, D.P., 
Wagner, E.F., Metcalf, D., Nicola, N.A. and Gough, N.M. 1988. Myeloid leukaemia 
inhibitory factor maintains the developmental potential of embryonic stem cells. 
Nature 336, pp. 684–687. 
Wisniewski, T. and Konietzko, U. 2008. Amyloid-B immunisation of Alzheimer’s 
disease. Lancet Neurology 7(9), pp. 805–811. 
Yamamoto, H., Kihara-Negishi, F., Yamada, T., Hashimoto, Y. and Oikawa, T. 1999. 
Physical and functional interactions between the transcription factor PU.1 and the 
coactivator CBP. Oncogene 18(7), pp. 1495–501.  
Yang, Z.F., Poon, R.T., Luo, Y., Cheung, C.K., Ho, D.W., Lo, C.M. and Fan, S.T. 
2004. Up-Regulation of Vascular Endothelial Growth Factor (VEGF) in Small-for-Size 
Liver Grafts Enhances Macrophage Activities through VEGF Receptor 2-Dependent 
Pathway. The Journal of Immunology 173(4), pp. 2507–2515.  
Yokomizo, T., Hasegawa, K., Ishitobi, H., Osato, M., Ema, M., Ito, Y., Yamamoto, M. 
and Takahashi, S. 2008. Runx1 is involved in primitive erythropoiesis in the mouse. 
Blood 111(8), pp. 4075–80.  
Zhao, T., Xia, Y., Li, L., Zhu, G., Chen, S., Feng, H. and Lin, J. 2009. Bovine serum 
albumin promtoes IL-1beta and TNF-alpha secretion by N9 microglia cells. 
Neurological Sciences 30(5), pp. 379–383. 
Zielasek, J. and Hartung, H.P. 1996. Molecular mechanisms of microglial activation. 
Advances in neuroimmunology 6(2), pp. 191–22.  
 
 
 
  Appendices 
195 
 
APPENDICES 
APPENDIX I 
I.I PU.1 SEQUENCED REGION (825BP) 
GGATCCATGTTACAGGCGTGCAAAATGgaagggtttcccctcgtcccccctccatcagaagacctggt
gccctatgacacggatctataccaacgccaaacgcacgagtattacccctatctcagcagtgatgggg
agagccatagcgaccattactgggacttccacccccaccacgtgcacagcgagttcgagagcttcgcc
gagaacaacttcacggagctccagagcgtgcagcccccgcagctgcagcagctctaccgccacatgga
gctggagcagatgcacgtcctcgatacccccatggtgccaccccatcccagtcttggccaccaggtct
cctacctgccccggatgtgcctccagtacccatccctgtccccagcccagcccagctcagatgaggag
gagggcgagcggcagagccccccactggaggtgtctgacggcgaggcggatggcctggagcccgggcc
tgggctcctgcctggggagacaggcagcaagaagaagatccgcctgtaccagttcctgttggacctgc
tccgcagcggcgacatgaaggacagcatctggtgggtggacaaggacaagggcaccttccagttctcg
tccaagcacaaggaggcgctggcgcaccgctggggcatccagaagggcaaccgcaagaagatgaccta
ccagaagatggcgcgcgcgctgcgcaactacggcaagacgggcgaggtcaagaaggtgaagaagaagc
tcacctaccagttcagcggcgaagtgctgggccgcgggggcctggccgagcgGCGCCACCCGCCCCAC
TGAGGATCC 
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I.II PCAGIG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pCAGIG
6135 bp
CAG Enhancer
IRES
EGFP
Ampicillin Resistance
Rb Glob PA Terminator
EcoRI (1720)
BamHI (3806)
BamHI (4143)
AseI (27)
AseI (3751)
AseI (4155)
AseI (5390)
  Appendices 
197 
 
I.III PIRES2-EGFP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pIRES2-EGFP
5308 bp
CAG Enhancer
IRES
EGFP
NeoR/KanR
CMV Promoter
BamHI (661)
EcoRI (630)
AseI (8)
BglII (610)
SalI (640)
XhoI (614)
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I.IV PCAGG-IRES-GFP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pIRES2 EGFP CAG
6406 bp
CAG Enhancer
SV40 Enhancer
IRES
EGFPF1 ori
pBR322 ori
NeoR/KanR
SV40 Promoter
TKPA Term
BamHI (1759)
EcoRI (1729)
CAGG-IRES-GFP 
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I.V PCAGG-PU.1-IRES-GFP 
 
 
  
pIRES2 EGFP CAG PU.1
7226 bp
CAG Enhancer
SV40 Enhancer
IRES
EGFP
F1 ori
pBR322 ori
PU.1
NeoR/KanR
SV40 Promoter
TKPA Term
EcoRI (1729)
BamHI (1760)
BamHI (2579)
CAGG-PU.1-IRES-GFP 
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APPENDIX II 
II.I QPCR PRIMER DATA SHEETS 
 
RUNX1 
Accession Number NM_001754.4 
Forward Sequence (5’3’) CTGCCCATCGCTTTCAAGGT (20) 
Tm (°C) 59.4 
GC content 55% 
Reverse Sequence (5’3’) GCCGAGTAGTTTTCATCATTGCC (23) 
Tm (°C) 60.6 
GC content 47.8% 
% Efficiency 105.5% 
 
 
 
 
 
 
 
 
 
y = -3.1947x + 29.852
R² = 0.9795
0.00
5.00
10.00
15.00
20.00
25.00
30.00
0 0.5 1 1.5 2 2.5 3 3.5
Log[RNA]
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PU.1 
Accession Number NM_001080547.1 
Forward Sequence (5’3’) CCAGCTCAGATGAGGAGGAG (20) 
Tm (°C) 61.4 
GC content 60% 
Reverse Sequence (5’3’) CAGGTCCAACAGGAACTGGT (20) 
Tm (°C) 59.4 
GC content 55% 
% Efficiency 94.8% 
y = -3.4531x + 30.886
R² = 0.9521
0.00
5.00
10.00
15.00
20.00
25.00
30.00
0 0.5 1 1.5 2 2.5 3 3.5
Log[RNA]
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y = -3.4077x + 32.494
R² = 0.9683
0.00
5.00
10.00
15.00
20.00
25.00
30.00
35.00
0 0.5 1 1.5 2 2.5 3 3.5
Log[RNA]
 
 
  
IBA-1 
Accession Number NM_001623.3 
Forward Sequence (5’3’) GCTGAGCTATGAGCCAAACC (20) 
Tm (°C) 59.4 
GC content 55% 
Reverse Sequence (5’3’) TCATCCAGCCTCTCTTCCTG (20) 
Tm (°C) 59.4 
GC content 55% 
% Efficiency 96.5% 
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CD45 
Accession Number NM_002838.4 
Forward Sequence (5’3’) CATTTGGCTTTGCCTTTCTG (20) 
Tm (°C) 55.3 
GC content 45% 
Reverse Sequence (5’3’) TTCTCTTTCAAAGGTGCTTGC (21) 
Tm (°C) 55.9 
GC content 42.9% 
% Efficiency 92.7% 
y = -3.5106x + 37.497
R² = 0.959
0.00
5.00
10.00
15.00
20.00
25.00
30.00
35.00
40.00
0 0.5 1 1.5 2 2.5 3 3.5
Log[RNA]
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IL-1β 
Accession Number NM_000576.2 
Forward Sequence (5’3’) ACAGATGAAGTGCTCCTTCCA (21) 
Tm (°C) 57.9 
GC content 47.6% 
Reverse Sequence (5’3’) GTCGGAGATTCGTAGCTGGAT (21) 
Tm (°C) 59.8 
GC content 52.4% 
% Efficiency 105% 
y = -3.2051x + 33.286
R² = 0.9803
0.00
5.00
10.00
15.00
20.00
25.00
30.00
35.00
0 0.5 1 1.5 2 2.5 3 3.5
Log[RNA]
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TNF-α 
Accession Number NM_000594.3 
Forward Sequence (5’3’) CCCAGGGACCTCTTCTCTAATC (21) 
Tm (°C) 61.8 
GC content 57.1% 
Reverse Sequence (5’3’) ATGGGCTACAGGCTTGTCACT (21) 
Tm (°C) 55.9 
GC content 33.3% 
% Efficiency 93.64% 
  
y = -3.4843x + 35.357
R² = 0.9425
0.00
5.00
10.00
15.00
20.00
25.00
30.00
35.00
0 0.5 1 1.5 2 2.5 3 3.5
Log[RNA]
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NaV1.5 
Accession Number NM_198056.2 
Forward Sequence (5’3’) CATTTCAGGGCTGAAGACCA 
Tm (°C) 57.3 
GC content 50% 
Reverse Sequence (5’3’) GGCAGAAGACTGTGAGGACC 
Tm (°C) 61.4 
GC content 60% 
% Efficiency 91.7% 
y = -3.5357x + 39.001
R² = 0.9803
30
31
32
33
34
35
36
37
0 0.5 1 1.5 2 2.5
Log[RNA]
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NaV1.6 
Accession Number NM_014191.3 
Forward Sequence (5’3’) GGCAATGTTTCAGCTCTACGC 
Tm (°C) 59.8 
GC content 52.4% 
Reverse Sequence (5’3’) ATTGTCTTCAGGCCTGGGATT 
Tm (°C) 59.8 
GC content 47.6% 
% Efficiency 103.8% 
y = -3.2339x + 41.229
R² = 0.9967
33
34
35
36
37
38
39
40
0 0.5 1 1.5 2 2.5
Log[RNA]
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Kir2.1 
Accession Number NM_000891.2 
Forward Sequence (5’3’) GGTTTGCTTTGGCTCAGTCG 
Tm (°C) 59.4 
GC content 55% 
Reverse Sequence (5’3’) GAACATGTCCTGTTGCTGGC 
Tm (°C) 59.4 
GC content 55% 
% Efficiency 104.4% 
 
 
  
y = -3.2215x + 42.395
R² = 0.9913
34.5
35
35.5
36
36.5
37
37.5
38
38.5
39
39.5
0 0.5 1 1.5 2 2.5
Log[RNA]
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CD34 
Accession Number NM_001025109.1 
Forward Sequence (5’3’) CTTTCAACCACTAGCACTAGCC (22) 
Tm (°C) 60.3 
GC content 50% 
Reverse Sequence (5’3’) TGCCCTGAGTCAATTTCACTTC (22) 
Tm (°C) 58.4 
GC content 45.5% 
% Efficiency 104.15% 
y = -3.2262x + 42.115
R² = 0.9771
32
33
34
35
36
37
38
39
0 0.5 1 1.5 2 2.5 3 3.5
Log[RNA]
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TREM2 
Accession Number NM_018965.3 
Forward Sequence (5’3’) CTGGAGATCTCTGGTTCCCC (20) 
Tm (°C) 61.4 
GC content 60% 
Reverse Sequence (5’3’) AGAAGGATGGAAGTGGGTGG (20) 
Tm (°C) 59.4 
GC content 55% 
% Efficiency 98.9% 
y = -3.348x + 36.258
R² = 0.9426
0
5
10
15
20
25
30
35
40
45
-2 -1 0 1 2 3
Log[RNA]
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FLK1 
Accession Number NM_001025366.2 
Forward Sequence (5’3’) GGCCCAATAATCAGAGTGGCA (21) 
Tm (°C) 59.8 
GC content 52.4% 
Reverse Sequence (5’3’) CCAGTGTCATTTCCGATCACTTT (23) 
Tm (°C) 59.8 
GC content 43.5% 
% Efficiency 101.9% 
 
  
y = -3.2769x + 37.989
R² = 0.9315
0.00
5.00
10.00
15.00
20.00
25.00
30.00
35.00
40.00
0 0.5 1 1.5 2 2.5 3 3.5
Log[RNA]
  Appendices 
212 
 
 
  
 
  
CD11c 
Accession Number NM_00128675.1 
Forward Sequence (5’3’) GGAAGACCCTTCTCCAAAGC (20) 
Tm (°C) 59.4 
GC content 55% 
Reverse Sequence (5’3’) CAGAGGAGCTGACAGCCTTC (20) 
Tm (°C) 61.4 
GC content 60% 
% Efficiency 95.1% 
y = -3.4455x + 42.031
R² = 0.9754
32.00
33.00
34.00
35.00
36.00
37.00
38.00
0 0.5 1 1.5 2 2.5 3
Log[RNA]
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CD80 
Accession Number NM_005191.3 
Forward Sequence (5’3’) AGGGAACATCACCATCCAAG (20) 
Tm (°C) 57.3 
GC content 50% 
Reverse Sequence (5’3’) CAAACTCGCATCTACTGGCA (20) 
Tm (°C) 57.3 
GC content 50% 
% Efficiency 95.2% 
y = -3.4423x + 41.086
R² = 0.9587
31.00
32.00
33.00
34.00
35.00
36.00
37.00
38.00
0 0.5 1 1.5 2 2.5 3
log[RNA]
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NG2 
Accession Number NM_001897.4 
Forward Sequence (5’3’) AGAAGCAAGTGCTCCTCTCG (20) 
Tm (°C) 59.4 
GC content 55% 
Reverse Sequence (5’3’) CCACTCAGCAGTCAGACCCT (20) 
Tm (°C) 61.4 
GC content 60% 
% Efficiency 105% 
 
 
 
 
  
y = -3.2051x + 38.914
R² = 0.9901
30
31
32
33
34
35
36
0 0.5 1 1.5 2 2.5 3
Log[RNA]
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y = -3.1126x + 25.09
R² = 0.987
0
5
10
15
20
25
30
35
-1.5 -1 -0.5 0 0.5 1 1.5 2
Log[RNA]
 
Β-Actin 
Accession Number NM_001101.3 
Forward Sequence (5’3’) CCCAGCACAATGAAGATCAA (20) 
Tm (°C) 55.2 
GC content 45% 
Reverse Sequence (5’3’) ACATCTGCTGGAAGGTGGAC (20) 
Tm (°C) 59.4 
GC content 55% 
% Efficiency 109% 
 
   
 
